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Genomic Evolution of Glioblastoma
Erik Ladewig
Understanding how tumors evolve and drive uncontrolled cellular growth may lead to
better prognosis and therapy for individuals suffering from cancer. A key to understand-
ing the paths of progression are to develop computational and experimental methods to
dissect clonal heterogeneity and statistically model evolutionary routes.
This thesis contains results from analysis of genomic data using computational meth-
ods that integrate diverse next generation sequencing data and evolutionary concepts to
model tumor evolution and delineate likely routes of genomic alterations. First, I intro-
duce some background and present studies into how tumor genomic sequencing tells us
about tumor evolution. This will encompass some of the principles and practices related
to tumor heterogeneity within the field of computional biology. Second, I will present a
study of longitudinal sampling in Glioblastoma (GBM) in cohort of 114 individuals pre-
and post-treatment. We will see how genomic alterations were dissected to uncover a
diverse and largely unexpected landscape of recurrence. This details major observations
that the recurrent tumor is not likely seeded by the primary lesion.
Second, to dissect heterogeneity from clonal evolution, multiple biopsies will be added
to extend our longitudinal GBM cohort. This new data will introduce analyses to explicate
inter and intra-tumor heterogeneity of GBM. Specifically, we identify a metric of intra-
tumor heterogeneity able to identify multisector biopsies and propose a model of tumor
growth in multiple GBM. These results will relate to clinical outcome and are in agree-
ment with previously established hypotheses in truncal mutation targeting. Fourth, I will
introduce new models of clonal growth applicable to 2 patient biopsies and then fit these
to our GBM cohort. Simulations are used to verify models and a brief proof is presented.
Finally, I include within Appendix a supplemental study in Hodgkins lymphoma, a mostly
childhood lymphoma that was analyzed from noisy next generation sequencing data to
uncover prevalent potentially targetable mutations in the JAK-STAT pathway.
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1.1 Zur Frage der Entstehung maligner Tumoren
”In his treatment of the theory Boveri gives its application to most of the well-known
phenomena met with in cancer growth, and meets some of the arguments which have
been brought against it. From the nature of the case the theory is difficult if not impossible
to analyze by direct experiment and for this reason,as well as for its impracticality, it is
probable that the hypothesis will not be favorably received by the medical profession.” -
Gary N. Calkins, Columbia University, Department of Zoology
In 1914 Theodore Boveri published a hypothesis ”Zur Frage der Entstehung maligner
Tumoren” [1] which translates to ”on the question of the development of malignant tu-
mors”. His hypothesis was that mammalian tumors might result from abnormal mitosis
leading to unequal distribution of the chromosomes in the resulting cells. This was based
on his own research in sea urchins. Some had formed mitotic abnormalities (aneuploidy)
that later resulted in abnormal development of the organism. He had extended his hy-
pothesis to include other assumptions, for example: lost chromosomes are never replaced
and the abnormal cell, if it divides further, must give rise to similar abnormal cells, the
malignant tumor always arises from one single cell and this primordial cancer cell arises
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by abnormal division as an otherwise normal tissue cell and may start from any one of a
large number of different causes [1]. At the time only a few of Boveri’s hypotheses could
be verified, but in the past 100 years many of Boveri’s assumptions have proven correct.
1.2 Tumor Clonal Evolutionary Model
More than 60 years later Peter Nowell, a professor of pathology in the School of Medicine
at the University of Pennsylvania would suggest a model of tumor evolution in which
cell populations follow stepwise genetic variation [2]. It was Nowell and his student who
first identified a small minute chromosome upon inspection of two patient samples with
chronic myelogenous leukemia (CML). With improved cell preparations they confirmed
that 7 CML patient samples contained reciprocal translocation of chromosome 9 and 22:
t(9;22)(q34;q11), later called the Philadelphia chromosome. This consistent chromosomal
event provided strong evidence to support Boveri’s hypothesis [3].
Nowell would later describe his model with an example in which a normal cell ex-
periences a single induced alteration sufficient to make it ”neoplastic”. The neoplastic
cell or neoplasia escapes from the normal growth of the cell to one that provides a se-
lective growth advantage [2]. This advantage initiates a cascade of events that endows
cells growth advantage over neighboring cells and leads to neoplastic proliferation. After
a series of mitotic divisions daughter cells may subsequently undergo genetic instability
and mutant cells are produced to form the expanding tumor population, forming the basis
of his clonal evolutionary theory of tumor populations.
A model of clonal tumor evolution is pictured using an Acute Leukemia tumor initi-
ated by a carcinogen 1.1. A normal cell, called N exposed to carcinogen divides to produce
a cell T1 that has acquired a growth advantage and begins to proliferate. As T1 divides
it becomes genetically unstable and acquires mutations of which many are deleterious or
neutral due to metabolic or immunological disadvantage. While deleterious clones are
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removed from the population, some mutations become favorable giving rise to daughter
cells. This selection continues as the progeny progress toward a more invasive tumor
population. In a step-wise manner this process will eventually endow loss of differenti-
ation, resistance to treatment, and metastatic behavior. This happens in a manner that
may appear to mirror biological characteristics with genetic selection. Although, Nowell
admits that even a large number of cells may be affected by a carcinogen he favors a single
cell, or at most, a very few cells are the origin of the macroscopic tumor that may ulti-
mately develop [2]. This model implicates a single mutated cell gives rise to tumors, and
that any subsequent alterations that confer growth advantage give rise to more adapted
subpopulations of the original neoplasm.
Nowell affirms the need to answer questions related to the nature of the neoplastic
event, and significance of exogenous influence and inherited defects in tumor initiation,
and such events should not require chromosomal structural alteration. At the time most
initial events could not be visualized with current methods. It is now widely accepted
that tumors follow a clonal evolutionary model whereby a parental clone passes genetic






















Fig. 1.1: A model of clonal evolution in Neoplasia
Amodel of clonal evolution in neoplasia. Normal progenitor cell is exposed to carcinogen
and produces a diploid tumor cell T1 with growth advantage mutation permitting clonal
expansion. Acquired mutations generation new cells labeled T2 which produce T3. Some
cells are lost, indicated in dark gray. A more favorable variant appears in T4 and step-wise
progression continues to gives rise to T5 and an eventually maligant clone T6. Adapted
from Figure 1 [2].
Cancer is the result of an orchestrated set of genomic alterations that conspire to
drive uncontrolled cellular growth. There are differing hypotheses for the development of
cancer. Tumors can arise from a single mutation, i.e. monoclonal origin [2], or multiple
misregulated processes can give rise to polyclonal neoplasms [4]. A model of cancer
stem cells is supported by the inherent features of stem cells - self renewal, and clonal
expansion.
The British physician and cancer researcher D. W. Smithers wrote in The Lancet, in
1962, ”Cancer is no more a disease of cells than a traffic jam is a disease of cars. A traffic
jam is due to a failure of the normal relationship between driven cars and their environ-
ment and can occur whether they themselves are running normally or not.”
In this thesis we will examine the clonal relationships of cancer by looking deep into
the cell’s DNAover a period of time and space through the lens of genomics. Wewill relate
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background material to how cancer studies in cross-sectional, longitudinal and multi-
sectional studies have informed our current view of tumor evolution and heterogeneity.
Throughout the background I discuss relevant results from analysis performed in the later




In Charles Darwin’s foundational publication On the Origin of Species he described evolu-
tion as descent with modification, whereby parental traits modified by natural selection
are passed on to descendants. DNA mutations create genetic variation and are essential
mechanisms of change that allow advantageous traits for survival to be inherited from
one generation to the next. Mutations are required building blocks for operations such
as genetic drift, a process that creates random birth and death events, and for selection,
a directed process that leads to an increase in the frequency of selected alleles or geno-
types. DNA mutations are fundamental forces of evolution that influence the fate of new
genotypes and shape future phenotypes.
Cancer Genomics
Next generation sequencing has created new opportunities and brought unprecedented
growth for biological discovery. Consortium such as The Cancer Genome Atlas (TCGA)
and International Cancer Genomics Consortium (ICGC) currently catalog mutations in
dozens of tumor types (currently, TCGA N=34 tumor types, ICGC, N=90 tumor projects).
This has enabled new insights for tumor classification, onco-gene and tumor suppressor
identification, drug resistance, and fostered the field of cancer genomics.
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Accelerated by computational methods capable of detecting biological signal, cancer
genomics has demonstrated the value of unbiased genomic analyses in the characteri-
zation of human tumors to identify useful genetic alterations for the classification and
therapy of neoplasias. [5]. Discerning mutations important to a tumor’s progression crit-
ically impacts the design of targeted cancer therapies.
DNA Alignment
DNA in its simplest form is depicted as a linear sequence of letters from the alphabet
[A,C,G,T*] representing the nucleotides adenine, cytosine, guanine, and thymine, respec-
tively. DNA sequencing is the symbolic representation of the order of nucleotides in the
DNA. Next generation sequencing (NGS) sequences DNA from millions of small frag-
ments in parallel to produce short nucleotide sequences called genomic reads.
Sequence alignment to a reference genome orientates genomic reads by finding a best
match between their sequence and the reference. This facilitates downstream comparison
of any number of sequenced genomes that share a common reference. DNA differences in
tumor and control sample infer nucleotide and structural alterations of the cancer genome.
Many factors influence the quality of DNA alignment andmutational detection. Biological
and technical issues include sample preparation [6], sample purity [7], mutagenic damage
[8], sequencer reaction [6, 9], and downstream computational assumptions. Comparative
mutational analysis rely on methods able to mathematically or statistically estimate true
biological signal from potential noise.
These are the IUPAC designated symbols for DNA nucleotides. *In RNA the base is uracil and the
letter U is used in place of T.
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2.1 Tumor Genetic Heterogeneity
Genetic heterogeneity contributes to adaptation, therapy resistance and immune evasion.
This diversity builds upon the evolutionary history of a tumor and can be viewed as a
Darwinian process of clonal replacement [2] in which pressures such as treatment or
micro-environment ablates vulnerable cells while positively selecting for resistant clones.
Cellular heterogeneity in tumors was already described by experimentalists and patholo-
gists of the 19th century. In 1838 the laboratory of German physiologist Johannes Mueller
pioneered the field of pathology when he and his students documented microscopy of hu-
man tumors. It was his student Theodor Schwann who observed that cancer is cellular
and grows from what resembles normal tissue [10]. Later, it was Mueller’s student the
now famous pathologist Rudolf Virchow who determined that all tumors originate from
normal cells [11].
Tumor evolution fortuitously modifies genes identified as tumor suppressors and
oncogenes. Oncogenes provide an advantage to the tumor and promote growth, invasion
and metastasis while tumor suppressors mediate checkpoint and DNA damage repair.
Mutations are generally classified in two ways: drivers and passengers. Both tumor sup-
pressors and oncogenes are considered drivers that provide advantages to progression.
Passenger mutations represent neutral or deleterious events to the tumor clone that do
not confer a fitness advantage. Distinguishing seemingly random passenger events from
tumor driver related alterations selected for during progression is an area of focus in the
field of cancer genomics research [12].
Inter and IntraTumor Heterogeneity
Somatic mutations act on one or more stages of evolution to create clonally unique cells
both spatially and temporally. These cell differences can occur in tumor by tumor man-
ner, called intertumor heterogeneity, or among cells within a single patient’s tumor as
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intratumor heterogeneity. Intertumor heterogeneity denotes changes in genotype and
phenotype due to etiological and environmental changes in different patient tumors [13].
Intratumor heterogeneity refers to genomic and biologic variations gained by tumor evo-
lution in response to various microenvironments [2, 13]. Tumor heterogeneity raises
questions about the biological relevance of subclonal mutations, those mutations only
present within a fraction of the tumor, do clonal populations compete or cooperate, can
heterogeneity influence a tumor’s classification?
Next generation sequencing measures intratumor heterogeneity (ITH) using assays in
whole genome sequencing (WGS), whole exome sequencing (WES), ultra-deep sequenc-
ing (UDS) of targeted regions, and single cell profiling. WGS can capture the entire
genome’s DNA and is ideal for accurate copy number analysis. Although, due to costs
typical depths are generally <50x which is insufficient to accurately measure subclonal
mutational allele frequencies, let alone clonal structure [14–16]. WES widely reports se-
quencing depths in excess of 100x to allow accurate detection of most clonal mutations,
however solid tumor tissues containing many subclonal variants may often require even
greater depths [14, 17]. Increasing the number of samplings either over time or from
multiple solid tissue biopsies assists to capture sufficient intratumor heterogeneity. Lim-
itations of WES include missed variants in non-targeted regions and insufficient depth
to accurately resolve the clonal structure of many tumors, particularly solid tissue tu-
mors replete with normal infiltration. In addition, methods to infer copy number data
are typically less accurate when compared to whole genome sequencing or SNP arrays.
The nature of assaying single cells is ideal for uncovering intratumor heterogeneity. Ultra
deep sequencing has sufficient depth to estimate subclonal and clonal structure, however
regions are limited in scope and this approach is often used after somatic variants were
identified in WES or WGS. Single cell sequencing of whole genome and whole exome are
increasingly used and offer the most straightforward approach. Single cell transcriptome
analysis used to measure inter and intra-tumor expression heterogeneity and is now in-
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creasingly employed in copy number inference. Technical and cost related issues will
need to be overcome before genomic and transcriptomic single cell sequencing becomes
the standard approach to measure tumor heterogeneity.
SNV
Somatic single nucleotide variant (SSNV) analysis utilizes nucleotide counts measured
at the same allele in normal and tumor cell populations. The rationale is that aberrant
somatic alleles will become fixed in a tumor population following clonal expansion and
therefore exhibit different frequencies from the normal [18].
In chapters 3, 4, and 5 our studies of Glioblastoma evolution heavily relied on proper
mutational analysis from whole exome sequencing of normal, initial, and recurrent sam-
ples in 93 patients. We employed methods to reduce spurious variant discovery by up-
dating an in-house variant caller called SAVI (statistical algorithm for variant frequency
identification) that was previously calibrated using other cancers. To reduce the false
positive rate and indicate potential false negatives in GBM we optimized the algorithm
by calibrating variant calls with a subset of sanger validated variants.
We curated a list of frequently modified GBM genes from the literature to define a set
of known and potential drivers. We found that the frequency of mutations were similar
in both the initial and recurrence samples for many driver genes. Exclusive mutations
in MSH6, PRDM2 and the gene LTBP4 were recurrently mutated only in relapse. LTBP4,
a novel candidate in GBM is known to have a role in the TGF-β pathway, (please see
chapters 3 and 4 methods for details).
CNV
Copy number variation (CNV) analysis detects regions of the genome that have un-
dergone chromosomal change due to deletion, duplication, translocation and inversion.
CNVs are commonly detected from genotyping arrays or next generation sequencing
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(NGS). Array based methods include comparative genome hybridization (CGH) and SNP
arrays. CGH arrays measure fluorescence ratio of a labeled target and reference DNA
using either arrays of bacterial artificial chromosomes or long synthetic oligonucleotides.
SNP chips detect copy number change by measuring hybridized intensities of short frag-
ments of DNA to the genome. SNP arrays are limited by the informative number of
SNPs in the genome. NGS detection of DNA copy number change performed with whole
genome and whole exome data compares stretches of DNA in an experiment versus con-
trol to identify breakpoints and simultaneously measure depth, breadth, read length, and
average span between reads [19].
Most initial and recurrent GBM samples contained chromosomal alterations as fre-
quent and common gains of chromosome 7 and deletion of chromosomes 9 and 10. Each
of these modifications targeted driver genes such as the oncogene epidermal growth fac-
tor receptor (EGFR) on chromosome 7 targeted in 42% of diagnoses and in 34% of recurrent
cases. The tumor suppressor phosphatase and tensin homolog (PTEN) on chromosome 10
was lost in initial and recurrent tumors in 37% and 34% of cases, respectively. The most
modified gene in GBM was Cyclin Dependent Kinase Inhibitor 2A (CDKN2A) on chro-
mosome 9 found to be lost in 47% of diagnoses and 52% of recurrent samples. Finally, a
known tumor specific receptor called EGFRvIII born via chromosomal deletion of exons
2-7 was harbored in 11% (13/114) of patients.
Fusions
Gene fusions are the result of chromosomal aberrations that join two segments of DNA
to produce a hybrid gene transcript. Gene fusions such as BCR-ABL1 in chronic myel-
ogeneous leukemia, FGFR3-TACC3 in glioblastomas, and EML4-ALK in non-small cell
lung tumors are highly oncogenic drivers [20–22]. Some fusions explain rare cancers
such as DNAJB1-PRKACA in fibrolamellar hepatocellular carcinoma of which there are
fewer than 1000 cases per year [23]. Screening for such events is crucial as many repre-
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sent promising candidates for therapy. We discovered gene fusions in FGFR3-TACC3 that
were highly expressed in both the initial and recurrence samples. Other fusions involv-
ing the gene EGFR with multiple partners (chapter 3) and a fusion of ATRX and ATB8B4
(chapter 4) were identified. Perhaps indicative of a therapy related event, the gene O-
6-Methylguanine-DNA Methyltransferase (MGMT) was found in one patient’s relapse
sample multiple times with the same breakpoint in three different fusion transcripts.
Purity and Ploidy
Accurate inference of mutational allele frequency and copy number are crucial to esti-
mating historical relationships of cancer genomes. Solid tissue tumor cells are often inter-
mixedwith an unknown proportion of normal cells so that themeasured allele frequencies
of somatic variants are misreported due to the presence of non-cancerous alleles. This is-
sue is compounded by tumor ploidy resulting from gross chromosomal abnormalities that
alter measured frequencies from their true value. Previously, a pathologist would estimate
tumor content primarily visually or through image analysis. There are now methods to
estimate the purity and ploidy of a sample directly from DNA copy number data [24, 25]
and using next generation sequencing [25–28]. Some methods also estimate purity from
expression profiles [29]. One issue in purity and ploidy estimation is identifiability, in that
different combinations of purity and ploidy can explain the observed data [30]. Many al-
gorithms using only copy number, only somatic nucleotide variants or both, will offer po-
tential solutions for consideration. For instance, Absolute uses precomputed karyotypes
for different cancers to offer best possibilities. For our studies in GBM a combination of
ASCAT, Absolute, and Sequenza using both CNV and SNV data to infer sample purity
and ploidy were utilized. In 10 different samples Affymetrix SNP6 chip containing more
than 1.8 million genetic markers was first analyzed with ASCAT and Absolute. The ex-
ome profiles from these 10 samples were then compared and calibrated for the remaining
178 cases. Mean purity estimates of 65% and 45% with mean ploidy of 3.12 and 2.38 was
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estimated for our longitudinal and ITH cohorts, respectively.
Measures of ITH
Once dependable mutation and CNV annotations are complete estimation of sample pu-
rity, ploidy, and clonal composition often follow to help dissect Intratumor heterogeneity
(ITH) [15, 16, 24, 25, 31]. Clonal inference characterizes the population structure of tu-
mor clones from next generation sequencing data under the clonal evolutionary model
put forth by Nowell and Boveri [1, 2]. The cellular frequency is a CNV adjusted and
tumor purity corrected measure of allele frequency often used by a range of tools to esti-
mate clonal population structure. Estimating the fraction of tumor cells carrying a given




∗ ρ ∗ ηT + (1− ρ)ηN
ρ
) (2.1)
Where ρ is the fraction of cells in the sample that are tumor derived; r is the number of
reads out of R reads reporting the variant allele; and ηT and ηN are the copy number of
the genome at the base in the tumor and normal genomes, respectively [14].
Most clonal decomposition tools to help resolve clonal structure and accurate detec-
tion of subclonal variants are designed for ultra-deep targeted sequencing. One of the first
methods modeled observed patterns of clonal and subclonal mutations from one deeply
sequenced ER-positive breast tumor using a hierarchical Bayesian Dirichlet process [32].
Newer methods provide clonal population structure inference from multiple deeply se-
quenced samples of the same cancer using hierarchical bayes, or variational bayesian
mixture modeling [15, 16]. Other methods designed for WGS incorporate phylogenetic
tree construction with population structure [31] or improved subpopulation and purity
estimation [33].
A simple measure of diversity is the number of clones in a neoplasm. A metric to
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Here pi is the frequency of clone i in the neoplasm. Shannon’s index or entropywas devel-
oped by Claude Shannon to quantify the uncertainty in strings of text. Since DNA can be
represented as a string we can quantify the uncertainty of predicting the next nucleotide
to appear [34]. The level of uncertainty corresponds with the amount of presumed tumor
heterogeneity.
In chapter 4 we used a metric of diversity from population genetics called Nei’s ge-
netic distance. This was used to assess the mutational similarity among multiple tumors
by taking into account the heterogeneity within similar tumor populations. GBM patient
samples were categorized as (Local, 5-ALA, Multiple Lesion, Longitudinal Local, Longi-
tudinal Distant) depending on the type of lesion. Local sections are multiple biopsies
from adjacent regions within the same tumor, 5-ALA are also locally adjacent regions in
which patients were given 5-aminolevulinic acid (populations of cells stained for tumor
cellularity), multiple lesions are those tumor foci separated by 2 cm. or more, longitudi-
nal local are locally adjacent biopsies from different time points, and finally longitudinal
distal samples are those which have multiple lesions at different times. For each patient
multiple biopsies were sequenced and Nei’s distance was calculated for every possible
sample pair for that patient. Sample pairs from the same patient were plotted by their Nei
distance and grouped according to the same spatial or longitudinal category. Comparison
between categories found significant differences between local and multiple lesions. We
input CCFs for each patient’s sample as follows. Let X = all CCF of sample 1 and Y = all
CCF of sample 2:
D = − log
∑
(xiyi + (1− xi)(1− yi))√∑
(xi2 + (1− xi)2)
∑
(yi2 + (1− yi)2)
(2.3)
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From this metric we were able to compare across categories for statistically significant
differences in intra-tumor heterogeneity (please see chapter 3 for more details).
Tumor Classifications
Breast cancer subtypes were first classified into luminal A, luminal B, HER2-enriched,
triple-negative/basal-like, and normal-like breast using unsupervised clustering of global
gene expression extracted from frozen tissue [35]. The current adoption of a 50 gene set
called PAM50 has defined intrinsic prognostic subtypes from pervasive differences in gene
expression of breast tissue, whereby a risk of relapse score is assessed on relative distance
to the centroid of each subtype. [36, 37].
Primary Liver cancers consist of two major histological types, hepatocellular carcino-
mas (HCC) and intrahepatic cholangiocarcinoma (ICC). HCC represents approximately
90% of all primary cases worldwide. There are several defined subtypes, but no mutation
specific markers exist and subtype definition is based on stemness marker expression.
Established methods for tumor subtype classification of gliomas include histological,
and molecular based assays informed by genetics, epigenetics and transcriptomics. The
first expression classification of GBMused gene signatures in 840 genes that distinguished
4 subtypes: classical, neural, proneural, and mesenchymal [38]. Proposed refinements
driven by new discoveries in cancer genomics and single cell expression are now refining
these classifications to better account for ITH [39, 40]. In our study of GBM recurrence
we found existing TCGA expression based subtypes were not a stable indicator of tumor
subtype between initial and recurrent tumor samplings. Further examination of single
cell expression in multicentric/multifocal GBMs found inconsistencies within individual
cells of the same tumor that agreed with our prior observation in bulk data. Neither
biopsy location nor time of the disease were in agreement between samples (see chapters
3 and 4, respectively). Interestingly, in multiple GBM cases, those with lesions separated
by 1 cm. or more [41] were found more often to contain cells that were a mesenchymal
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subtype implying that these highly heterogeneous tumors tended to be more aggressive
than solitary lesions.
The 2016World Health Organization (WHO) established histological classifications to
help distinguish low (LGG) and high grade (GBM) gliomas. Molecular markers were also
included to further divide LGG based on mutational status of isocitrate dehydrogenase
(IDH) to classify CpG methylation phenotype (G-CIMP) and Non G-CIMP. Co-deletion of
chromosomes 1p and 19q (1p/19q) further divides LGG into oligodenrogliomas and astro-
cytomas. Oligodendrogliomas have a concurrent loss of 1p/19q and diffuse astrocytomas
have an intact 1p/19q, but harbor mutations in ATRX and TP53 [42]. IDH1 is also an
indicator for progression free survival in GBM and in diffuse and anaplastic astocytomas
[43]. GBMs can be separated into secondary GBMs mutant for IDH1, into Primary/De-
novo GBM with IDH1 wildtype, and GBM NOS a diagnosis reserved for tumors without
full IDH evaluation [44].
Patterns of Mutation
In mitotic cells a baseline mutational rate can be measured. In cancer cells there is often
accelerated mutational rates as a consequence of intrinsic pressures such as DNA damage
repair and oxidative stress, or due to extrinsic mutational pressures, for example exposure
to toxins or ultraviolet light. A pan cancer analysis of 30 different tumors identified 21
specific signatures of mutation, each governed by a mutational process that may include
DNA damage or DNA maintenance mechanisms [45].
In GBM Stupp therapy is the standard of care ([46]) and calls for surgical resection and
daily radiation accompaniedwith adjuvent chemotherapeutic agent temozolomide (TMZ).
Our study of therapy treated GBMs in chapter 3 has shown pressure from therapy in post
treatment hypermutated tumors resemble a previously identified mutational signature
enriched in T>C transitions, called signature 11 [45] (Fig. 2.1). This mutational signatures
relates to the standard of care for glioma patients and can be found in patients diagnosed
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Fig. 2.1: Mutational Signature of Alkylating Agents
Also known as signature 11, this signature was shown in associationwith patient histories
between treatments with the alkylating agent temozolomide. Mutations exhibit a strong
transcriptional strand-bias for C>T substitutions that originate on guanine nucleotide.
Such mutations are repaired by transcription-coupled nucleotide excision repair. (Image
with permission from: https://cancer.sanger.ac.uk/cosmic/signatures)
as low or high-grade [47, 48]. TMZ is an orally administered chemotherapy that increases
overall survival from 12.1 to 14.6 months. It is able to penetrate the blood–brain barrier
and prevent DNA replication by alkyl group-mediated crosslinking of DNA [49]. This
creates DNA lesions when a mutagenic product of TMZ called O6-methylguanine (O6-
meG) is formed by alkylation of the oxygen atom of Guanine. When unrepaired by AGT,
the protein encoded by MGMT, these lesions can then be copied by DNA polymerase
and pair with either the correct Cytosine nucleotide or an incorrect Thymine. In the
later case, a C:G → T:A mutation will be generated and recognizable by the mismatch
repair pathway (MMR) [50]. A functioning MMR pathway leaves the O6-meG unrepaired
and instead introduces single stranded breaks that are converted to potentially apoptotic
double stranded breaks at replication forks [51].
In cancers such as melanoma and GBM hypermutated tumors accrue thousands of
de-novo DNA mutations [45, 48, 52, 53]. Within our GBM cohort 17% (17/100) of patients
relapse with hypermutated genomes. Hypermutated tumors appear to be a consequence
of MMR pathwaymutations as an evolutionary response to confer resistance to alkylating
agents such as TMZ. Our data shows that concurrent mismatch repair (MMR) associated
proteins were mutated post treatment in all hypermutated cases (see chapter 3).
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2.2 Gradualism
Step-wise evolution is characterized by discrete steps over timemarked by relatively small
genomic changes that do not destabilize the DNA structure [12].
The seminal work by Fearon and Vogelstein on clonal expansion during colorectal
tumor formation found distinct predictable paths of progression based on DNA muta-
tions. Their work has shown that various stages in colorectal tumorigenesis contain
mutations in all or virtually all neoplastic cells. These clonally represented alterations
provided evidence that it was the alterations themselves that provided growth advantage
to the tumor cells, allowing these cells to outgrow other neoplastic cells of the tumor
[54]. Their model for the genetic basis of colorectal neoplasia has shown most colorectal
carcinomas arise from ademomas that gradually progress through presumably successive
waves of clonal expansion, concordant with Nowell’s model based on the hypothesis of
Boveri. This model depicts a progression of colorectal neoplasia over a period measured
in decades. There are three distinct stages of adenoma formation that lead to carcinomas:
loss of APC, mutation of KRAS and loss of TP53 (Fig. 2.2) A preferred order for colorectal
tumorigenesis exists, although exceptions were noted. Their conclusion was that the pro-
gressive accumulation of these alterations are the ”most consistent feature of the clinical
and histopathological progression of colorectal tumors”. These biomakers provide infor-
mative and potentially actionable data in determining not only the advanced stage that































Fig. 2.2: A Genetic Model for Colorectal Tumorigenesis
Adapted from Figure 3 [54]
Linear Evolution
A linear evolution model posits a gradual step-wise clonal evolution. Driver mutations
confer selective advantage such that the most advanced and aggressive clones will out-
grow all other competing clones to overtake the population. This process resembles a
selective sweep in which beneficial mutations reach fixation due to strong positive nat-
ural selection. The pattern of mutation arising from linear evolution is straightforward
and the model is conceptually simple to understand. Very few studies report linear evo-
lution as it does not reflect the nature of clonal growth in most tumors [55]. The model
of colorectal tumor carcinogensis is a classic example of linear evolution. Experimen-
tal evidence from assaying individual genes agrees with this hypothesis, however more





















Fig. 2.3: Linear model of tumor growth
A linear evolution in which new clones incur mutation to become proliferative. Colors
indicate different clones.
Branching Evolution
Following the ideas of Nowell and the study of colorectal carcinogenesis a cell endowed
with advantageous features will continue to expand and produce progeny that will even-
tually outgrow other cells. These clonal advantages are a result of natural selection, in-
fluenced by time and space as different requirements may be present in differing regions
of the tumor. As mutations are acquired two possibilities are presented, either the less
fit subclones lose out to the dominating clone or they are maintained and contribute to
the tumor’s milieu. Maintained subclones contribute as distinct branches within the phy-
logenetic tree that can create new potential for evolution. Such a branching model of






















Fig. 2.4: Branching model of tumor growth
A branchingmodel of evolution in which newmutations produce new clones that co-exist
and grow in parallel with existing clones. Colors indicate different clones.
Mutational patterns of branching evolution characterized by next generation sequenc-
ing have described numerous subclonal driver and passenger mutations that permeate the
tumor. Studies have detailed frequent driver mutations occur as clonal in one cancer and
subclonal in others. Subclonal mutations in the gene PIK3CA are commonly found in
solid tumors such as breast [56], colorectal [57] ,brain metastases [58], and clear cell renal
carcinomas [59]. In our studies of GBM we observed PIK3CA to be an early clonal alter-
ation in primary and recurrent Glioblastomas (chapters 3 and 4). Clonal and subclonal
mixtures of TP53 mutations have been reported and while some were clonal in human
non-small cell lung cancer [60, 61] or tended to be earlier events in Glioblastomas [62]
others tumors such as CLL [63] harbored later TP53 events. We will detail several studies
in branching evolution and ITH.
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Single Sample
Dissection of ITH from a single sample provides unique challenges as one cannot compare
multiple time or spatial positions in which to infer evolution. To reconstruct the genomic
history of 21 breast tumors Nik-Zainal et al [14] began by deeply sequencing 1 ER-positive,
HER2-positive sample to 188-fold depth. Careful analysis of somatic mutations from a sin-
gle time point revealed evidence of varying subclonal populations. Simple observations
from variant allele frequencies presented evidence for distinct tumor clones acquired at
different times during tumor growth. Specific chromosomal copy number events such as
1q trisomomywere found clonally represented in all cancer cells. Accompaniedmutations
at the third arm of 1q naturally revealed reduced variant allele frequencies to earlier clonal
alterations on chromosome 13, which were estimated to be later subclonally deleted. The
fidelity of variant analysis owed to the depth of sequencing yielded key insights into tu-
mor evolution and new algorithms to cluster variant allele frequenciest (VAFS) and infer
subclones. Their data supported an idea that a significant amount of time is spent driv-
ing subclonal evolution and that a most recent common ancestor (MRCA) appeared quite
early in molecular time.
Longitudinal
Deep sequencing has brought to light subclonal representation and polyclonal origin in
Acute Myeloid Leukemias (AML). Griifith et al [17] performed sequencing that covered
up to 312x whole exome and 433x whole genome coverage in matched normal, primary
and relapse samples of AML. They identified 38 putative relapse specific variants where
the VAF in the primary was 0.23%. Using amplicon sequencing and digital droplet PCR
they discovered all of these variants existed in the initial sample. A selection of 11 sub-
clonal variants sequenced from 7 distinct time points revealed nearly lost mutations (only
detectable with deep sequencing) later returned to detectable frequencies at relapse. Their
study corroborated the necessity of deep sequencing to accurately infer tumor cell popu-
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lations from bulk genomic data. Through systematic evaluation of sequencing depth the
author’s determined coverage of at least 500x was necessary to reliably assign the major-
ity of variants to the correct subclone. A secondary conclusion was that in addition to
deep sequencing for proper variant identification several different somatic variant callers
(7 in their study) employing rounds of filters were obligatory to define a final ”platinum”
quality list of variants.
Differences in mutational composition of the initial and recurrent disease are known
to play a role in treatment failure [48]. In low grade gliomas (LGG) 43% of cases in a study
of 23 sequenced exomes in matched initial and recurrent tumors found that at least half
of the mutations detected in the initial tumor were not found at recurrence. This included
putative driver mutations in TP53, ATRX, and others. Genomic alterations in recurrence
tumors found to be distinct from those in the diagnosis suggest that the recurrent tumor
clones might have diverged at a very early stage of their evolution. This pattern of exclu-
sive mutations was seen most in 6 of 10 patients treated with the chemotherapeutic drug
temozolomide (TMZ) and then later progressed to secondary GBM.
In an analysis of whole exome samples in 114 GBM patients, 96 obtained in triplicate
(normal, initial, and recurrence) at pre and post treatment stage we revealed extensive
subclonal mutations resulting in highly branched evolutionary patterns. When we ex-
cluded hypermutated patients we found that only 45% of mutations were shared by ini-
tial and recurrence tumors. Our observations led us to develop a simple monophyletic
model of branching evolution to describe clonal mutations at diagnosis that were later
lost in recurrence. One potential conclusion was that in > 50% of tumors the dominant
clone presented at the initial stage was not a direct ancestor of the dominate clone at re-
lapse. In addition to DNA mutations high ITH appeared to influence subtype expression
classification. Longitudinal analysis permitted observations of expression based subtype
switching from one class to another in initial to relapse samples of the same patient in
67% of GBM cases. In addition to expression subtype switching we searched for and found
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clonal switching of DNA mutations. This phenomenon in which a putative clonal muta-
tion presented at diagnosis was later replaced by another mutation in that same gene at
recurrence was seen in 7 GBM drivers, including PDGFRA, EGFR and TP53. See chapter
3 for more details.
Multisector
Heterogeneity within tumors profiled from multisector sampling revealed that putative
clonal mutations were detected in only some sectors and completely absent from others.
Such mutations thought to be clonal, perhaps potential therapeutic targets were discov-
ered to be subclonal alterations only after examination of multiple biopsies. In other
cancers stochastic factors such as neutral drift can limit these models but our knowledge
of these processes is still relatively rudimentary [64]. Multi-sector sampling therefore has
a valid role in determining the presence of driver mutations and overall mutational load
of the tumor.
In pancreatic tumor data generated by whole exome sequencing of initial carcino-
gensis to metastasis there was seen no difference in mutational load nor spectrum of
mutations among the two time points. The extent to which subclonal mutations accu-
mulate and contribute to metastatic progression was a fundamental question. Multiple
additional samples were obtained from metastatic lesions and further characterization of
mutations found those mutations that exist in all samples are founder or truncal muta-
tions and progressor or subclonal alterations were those found in only one sample [65].
Founder mutations were mostly represented by activation of KRAS and by inactivating
mutations consistent with the pancreatic model of carcinogenesis [66]. Those lesions in
metastases contained subclonal mutations that appeared to be clonally related but not
found in the primary. This suggested the ancestral clones of metastasis were genetically
distinct from the parental clones due to subclonal diversification. The author’s concluded
that the primary carcinomas are mixtures of numerous subclones. Each subclone then
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independently expanded to constitute a larger population of cells, some of which may
have greater potential to seed distant metastases [65].
Studies of tumors without prior models of growth have been performed in breast can-
cers. Whole genome and targeted sequencing averaging 166x from 12 patient primary
breast tumors were assessed for spatial distribution of subclones [56]. Of these, 8 demon-
strated significant heterogeneity of point mutations within differing regions of the tumor,
and in patient lymph node metastatic lesions. Some mutations were erroneously identi-
fied as clonal when considering only one section, but correctly labeled as subclonal from
multiple biopsies. The author’s indicated that geographical expansion was the predomi-
nate pattern of heterogeneity in these tumors, but that they also found significant inter-
mingling of subclonal mutations across differing sections within a few samples. This is
characteristic of other tumors in follicular lymphoma and colerectal cancer where there
is an absence of selective sweeps, uniformly high subclonal composition and mixing in
distant regions of tumor glands described as a ”Big Bang” model of colorectal growth [67].
Surprisingly, these analyses also discovered separate foci in multifocal cancer that were
clonally related and contained private clonal alterations with very high allelic fractions
within many individual foci.
Our work own study in Intratumor heterogeneity demonstrated spatially separated
tumor fragments from the same tumor mass analyzed from whole exome data in 52 indi-
viduals shared many of the same genomic and expression signatures. We discovered that
cancer cell frequencies of both clonal and subclonal alterations were more similar across
locally adjacent resected regions than in geographically separated or long-term recur-
rence samples. Using Nei’s genetic distance, a widely used metric of genetic diversity in
population genetics, distances between every tumor pair were calculated and compared
to other regions. This indicated multiple lesions and long-term tumors appeared to con-
tain much greater ITH in comparison to local samples. Representative MRI images of the
lesions analyzed can be found in Fig. 2.5. For further details about the study please see
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chapter 4.
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Fig. 2.5: Spatial MRIs of Glioblastoma
Magnetic Resonance Imaging of spatially distinguishable glioblastoma lesions A. Solitary
Lesion. C. Multicentric GBM, lesions are located apart in different lobes or hemispheres.
D.Multifocal GBM, lesions are retained in same hemisphere. Dissemination or growth of
tumor cells by a preformed route like commissural fibers, cerebrospinal fluid pathway or
by local metastasis
2.3 Saltationism
The rate of a tumor’s mutations may not always be stable, particularly if the growth of the
tumor varies throughout time. Researchers have come to appreciate that a gradual accu-
mulation of genetic ”hits” or mutations might be too simplistic an idea. In 1972 Stephen
Gould and Niles Eldredge offered a new interpretation of geologically and instantaneous
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origination and subsequent stability of palaeontological ’morphospecies’ called ”Punc-
tated Equilibrium’. It was often called phyletic gradualism and challenged Darwin’s long
standing theory of gradual evolution [68]. Studies in karyotype experiments have found
genome level stochastic events that promote cancer cells may also accumulate mutations
in punctated phases of evolution. These phases are precipitated by bursts of copy num-
ber alterations such as kataegis; a localized hypermutation pattern, or chromothrypsis;
characterized by multiple clustered genetic rearrangements and deletions affecting one
or a few chromomes. Such genome instability results in large heterogeneity among cells.
Although Charles Darwin was aware of macro-mutations or saltations his ideas were
based on the concept ”That natural selection will always act with extreme slowness..and
variation is apparently always a very slow process”.
Malhotra et al. investigated complex genomic rearrangements by mapping somatic
structural variation breakpoints in 64 cancer genomes from 7 tumor types. While most
structural variations can be canonically categorized, i.e. deletions, duplications, inser-
tions, inversions, translocations, some are extraordinarily complex mixtures of these
types. From those analyzed it was found GBM had a significantly higher number of com-
plex genomic rearrangements than any other tumor. Their analysis found more than 50%
of complex genomic rearrangements were one-off mutations [69].
In prostate cancer 57 tumor/normal matched (55 treatment naive) whole genomes re-
vealed collections of broken DNA ends that appeared to be shuffled and ligated to one
another. This aberrant process described as a “chain” in which two rearrangement break-
points map to the reference genome near breakpoints. Regions of complex rearrangement
harbored cancer associated genes such as PTEN, RB1, and FOXO1. The author’s termed
this distinct class of genomic restructuring ”chromoplexy” [70]. With additional clon-
ality analysis of mutations the author’s observed clonal deletions in FOXP1 and NXK3
along with mutation of FOXA1 implying these are early events. Deletions in PTEN were
always subclonal often indicating a later event, and one the author’s believed promoted
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early tumor progression. Then in 2018 researchers uncovered an evolutionary adaptation
to therapy upon inspection of metastatic castration resistant prostate cancers (mCRPC).
Their comparison to the previous pre-treatment samples discovered 71% of resistant tu-
mors were highly enriched in DNA amplification of the Androgen Recceptor (AR) gene
or in recurrent tandem duplications of an upstream enhancer of AR [71]. Despite the
large chromosomal alterations that conspired to amplify the AR locus region the author’s
suggest that post-treatment amplifications appeared in a step-wise manner to enable a
transition to castration-resistance. Although there is no foolproof method to distinguish
between complex and step-wise rearrangments, this may demonstrate that both types
help to drive progression and resistance in prostate cancer.
Finally, in a study of single-nucleus sequencing of 1,000 cancer cells from 12 triple-
negative breast cancers Gao et al. clustered single cell copy number profiles. He dis-
covered between 1 and 3 major clonal sub populations in each tumor shared a common
progenitor. The major events separating these populations were related to copy-number
alterations that accumulated in short punctuated bursts. The data led to a hypothesis that
these chromosomal bursts occurred very early in tumor evolution prior to stable clonal
expansions [72].
Saltations continues to fundamentally challenge that the only notion of mutational
changes in clonal evolution of tumors are gradual.
2.4 Mutational Ordering
Theodosius Dobzhansky in 1973 wrote ”There are no alternatives to evolution as history
that can withstand critical examination” in an essay titled Nothing in biology makes sense
except in the light of evolution. Fearon and Vogelstein’s model of colorectal tumor forma-
tion demonstrated an evolutionary preferred order of mutations; loss or mutation of APC,
mutation of KRAS and loss of TP53. Although, an ordering of mutations is not immutable
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in colorectal tumor formation it was one of the first tumors observed to be shaped by
genetic alterations in a clear step-wise order.
Patients with myeloproliferative disorders were screened for a specific Janus Kinase
2 (JAK2) V617F mutation and Tet Methylcytosine Dioxygenase 2 (TET2). These two mu-
tations were found to influence clinical features, clonal evolution, and therapy response.
Specifically, the order of mutations was seen to affect proliferation of a certain JAK2 mu-
tant and the capacity of double-mutants to form colony forming cells. When a TET2
mutation was acquired first the transcriptional landscape was altered by preventing JAK2
mutant from up-regulating genes associatedwith proliferation. Acquisition of a JAK2mu-
tation on a TET2-nonmutant background enhanced proliferation of hematopoietic stem
and progenitor cells. Clinically, patients with earlier JAK2 mutations had a greater like-
lihood of presenting with polycythemia vera than with essential thrombocythemia, an
increased risk of thrombosis, and an increased sensitivity of JAK2-mutant progenitors to
ruxolitinib in vitro [73].
Pancreatic cancer can be described with a well defined model of tumor progression.
Pre-cursor lesions called intraepithelial neoplasias (PanINs) define the initiation of pan-
creatic carcinogenesis. Early phase or PanIN-1 includes telomere shortening and activa-
tion mutations in KRAS. An intermediate phase called PanIN-2 involves inactivating or
epigenetic silencing mutations in p16/CDKN2A involved in cell-cycle regulation, and late
stage in PanIN-3 includes inactivation of tumor suppressor TP53 to abrogate DNA dam-
age control and SMAD4 involved in TGF-β signaling [65, 66]. These genetic hits represent
3 core pathways in pancreatic tumor initiation.
Similarly to the colorectal model of carcinogensis pancreatic tumors are shaped by
successive waves of tumor heterogeneity that accumulate over time from parental clones.
A second wave assumes clones arrise from pre-existant populations of cancer stem cells
that continuously give rise to new populations. While either model is supported, it was
noted that cells that undergo epithelial to mesenchymal transition can generate stem-cell
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like qualities, giving the illusion of a stem-cell population. In either case a computational
model was designed to address whether poor prognosis relates to late diagnosis or to early
metastasis. The model incorporated number of somatic alterations, driver vs passenger,
founder vs progressor, and relative proportion of cells during progression periods. Their
model estimated an overall time of 22 years from initiation to death; 12 years was the
average approximate time from the initiating event and then another 7 years to devel-
opment of metastatic subclones and an average of 3 years until death from the disease
[65].
In our studies of GBM we analyzed the evolutionary trajectories of 93 pre-/post-
treatment biopsies using a tumor evolutionary directed graph [74]. While a definitive
order of mutations was not found general patterns emerged indicating an order of mu-
tations according to the relative times between biopsy samplings. Gene mutations found
in IDH1, PIK3CA, and ATRX were frequently found to be in common to the initial and
relapse samples and labeled as earlier events. Such mutations were also inferred to have
larger cellular frequencies indicating clonal alterations had, naturally persisted through-
out the generations and are very likely glioma driver mutations. Later events found ex-
clusively in relapse samples included nucleotide mutations in the genes EGFR, MSH6 and
LTBP4 (Fig. 3.4D). For more details, see chapter 3
2.5 Clonal evolution or Cancer Stem Cells
Although much controversy exists around the cancer stem cell (CSC) hypothesis there is
evidence of a hierarchically structured cell lineage that can sustain long term tumor clonal
maintenance by a self-renewing subpopulation of cells [75]. The last decade has provided
proof that heterogeneous pools of stem cell populations encompassing different cell types
can be found in many tissues. Historical evidence for cancer stem cells began with studies
in human acute myeloid leukemia and was extended to carcinomas. It suggested that tu-
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mor cells were differentiated in much the same manner as embryological or normal tissue
development. Tumor tissues were considered caricatures of normal ones that retain many
of the same architectural features present in the complex three-dimensional structures of
their parent tissues [76].
The CSC hypothesis extends these observations to ask if tumors also contain patho-
logical stem cell populations that sustain their long-term growth? This implies only a
minority population of stem cells are endowed with self-renewal potential, have also ac-
quired tumor-related features such as uncontrolled cell growth, and can differentiate into
phenotypically diverse and atypical progeny [76]. The identification and study of most
CSCs follows a similar experimental outline. Cell marker or markers are identified from
heterogeneous population expression in a tumor of interest. Cell types are then sorted and
transplanted into immunodeficent mice. Such studies in mice have revealed that multiple
stem and progenitor cells have the capacity to generate tumors [77].
Transplantation is a required definitive functional assay [78]. For brain tumors this
requires inter-cranial transplantation that recapitulates the cellular heterogeneity present
in the parent tumor [77]. Putative brain tumor stem cells often called glioma stem cells,
in the case of GBM, have shown the ability to grow as spheres where they can then be
evaluated for self-renewal and differentiation at the single-cell level [79]. Though CSCs
possess the ability to grow as spheres not all neurospheres grow from stem cells. A neuro-
sphere assay alone cannot identify stem cells, instead it can be used to evaluate the cell’s
potential to behave as a stem cell in external conditions [77, 79].
CSCs have been identified in gliomas and many other cancers. In GBM CSCs were
shown to contribute to propagation and therapy resistance [80, 81]. Markers of glioma
CSCs including SOX2, OCT4, OLIG2, MYC, NESTIN, have been linked to tumor propagat-
ing cells but are also associated with neural stem and progenitor cells [77, 81]. Discerning
accurate markers of stemness are essential and ongoing.
The original CSC model assumed a one directional hierarchy such that only CSCs can
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generate the bulk of tumor via symmetric or asymmetric division. Accumulating evi-
dence accounts for a CSC plasticity model that permits dynamic ability of bidirectional
conversion from a non-CSC state to a CSC state and vice versa. This model presumes both
stemness and plasticity are determined by intrinsic and extrinsic cues. As a consequence
non-CSCs can serve as reservoir to create CSC populations throughout tumorigenesis
[82]. A hierarchically structured cell lineage conjures images of a root or progenitor that
gives rise to subsequent populations of cells. A more recent experiment in intestinal tu-
mors challenged this notion by showing multiple functionally distinct CSC populations
cooperate in progression of human colorectal carcinogensis. This study provided evi-
dence for differing phenotypes that work in equilibrium, but are restricted, perhaps due
to micro-environmental factors from fully rescuing metastatic behavior [76, 83].
With the CSC hypothesis tumors may mirror the phenotypic architecture of the tissue
even though some cancer cells are genetically identical. This can occur if cells occupy
different positions within the differentiation hierarchy [77, 78]. Genotypic heterogeneity
could also be described and the possibility of multiple cancer stem clones sharing a single
clone of origin is a possibility. There are misconceptions about CSCs that indirectly lead
to disagreements about the CSC hypothesis. In fact, one misconception is that CSCs are
generated from normal stem cells. CSCs may or may not be generated from stem cells.
Progenitor cells which generally represent the largest population of proliferative pool in
the organ may acquire the ability to self-renew [78, 84].
It is thought that CSCs provide advantages to tumor propagation by residing in niches
where they are difficult to target and often quiescent. Dormancy is believed to be an
attribute of stem cells and may complicate therapies as these CSCs can maintain genetic
code for longer periods than their progeny [78]. Resistance to chemotherapy and targeted
inhibitors could be a fundamental characteristic of these cells and may explain recurrence
and metastasis after long periods of remission.
Clonal evolution proposes continued adaptations endow advantages in some cells via
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natural selection [2, 3]. Both clonal evolution and CSC hypothesis presume tumors orig-
inate from a single progenitor cell that has gained proliferative advantage through ac-
quired mutations [78] . Although there is no denying that cancer cells are immortal at
the population level and they share common features with proposed cancer stem cells
the obvious dissimilarities between Nowell’s hypothesis of clonal evolution and the CSC
hypothesis show these models are conceptually very different. The debate over the CSC
hypothesis will likely continue.
2.6 Single Cell
The nature of tumor heterogeneity includes a complex ecosystem of malignant cells, en-
dothelial cells, infiltrating immune cells, tumor vasculature, and a complex network that
includes the extracellular matrix (ECM). This influences the complex spatial organization
and temporal heterogeneity of the tumor microenvironment [82, 85].
Current approaches focused on single DNA sequencing of tumors isolate individual
cells, perform whole genome amplification and then compare genomic profiles. Single
cell profiling has the potential to offer full clonal composition, but issues in technical bias
and cost have limited its use.
Single cell copy number profiles in triple negative breast cancer and resulting liver
metastasis revealed punctated evolution and three distinct clonal populations. Lack of
private primary mutations indicated that the liver metastasis sample emerged from the
primary population [86]. To study this more carefully a follow-up study sequenced triple
negative breast cancers with single cell exome and ultra deep bulk data for validation.
Similar to the first study early chromosomal abnormalities were found. Ultra deep data
validated extensive clonal diversity and large numbers of subclonal variants. Data from
single cell whole exome sequencing did not find evidence of two single cells with the
same genotype. These observations led to a hypothesis that two evolutionary models
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were at play. The first model of punctated evolution gave early rise to massive chromo-
somal alterations that stabilized the tumor mass. This was followed by single nucleotide
mutations following a gradual evolution [87]. These observations of distinct clonal pop-
ulations that led to the hypothesis of two evolutionary models were possible only with
single cell sequencing.
A flood of single cell expression studies have revealed cell heterogeneity in many or-
ganisms and biological systems. A single cell transcriptional study of melanoma hetero-
geneity was used to classify malignant and non-malignant cells by hierarchical clustering
of each cell’s gene expression. Clusters of non-malignant cells revealed the presence of
immune and endothelial cells. Cell cycle states were inferred and principal component
analysis identified transcriptional programs associated to intrinsic resistance to RAF and
MEK inhibition. Both melanomas and cell lines treated with RAF and MEK inhibitors
validated the group’s findings that a drug-resistant population existed prior to treatment
[Tirosh2016b].
Cancer studies in GBM from Patel et al. [40] compared single cell GBM expression
profiles in five different tumors. Their results revealed intra-tumor heterogeneity identi-
fied through clustering expression by genomic location. Clustering distinguished char-
acteristic GBM amplifications and deletion events in transformed cells while singling out
a putative subpopulation of non-tumor cells. Comparison of single cell profiles to the
established TCGA classification scheme in GBM were shown to capture ”hybrid” states
in which a single cell scored highly for two subtypes. Grouping of single cells by low,
medium, and high heterogenous expression subtype suggested that a greater proportion
of cells with alternate subtypes was associated with decreased survival.
Within our GBM cohort we characterized the heterogeneity of expression profiles
using single cell RNA-Seq of seven different samples from three patients. Overall,
expression-based cell subtypes were not clearly determined by location or time (Fig. 4.3),
consistent with the study mentioned [40]. To make sure this observation was not due to
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the limitations of this classification and to capture the transcriptional similarity among
different cells, we used topological data analysis to summarize and reduce the dimen-
sionality of large data sets while retaining local high dimensional structure [88], [89]. We
found in bulk whole exome sequencing (WES) and confirmed using ultra-deep sequencing
and single-cell analysis that cells from the recurrent tumor shared genomic and expres-
sion features with the left initial tumor cells (Fig. 4.3b). Our analysis also revealed the
presence of transcriptional heterogeneity within the individual samples. A subset of left-
initial tumor cells was characterized by upregulation of mitotic genes not found in either
right or recurrent sections (Fig. 4.3d).
Ultimately, tumor evolution occurs at the single-cell level, and single-cell methods
provide a powerful approach to assess tumor heterogeneity without the confounding ef-
fects of mixed cell populations. As this technology matures the analyses and insights into
tumor evolution and drug resistance will advance forward to answer pressing questions
and bring to light many new ones.
2.7 Precision Medicine
Decades of mutational discovery has led to breakthroughs in cancer treatment, but ac-
curate prediction for individual patients remains a formidable challenge [64]. Cancers of
the same type differ genomically so that no two individuals are thought to have the exact
same somatic mutational profile [22, 64]. Advancements in treatment and proper cancer
diagnosis may regularly include genomic sampling of DNA for tumor-associated alterna-
tions. Well-documented tumor alterations have lead to improved treatment by identifying
patient subpopulations that benefit from specific therapeutics. Endocrine therapy is the
most common approach to treat Estrogen Receptor positive breast cancer and has shown
5 year survival rates in stage III and below are nearly 70% [90]. Targeted therapy of
metastatic melanoma in patients that harbor BRAF(V600E) mutations and receive BRAF
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inhibitor treatment have shown remarkable responses [91]. The effectiveness of these
treatments varies and in many patients resistance develops.
It is known that ITH contributes to overall tumor fitness, progression, and is a key
factor to therapeutic failure [61, 92–94]. Therapy resistance is a leading cause of cancer
mortality and may emerge due to two general mechanisms. Intrinsic resistance considers
both the body’s ability to efficiently clear chemotherapeutic drugs as well the fate of drugs
interacting within the body [95]. Extrinsic resistance mechanisms allow cancer cells to
evolve selective genetic and/or epigenetic alterations and facilitates treatment escape [12].
Tumors with a large amount of heterogeneity may create evolutionary avenues of
resistance. Those alterations that are found in every cell may expose a potential weak-
ness for targeted inhibitors. For example, Glioma-CpG Island Methylator Phenotype or
(G-CIMP) tumors belong to the Proneural subgroup, have a diagnosis generally more fa-
vorable to non-GCIMP and can be identified by mutated IDH1 gene [96, 97]. Efforts to
target IDH1 gene mutations may appear attractive as these are most likely inaugural al-
terations found in 80% of low grade gliomas, chondrosarcoma (60%), cholangiocarcinoma
(20%), and in about 10% of acute myeloid leukemias (AML) [98].
Relapsed AML patients have shown promising results with an IDH1/2 inhibitor called
Enasidenib, where 19% attained complete remission and an overall response rate of 40%
[99]. It was shown that unlike glioma, IDH1/2 mutated patients with relapsed AML [100]
and chondrosarcoma [101] are not associated with prolonged patient survival. Although
clinical trials in glioma are still underway, prior evidence of improved outcome with IDH1
mutation and additional evidence that IDH1/2 mutated cells are sensitized to radio and
chemotherapy suggest current strategies to target this mutation could have mixed results.
We recently isolated 28 patient derived cell lines (PDCs) from 11 Glioblastoma indi-
viduals and screened 40 different cancer-related compounds. In a subclonality analysis
calculated frommultiple biopsies we found that an association existed with heterogeneity
and treatment response correlation (P=0.02). Multiple GBM samples that harbored clonal
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mutations in PIK3CA were found to be more responsive to PI3K-AKT-mTOR (PAM) path-
way inhibitors than PDCs from solitary tumors (P=1.87 * 10−6). One multicentric patient
GBM9 displayed highly heterogeneous drug responses. PDCs from the right side tumor
harbored an EGFR mutation and were sensitive to targeted EGFR inhibitors, but not sen-
sitive to MEK inhibitors. PDCs from the left side tumor harbored a clonal NF1 mutation
and were sensitive to MEK inhibitors but not to EGFR inhibitors. The PAM inhibitor that
targeted PI3K was effective in PDCs from both regions of the brain. Targeting of sub-
clonal alterations showed limited effect compared to targeting of the truncal mutation
(for details see chapter 4).
Some mutations are founding events, present in all clones and may represent bet-
ter targets for therapies. However, most mutations are recent events present in a sec-
tion of the tumor that may confer future therapy resistance. A gene fusion of BCR-ABL
known as the Philadelphia chromosome is found in most patients with chronic myeloid
leukemias (CML). An initial treatment of a tyrosine kinase inhibitor, imatinib yields a fa-
vorable response rate of 98%, however there is increasing evidence of acquired resistance.
Recurrence of CML is now linked to a minority population of mutational subclones that
harbor BCR-ABL1 kinase domain mutations, the essential target of imatinib [20]. Fur-
ther progression from CML to ALL blast crisis is also attributed to subclones that carry
a deletion of CDKN2A in addition to the BCR-AL1 mutations [78]. In EGFR mutant lung
cancers, a subclonal MET amplification was able to activate ERBB3/PI3K/AKT signaling.
This activated signaling caused resistance to EGFR kinase inhibitors both in vitro and in-
vivo[102]. In relapsed acute lymphoblastic leukaemia (ALL) a gain of function mutation
in the gene NT5C2(R367Q) is associated with resistance to chemotherapy. Ultra-deep se-
quencing experiments of 14 diagnostic DNA samples failed to detect NT5C2 mutations at
initial presentation, but did find acquired mutation of NT5C2 at relapse. In one patient
in complete remission an NT5C2 mutation was detected 37 days prior to clinical relapse.
The sensitivity of their assay (0.005%) was above the signal threshold to reliably detect
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the variant at diagnosis (0.00064%)[103].
Increasing evidence shows that for some tumors’ subclonal mutations may confer fu-
ture targets for therapy. Immune-mediated defense of cancer underlies immunotherapeu-
tic approaches. New antigens (neoantigens) arise as a consequence of the tumor’s somatic
mutations and are now being considered a possible vulnerability. Studies in melanoma
and non-small cell lung cancer, known to have particularly large somatic mutation bur-
den, have shown clinical benefit to boosting the immune system’s natural defenses [52,
104]. Immune checkpoint inhibitors unleash a patient’s own T cells to attack tumors.
Agents such as pembrolizumab an anti-PDL1 showed clinical benefit in non-small cell
lung cancer patients with higher nonsynonymous mutational burden [104]. In melanoma
anti CTLA-4 therapy was able to prolong overall survival in patients. A high mutational
load was correlated with sustained clinical benefit, but was not sufficient as some patients
having tumors with high mutational load did not respond to therapy [52].
Chimeric antigen receptors (CARs) are a patient’s own genetically modified T-cells to
express an artificial T-cell receptor. CAR-T cell therapy was used successfully in adult pa-
tients with B-cell acute lymphoblastic leukemia (B-ALL). Long term survival of patients
with B-ALL depends on a patient receiving complete remission status through salvage
chemotherapy and allogeneic hematopoietic stem cell transplantation (Allo-SCT). Five
patients were administered CAR modified T-cells targeted to CD19 antigen. A CD19 anti-
gen is expressed on normal B-cells and in most B-cell malignancies. After CAR-T therapy
all five patients showed complete remission status with no evidence of minimal residual
disease and 4 went on to receive Allo-SCT [105].
In CLL it was proposed that treatment benefits highly fit subclones [92]. Identification
of two general patterns of clonal growth emerged in CLL patients monitored at two time
points. One pattern estimated a clonal equilibrium could maintain the relative sizes of
each subclone in untreated samples. The rationale was that more timewas required before
a newer fit clone could outgrow existing dominant clones. In the second, however, one or
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more aggressive subclones could become dominant in treated samples and accelerated to
do so by a ”mass extinction” event following cytotoxic therapy that shifts the evolutionary
landscape [63].
Inherent complexities to improve cancer treatment will need to incorporate knowl-
edge of intertumor and intratumor heterogeneity. Our knowledge of therapy resistance




Clonal Evolution of Glioblastoma under Therapy
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3.1 Introduction
GlioblastomaMultiforme (GBM) is the most common and most aggressive type of pri-
mary brain tumor in adults [106]. Therapeutic options are limited, consisting of surgery
and treatment with radiotherapy plus an oral alkylating agent, temozolomide (TMZ). De-
spite TMZ’s benefits, the extension of patients’ survival averages 2.5 months, and tumors
invariably recur leading to fatal outcome [46]. Recent progress in large-scale sequencing
techniques has revealed the genomic landscape of the untreated tumor [107], [108], yet
very few studies have analyzed recurrent GBM, and patient cohorts are limited in size
[109–111].
The evolution of tumor cells under therapy can be viewed as a Darwinian process of
clonal replacement [2, 32, 112] inwhich treatment ablates vulnerable cells while positively
selecting for resistant clones. Studies of spatially distinct tumor fragments indicate that
Material in this chapter is published wholly or in part in [74]: Jiguang Wang, Emanuela Cazzato, Erik
Ladewig, Veronique Frattini, Daniel I S Rosenbloom, Sakellarios Zairis, Francesco Abate, Zhaoqi Liu, Oliver
Elliott, Yong-Jae Shin, Jin-Ku Lee, In-Hee Lee, Woong-Yang Park, Marica Eoli, Andrew J Blumberg, Anna
Lasorella, Do-Hyun Nam, Gaetano Finocchiaro, Antonio Iavarone and Raul Rabadan (2016)
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treatment failure is frequently complicated by intratumor heterogeneity (ITH), a common
phenomenon in low and high-grade glioma [48, 113–115]. Mutations of TP53 gene were
recently proposed to mark subclonal heterogeneity of GBM [111], but a clear pattern of
tumor evolution remains elusive. ITH and diversity in evolutionary trajectories preclude
the identification of general evolutionary patterns in GBM, especially when only limited
cohorts of patients are available.
To find genetic markers of progression and to elucidate the diverse evolutionary tra-
jectories by which GBM can occur and recur, we performed whole-exome and transcrip-
tome analysis of untreated and recurrent tumors from 114 GBM patients with correspond-
ing matched normal tissue.
3.2 Longitudinal Mutational Landscape of GBM
To elucidate the mechanisms driving the evolution of high-grade glioma under therapy,
we analyzed 293 whole-exomes and 141 transcriptomes from longitudinal tumor/matched
normal samples in 114 GBM patients (Fig. 3.1A). Recurrent GBM patients (89 diagnosed
with primary GBM) were collected from Istituto Neurologico C. Besta (INCB, R001-R019),
MDAnderson Cancer Center (R020-R029),The Cancer Genome Atlas (TCGA, R030-R042),
University of California San Francisco (UCSF, R043-R052), Kyoto University (KU, R053-
R055), and Samsung Medical Center (SMC, R056-R114). Whole-exome triplets of initial
tumor sample, recurrent tumor sample, and normal genomic DNA were sequenced from
93 patients. Transcriptomes of initial and recurrent tumor were sequenced from 65 pa-
tients. All but 14 patients received standard treatment, including TMZ(Stupp et al. 2005).
Greater than 200 fold mean target coverage was achieved in 84% of samples (246 out of
293). On average, 76% of coding bases within the exome were covered by at least 100
high-quality reads.
To identify somatic single nucleotide variants (SNVs) as well as short insertions and
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deletions (INDELs), we utilized the variant-calling software SAVI2 [18]. We included as
somatic variants only those with mutant allele frequency of 5% or more. From these
variants we selected 40 mutations from the INCB cohort for validation. Sanger sequenc-
ing successfully validated 98% (39/40) of the mutational calls as well as changes in allele
frequency between untreated and recurrent tumor (Supplementary Table 2 and Supple-
mentary Data 1). Untreated tumor samples harbor an average of 60 somatic mutations.
Recurrent tumor samples have 585 somatic mutations on average, but this figure is unrep-
resentative due to the presence of 17 patients (6 primary GBM and 11 secondary GBM)
with hypermutated recurrent tumors (>500 mutated genes per tumor). The remaining
non-hypermutated tumors have only 50 mutations on average. All hypermutated tumors
originated within TMZ treated patients. 16 out of 17 hypermutated samples gained muta-
tions in genes coding DNAmismatch repair proteins (MSH6, MSH2, MHS4, MSH5, PMS1,
PMS2, MLH1, and MLH2) (Fig. 3.1B).
We compared mutations found in the initial and recurrent samples for each of the 93
patients for whomwhole-exome triplets were available. Appearance of the samemutation
in both the initial and recurrent samples for a patient suggests that the mutation origi-
nated relatively early in that patient’s tumor development, while appearance only in one
sample suggests that the mutation may have originated after the clonal lineages leading
to the two samples diverged. We discovered that the mutations occurring in only one of a
patient’s two GBM samples outnumber the common ones in more than half of all patients
(57%, 53/93) (Fig. 3.1A) single-sample mutations (red and black) versus common muta-
tions (yellow)). We observed a number of significant associations not previously reported
for GBM that were exclusive to recurrence. These associations include co-occurrence of
MGMT promoter methylation and hypermutation (p-value=4×10-3, Fisher’s exact test,
only TMZ treated patients), co-deletion of RB1 and PTEN (p-value<10-4, Fisher’s exact










































































































































































































































































































































































































































Fig. 3.1: Mutation landscape of recurrent Glioblastoma.
(A) Number of somatic mutations. 114 Patients from six sources (Instituto Neurologico
C. Besta, MD Anderson Cancer Center, The Cancer Genome Atlas, University of Califor-
nia San Francisco, Kyoto University, and SamsungMedical Center). (B) Clinic and genetic
profile of patients. TMZ indicates Temozolomide; MMR represents mismatch repair path-
way (MSH6, MSH2, MSH4, MSH5, PMS1, PMS2, MLH1, MLH3 were considered). Hyper
Mut represents hypermutation. MUT indicates somatic non-synonymous mutations with
allele frequency >5% in at least one sample. AMP/DEL indicates copy number change
with segmentation mean >0.5, computed either by SNP/CGH array data or by whole-
exome sequencing data. TMZ represents Temozolomide. (C) Pyramids plot highlighting
the correlation between different features. Hypergeometric test was performed for each
pair of elements by considering Initial and recurrent tumors separately. The size of the
circle indicates significance level of the correlation. Any associations with p-value < 0.1
were illustrated in this plot. (D) 3-D bubble plot illustrating the mutation frequency of
somatic non-synonymous mutations in exclusively initial (red, left axis), exclusively re-
currence (black, right axis), and in common (yellow, upper axis). 93 patients with exome-
sequencing data in matched normal, initial tumor, and recurrent tumor were considered
in this analysis.
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Overall, our mutational analysis reveals both known and potentially novel driver gene
mutations in GBM. We observed mutations in known drivers of GBM(Frattini et al. 2013)
including TP53, PTEN, EGFR, PIK3CA, ATRX, IDH1, PIK3R1, and PDGFRA with similar
frequency in both untreated and recurrent tumors (Fig. 3.1D). We also identified hotspot
mutations in unreported potential driver genes in GBM. In particular, we found seven pa-
tients with PTPN11 nonsynonymous mutations (SHP2 protein) in the first SH2 and PTP
domains with a similar distribution to what has been found in juvenile myelomonocytic
leukemia(Stieglitz et al. 2015). A few genes appear exclusively mutated and expressed in
recurrent tumors (Fig. 3.1D), including LTBP4 (10/93), DNA mismatch repair gene MutS
Homolog 6, MSH6 (8/93), PRDM2 (10/93) and IGF1R (9/93) (for a complete list see Sup-
plementary Table 2). Interestingly all eight cases with mutations in MSH6 occurred in
hypermutated recurrences (p-value<10-4, Fisher’s exact test), and three of these cases in-
clude nonsense mutations in the gene, indicating that loss of function of MSH6 is related
to genomic hypermutation in GBM. This finding is consistent with previous observations
of the induction of a hypermutant genotype following treatment of glioma [116–119].
Recurrence-only mutated gene LTBP4 has been reported to be an activator of TGF-β sig-
naling by promoting the assembly, secretion and targeting of sites where TGF-β1 is stored
and/or activated [120]. Disruption of this gene causes abnormal lung development, car-
diomyopathy, and colorectal cancer in mouse [121].
To explore copy number variations (CNVs) of initial and recurrent GBM, recurrence-
based analysis, GISTIC2 [122], 3.2 and MutComFocal [123] were applied. We found copy
number alterations in several well-known GBM drivers. EGFR amplification, which is
frequently co-occurrent with EGFR SNVs and EGFRvIII, was observed in 42% of initial
tumors (44/104) and 34% of recurrent tumors (35/102), whereas CDK4 amplification was
detected in 19% of both initial and recurrent samples (20/104). Deletions in CDKN2Awere
the most frequent copy deletion in 47% (49/104) of initial samples and 52% of recurrent
tumors (53/102). PTEN displayed a similar prevalence of loss in initial 37% (38/104) and
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recurrent 34% (35/102) samples. We then defined a zygosity score (ZS) to identify regions
of loss of heterozygosity (LOH) (Methods). The median ZS of a normal diploid chromo-
some is expected to be near to 0.25. To identify potential tumor suppressors associated
to a two-hit mechanism, we analyzed genes with point mutations in regions with LOH
in non-hypermutated recurrent tumors. This analysis recapitulated known tumor sup-
pressors in GBM, including TP53 (14/78 samples), PTEN (9/78), and NF1 (3/78), and LOH
encompassing inactivating mutations in other genes not previously reported in GBM in-
cluding APC (R876*) (Supplementary Table 5).
Known and Novel Gene Fusion events Gene fusions known in initial GBM were
also detected in recurrent GBM using RNA-seq data and included FGFR3-TACC3 [21] and
EGFR fusions with multiple partners [107]. FGFR3-TACC3 fusions were highly expressed
in both the untreated and matched recurrent tumors, thus confirming the clonal nature
of these fusion events [21]. We also found rare fusions involving other Receptor Tyrosine
Kinase (RTK)-coding genes such as PDGFRA, MET and ROS. Interestingly, two patients
harbored in-frame gene fusions involving MGMT at relapse. Patient R114 harbored two
highly expressed in-frame fusions NFYC-MGMT, BTRC-MGMT and patient R056 at re-
currence presents the fusion SAR1A-MGMT. Of particular significance, these three fu-
sion transcripts carry the same breakpoint in the MGMT gene, and the reconstructed
open reading frame preserves the methyl-transferase and DNA binding domain (Supple-
mentary Table 6). The fusion transcripts were further validated by RT-PCR (Methods and
Supplementary Figure 5). MGMT is a gene that encodes for an O6-methylguanine–DNA
methyltransferase and epigenetic silencing of this gene has been associated with longer
overall survival in GBM patients under therapy [124]. Consistently, we observed that
MGMT methylation at diagnosis predicts longer survival (p-value=0.018). We also ob-




Supplementary Figure 1: GISTIC2 qplots of initial (A) and recurrent (B) tumors. Copy 
number segmentation files were generated by EXCAVATOR base on Whole Exome 
Sequencing data. The resulting seg files (genomic intervals), together with the union of 




PDGFRA, KIT, et al.!
BAI1, GLI4, et al.!
IGF2, et al.!
GRB2, RFNG, et al.!
NOTCH1, TRAF2, RXRA, GRIN1, et al.!
CDKN2A, CDKN2B, et al.!
ENO1, RERE, et al.!
PDGFRA, KIT, et al.!
EGFR, et al.!
BAI1, GLI4, et al.!
CDK4, et al.!
CACNA1G, ABCC3, et al.!






GRB2, RFNG, et al.!
APC2, MAP2K2, et al.!















Initial Tumor! Recurrent Tumor!!" #"
Fig. 3.2: CNV profiles in Glioblastoma.
(A) Initial and (B) recurrent tumors. Copy number segmentation files were generated by
EXCAVATOR base on Whole Exome Sequencing data. The resulting seg files (genomic
intervals), together with the union of whole exome probes from different platform were
used in GISTIC version 2.0.22.
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at relapse (p-value=6×10-3 in initial and 0.016 in relapse, Supplementary Figure 6). At
recurrence, but not in the initial tumor, low expression of MGMT is significantly related
to better prognosis (p-value=4×10-4).
Hypermutation Related to Temozolomide As indicated in (Fig. 3.1A), 17% of TMZ
treated GBM patients (17/100) relapsed with hypermutated tumors, yet there is no inci-
dence of hypermutation in non-TMZ treated patients (0/14). The median survival of hy-
permutated IDH1-wild-type primary GBM patients is 24 months, a slight increase from
other IDH1-wild-type primary GBM patients (18 months). The gain of mutations in the
mismatch repair pathway as well as the accompanying hypermutations in glioma patients
after treatment has been reported before(Hunter et al. 2006; Yip et al. 2009; Cahill et al.
2007; Chin et al. 2008) but the pattern of the hypermutated genes and the mechanism
causing the mutations remain unclear. To better explain patient mutational variation, we
grouped all mutations into four types: those identified in recurrent samples without TMZ,
those in untreated tumors, those in TMZ-treated but non-hypermutated cases, and mu-
tations in TMZ-treated hypermutated cases. Hypermutated recurrent tumors are highly
enriched with C>T (G>A) transitions (Fig. 3.3A). To identify additional markers of hyper-
mutation we extracted 10 bp of DNA sequence from the coding strand of hypermutated
loci. The motif analysis(Schneider and Stephens 1990) shows that hypermutation occurs
predominantly in the coding strand at the first cytosine of CpY elements (Fig. 3.3B). By
contrast, a pattern of mutations at CpR(Alexandrov et al. 2013) elements can be seen
in all other tumor types tested. Although we found no significant association in ratios
of silent/missense mutations in non-hypermutated tumors, recurrent hypermutated sam-
ples contained significantly greater numbers of silent mutations (Fig. 3.3C). Moreover,
hypermutationmay be related to expression of genes involved in tumor recurrence: In hy-
permutated tumors, those genes containing hypermutated loci are more highly expressed






















































































































Fig. 3.3: Temozolomide (TMZ) related Hypermutation (HM).
(A) Fraction of different types of nucleotide change. In this analysis, 93 patients with trios
of normal, initial and recurrent DNA data were considered. (B) HM Score and mutation
load. HM logo and non-HM logo were separately calculated based on all substitutions
from HM and non-HM samples. Given this, HM score of each sample was defined based
on its mutation pattern. If mutations in a sample follow the pattern of HM logo, the
samplewill have higher HM score. Patients with less than tenmutations in either initial or
recurrent samples were not considered in the analysis of B and C. (C) Silent/missense ratio
analysis. P-value was calculated by Ranksum test. (D) Expression comparison between
three gene clusters: HM genes, mutated (M) genes, and non-mutated (NM) genes. Mean
expression of three gene clusters in samples with expression data available (m=160) was
calculated to generate the box plot. The bottom and top of the box indicate first and third
quartiles, and the line inside is the median. Whiskers represent 1.5 IQR. P-values were
calculated by Ranksum test.
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3.3 Reconstruction of the main routes of GBM evolution
The number of mutations exclusive to untreated tumors, recurrent tumors, or those in
common can be used to describe an evolutionary tree. We developed a method to perform
statistics on the space of evolutionary trees [125] by embedding each tree within a sphere
(Fig. 3.4A). Here, the upper corner represents the fraction of mutations that are common
to both samples; the left corner represents the fraction exclusive to the untreated sample,
and the right corner the fraction exclusive to recurrence. Unsupervised clustering of the
different phylogenies identifies three clusters (Methods). The yellow group represents the
limiting case where few mutations are lost from diagnosis, similar to the classical model
of linear tumor evolution typified by previous treatment-naïve studies of colon cancer
[126]. Treatment however can change linear patterns [127]. The abundance of points far
from the right edge of the diagram suggests that in most patients, the dominant clones
prior to treatment appear to be replaced by new clones that do not share many of the
same mutations.
If many mutations in the initial sample are lost at recurrence, this suggests that the
clone dominant at recurrence originated (i.e., diverged from the clone dominant at di-
agnosis) relatively long before the initial sample was taken. Consistent with epidemio-
logical observations and classical models of tumor evolution of Armitage-Doll(Armitage
and Doll 1954) and Nordling(Nordling 1953), the number of mutations in the untreated
tumor increases with the patient’s age at diagnosis (Supplementary Figure 7D, average
of 0.6 protein changing mutations per year or 0.02 per Mb-year). Encouraged by this
concordance, we developed a mathematical model of branching tumor evolution with in-
dependent monophyletic origin for diagnosis and relapse. In our branching model (Fig.
3.4B), if a mutation occurs along the lineage common to both the initial and recurrent
samples, it will be clonal in both of these samples. If a mutation occurs along the lineage
leading to the most recent common ancestor (MRCA) of a single sample, then it will be
clonal in that sample and absent in the other. If a mutation occurs in a descendant of the
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MRCA of a sample, then it will be subclonal in that sample and absent in the other. Any
other pattern — a mutation that appears subclonally in both samples, or one that appears
clonally in one sample and subclonally in the other, would require either recurrent mu-
tation or “back-mutation”. An alternate model is also possible, in which the recurrence
stems from a lineage nested within the initial sample, perhaps selected by therapy. In
this case, a single mutational event could produce a variant that is present subclonally at
diagnosis and clonally at recurrence, but two events would be needed to explain loss of a
clonal mutation (Supplementary Figure 7A versus 7B). We find that 59% of patients (54 /
92) have at least four clonal mutations at diagnosis that are lost in the recurrence, support-
ing the branching model as the typical scenario. The picture is nuanced, however, as 17
patients have at least four subclonal mutations at diagnosis that become clonal at recur-
rence, supporting the alternate model as a minority scenario (Supplementary Figure 7C).
By accounting for the likelihood of each mutational pattern within our branching model,
we fit substitution rates before and after treatment, as well as the amount of time before
diagnosis that the untreated and recurrence lineages diverged (see Methods). Using a col-
lection of statistical criteria (see Methods), we found that 49% of patients analyzed (45/92)
fit well to the model, without requiring an unrealistic frequency of recurrent mutation
or “back-mutation”. The pre-treatment substitution rate was consistent among these 45
well-fitting patients (Fig. 3.4C), having a median and interquartile range of 0.028 subs
Mb-1 yr-1 and 0.018 – 0.041 subs Mb-1 yr-1. Statistics for all 92 patients were similar,
with a median (IQR) of 0.024 (0.018–0.035) subs Mb-1 yr-1. No relationship was observed
between the substitution rate and age of diagnosis (Supplementary Figure 8). Consid-
erably more variation was observed in post-treatment substitution rates, with 15 of the
92 patients exhibiting significantly higher mutation rates after treatment (Supplementary
Figure 9). All but one of these patients showed hypermutation, with over 500 variants

























































Fig. 3.4: Mathematical model of tumor evolution.
(A) Moduli space of GBM evolution trees. Each ball represents one patient, and different
colors represent three clusters in moduli space. (B)Model of branching tumor evolution.
This model assumes independent monophyletic origin for initial and recurrent tumors
sharing an ancestral clonal lineage (duration tS), after which they branch off from one
another (durations tI and tR1+tR2). After this clonal evolution, the lineage leading to
each sample diversifies for a duration tMRCA, during which subclonal variants can ac-
crue. Somatic variants accrue according to substitution rates u1¬ and u2 before and after
treatment, respectively. (C) Relationship between estimated substitution rates before and
after treatment, in substitutions per Mb-yr (median and interquartile range for each pa-
tient). Dashed line shows diagonal (pre- and post-substitution rates equal). Hypermutated
tumors shown in red, non-hypermutated tumors in light blue. Primary GBM diagnoses
shown as squares, secondary GBM diagnoses as diamonds. Black dot in center of symbol
shows patients who fit the model well. Yellow halo shows patients with TP53 mutated in
both the initial and recurrent samples. Patient R069 was not considered for evolutionary
analysis as no valid mutations were detected in the initial sample. (D) Cross-sectional
integration of longitudinal data by tumor evolutionary directed graph. Arrow represents
time order of mutations. Wider arrows represent there are more independent patients
containing the same order of mutation. The size of the node indicated the frequency of
the mutations in our cohort. 51
Estimates of divergence time suggest that the recurrent clone diverged from the un-
treated clone many years before disease was detected (Supplementary Figure 7E).Theme-
dian among the 45well-fitting patients had a divergence time of 12.6 years (range 2.3–50.5,
IQR 7.2–22.6). Since the remaining 47 non-fitting patients may fail the model’s assump-
tion that untreated and recurrent tumors be evolutionarily distinct (i.e., monophyletic),
we caution that divergence time for these patients be interpreted only as a heuristic mea-
sure of genetic difference between the two tumor samples. In general, uncertainty in
the divergence time was large, with the median well-fitting patient showing a 95% CI 24
years wide. Still, even the bottom of the 95% CI exceeded three years for a majority of
patients. To reveal the potential evolutionary trajectories of GBM under therapy a tumor
evolutionary directed graph (TEDG)([74]) was constructed for the 93 triplet samples.
As this analysis uses as input the fraction of cells harboring a particular mutation, we
estimated the purity of the tumor using ABSOLUTE([25]) (Supplementary Table 7) and
PyClone([16]) (Supplementary Table 8). The resulting TEDG indicates that mutations
in IDH1, PIK3CA and ATRX are early events, mutations in TP53, NF1, and PTEN occur
later, and mutations in MSH6 and LTBP4 are relapse-specific events (Fig. 3.4D). A more
complex set of possible evolutionary trajectories appears when copy number information
is included in the analysis (Supplementary Figure 10).
3.4 Clonal Replacement Events are Frequent in GBM
To discover the pattern of alterations in recurrent GBM compared with untreated tumors,
we performed in-depth investigations into any gains or losses of genetic alterations. The
epidermal growth factor receptor (EGFR) gene is known to be frequently amplified, mu-
tated, and rearranged in untreated gliomas(Kuan, Wikstrand, and Bigner 2001). To un-
cover the role of EGFR alterations in GBM evolution, we applied PRADA to detect EGFR
structure variance from RNA sequencing data(Torres-Garcia et al. 2014). By calculating
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junction reads we have found at least one junction read of EGFRvIII in 18% (12/67) of
initial tumors and 11% (8/76) of recurrent tumors (Supplementary Table 9). Interestingly,
nine patients lost EGFRvIII and one patient gained EGFRvIII at relapse (transcribed allelic
fractions>5%), indicating, first, that EGFRvIII is a late event originated after the clonal
lineages leading to the two samples diverged and, second, that EGFRvIII is more com-
mon in initial tumors and lost during treatment (Fig. 3.1D). An example is patient R005
whose untreated tumor harbors EGFR amplification and the S645C mutation. The EGFR
S645C mutation was lost in the recurrent tumor and replaced by EGFRvIII (Supplemen-
tary Figure 11). A switch between differently mutated versions of the same gene also
occurs in platelet-derived growth factor receptor alpha polypeptide (PDGFRA), another
RTK-coding gene frequently activated in GBM (Fig. 3.5B, and Supplementary Figure 11).
Mutation E229K, which is relatively common in cross-sectional mutation databases (e.g.
TCGA(Gao et al. 2013a)), appears to be a relatively late event, as it is exclusive to recur-
rence and replaces the initial mutation P443L (Fig. 3.5B). Mutational replacement also
occurs in the tumor suppressor TP53 (G105R to R337C in Patient R038, Fig. 3.5C) in EGFR
(A1201T to G598V in Patient R065, Fig. 3.5D). In all, we found that 11% (10 out of 93) of
recurrent GBM patients have clonal replacements within key drivers (Supplementary Fig-
ure 12). These clonal switching events within the same gene occur preferentially in genes
known to play a role in GBM (Fig. 3.5A, p-value<10-4). The strong association between
switching alterations and key driver genes (EGFR, TP53, PDGFRA) suggests (1) some of
these genes contribute to a late expansion both with treated and untreated tumors and (2)













































































Fig. 3.5: Clonal replacement in key driver genes.
(A) Mutations of seven key GBM drivers (EGFR, TP53, PDGFRA, PTEN, ATRX, NF1, and
RB1) were replaced by different mutations in the same genes. (B-C) Mutational replace-
ment in three different patients. Cancer cell frequency was estimated by Pyclone.
3.5 Expression Analysis and Subtype Switching
Based on its pattern of gene expression, GBM is commonly divided into four subtypes
[38], which display different responses to treatment. To study evolution of gene expres-
sion in GBM, we followed the ssGSEA method to subtype each tumor sample (Fig. 3.6A).
As expected, we found that IDH1 mutated patients are mostly classified as proneural
gliomas [42]; EGFR alterations are associated to classical subtype; and NF1 alterations to
mesenchymal subtype (Fig. 3.6B). We observed that all five hypermutated primary GBM
cases switched their subtypes (two to mesenchymal, one to neural and two to proneural).
Strikingly, we found that two-thirds of primary GBM cases (39/58) switch transcriptional
subtype at relapse, while secondary GBM cases are more stable (2/7 switched) (Fig. 3.6A).
Interestingly, mesenchymal subtype is the most stable primary GBM, switching in 55%
54
(12 of 22 primary GBM) of cases at recurrence; and mesenchymal subtype at recurrence
is associated with worse overall survival (p-value=3×10-3, Supplementary Figure 13). As
EGFRvIII is associated to the classical subtype (Fig. 3.6B), loss of this alteration in the
recurrent tumor is consistently associated to the transition from classical to other expres-
sion subtypes (Fig. 3.6A and 3.6C, p-value=8×10-3, Fisher’s exact test).
3.6 LTBP4 promotes tumor growth and reduces survival
We found that the gene Latent transforming growth factor beta binding protein 4 (LTBP4)
harbors significantly more mutations in recurrent than untreated GBM (Fig. 3.1D, Supple-
mentary Figure 14). The LTBP4 gene codes for a protein that belongs to the LTBP family,
which is implicated in the regulation of the TGF-β pathway, typically acting as activa-
tor of TGF-β signaling(Miyazono K 1991). Interestingly, activation of TGF-β is known to
drive aggressiveness of malignant glioma [128–131], and we found that high expression of
LTBP4 in recurrent tumors is associated with worse prognosis in IDH1-wild-type primary
GBM patients (p-value=7×10-3, Fig. 3.7B). Furthermore, mutations of LTBP4 are corre-
lated with higher expression of this gene (p-value<0.05, Fig. 3.7A). Further strengthening
the case that LTBP4 expression could drive tumor growth via TGF-β activation, elevated
expression of LTBP4 in GBM is associated with elevated expression of genes implicated
in the TGF-β pathway (Fig. 3.7C, Gene Set Enrichment Analysis FDR<0.05). To exper-
imentally validate the functional link between LTBP4 and TGF-β, we used lentiviruses
carrying two independent LTBP4 shRNA cassettes to silence the LTBP4 gene in the hu-
man glioma cell lines U87 and U251 (Fig. 3.7D). LTBP4 silencing in both cell lines re-
sulted in reduced expression of the ID genes ID1 and ID2, which are positively regulated
by TGF-β in glioma. Conversely, LTBP4 silencing also led to the up-regulation of RhoB






























































































































































































































































































































































































Initial Tumors Recurrent Tumors Initial Tumors Recurrent Tumors











































































































































































































































































































































































































































































































































































































































































































































































































Fig. 3.6: Expression-based Subtyping of Recurrent GBM.
(A) Expression based GBM subtyping. ssGSEA was performed to cluster each sample into
four subtypes (proneural, neural, classical, andmesenchymal). “*” indicates subtypes with
maximal enrichment score (ES). If the optimal subtype in initial and that in recurrent tu-
mor is different, a patient was labeled as switched. P-value was calculated by Fisher’s ex-
act test. (B) Association between expression-based subtype switching and genetic/clinic
features. The same analysis as in Figure 1C had been performed. (C)The stochastic matrix
of GBM subtypes. The large cohort of longitudinal GBM samples allows the construction
of probability transitionmatrix between four subtypes. The arrows indicate the frequency
of a patient to stay a subtype or to be switched from one subtype to another. A stationary
distribution was calculated based on this stochastic matrix, indicating the proportion of
these four subtypes after treatment.
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tent with the pro-tumorigenic role of TGF-β in GBM, LTBP4 silencing markedly impaired
proliferation of U87 and U251 glioma cells (Fig. 3.7G, 3.7H).
3.7 Discussion
Using longitudinal genomic and transcriptomic analysis of 114 GBM patients, we have
detailed the major routes of GBM evolution under therapy. GBM evolution is highly
branched, and specific alterations and evolutionary patterns are associated with treat-
ment. Our first observation from this analysis is that, despite 45% of mutations (in non-
hypermutated tumors) being shared between diagnosis and relapse samples, the domi-
nant clone at diagnosis is generally not a lineal ancestor of the dominant clone at relapse.
Instead, these two clones diverged from a common ancestor more than a decade before
diagnosis in most patients (Supplementary Figure 7E).
Since 11% of patients (10/93) exhibit replacement of one mutated version of a gene
(at diagnosis) with another, differently mutated version of the same gene (at relapse), it
is conceivable that genes associated with undergoing clonal completion are late driver
events. In fact, this mutational switching phenomenon is enriched 200-fold in genes
known to be implicated in GBM, including EGFR, TP53, and PDGFRA (Fig. 3.5A, Sup-
plementary Figure 13). This scenario of convergent evolution suggests that the common
ancestor of diagnosis and relapse clones had fewer driver alterations and therefore a less
aggressive phenotype. The accumulation of alterations in GBM cells therefore seems to
occur over a decade(s)-long growing phase that leads to a highly diverse population, each
clone experiencing a parallel series of expansions. Related to mutational switching, we
also find that two-thirds of primary GBM patients exhibit different transcriptional sub-
types at diagnosis and relapse. Our observation of subtype switching, considered to-
gether with recent findings that different parts of the same tumor can exhibit different
57










































































































































































































































LTBP4 wild type LTBP4 Mutation
LTBP4 Expression at Recurrencep-value = 0.048
Fig. 3.7: LTBP4 and TGF-β signaling pathway in recurrent GBM.
(A) LTBP4 mutation was related to its high expression. P-value was calculated by
Ranksum test. (B) Survival analysis of LTBP4 expression in IDH1-wild-type primary GBM
patients. High indicates z-score of LTBP4>0, while low are LTBP4<0. P-value was cal-
culated by log rank test. Only IDH1-wild-type primary GBM patients were considered
in this analysis. (C) Gene set enrichment analysis. Recurrent tumor samples from IDH1-
wild-type primary GBM were grouped according to LTBP4 expression. Samples with
high LTBP4 expression (z score>0) were enriched with TGF-β activity. (D) Western blot
of U87 and U251 glioma cells transduced with three independent sh-RNA, two against
LTBP4 (sh1 and sh2), and one non-target-shRNA (sh-NT) as control. β-actin was used
as loading control. (E-F) qRT-PCR of TGFβ target genes in U87 (E) and U251 (F); n = 9
(three biological replicates performed in triplicates) ± SD. Asterisk indicate statistical sig-
nificance. (G-H) Growth curve of a representative experiment using U87 (G) and U251
(H) glioma cells treated as in D (means of six experimental replicates) ± SD.
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GBM subtypes [40, 114], also calls into question the significance of the expression-based
classification as a prognostic marker prior to relapse.
Evolutionary dynamics generally appear similar before and after treatment: ourmath-
ematical model estimates typical substitution rates of 0.03 substitutions per Mb per year
during both periods, except in the 16% of cases that recur with hypermutated tumors. Hy-
permutated tumors, which are highly enriched for mutations at CpC dinucleotides [117],
harbor mutations in mismatch repair (MMR) genes, most commonly in MSH6, and can
exhibit 100-fold higher substitution rates ( 3 substitutions perMb per year). We found that
hypermutation preferentially targets highly expressed genes, suggesting that the muta-
genic mechanisms related to TMZ treatment and subsequent MMR alteration act more
efficiently in highly expressed regions of open chromatin.
Finally, and of particular relevance to discovery of novel GBM treatment, we uncov-
ered unique alterations associated with relapsed GBM. In addition to previously reported
mutations inMMR genes in 15% of patients (14/93), we foundmutations in the LTBP4 gene
in 11% of relapsed tumors (10/93). LTBP4 encodes a protein that binds to transforming
growth factor beta (TGF-β). The TGF-β signaling pathway has been associated in a variety
of biological contexts including proliferation, epithelial to mesenchymal transition(Yip et
al. 2009; Massague 2008), and apoptosis. We have provided both clinical and in vitro evi-
dence that LTBP4 activates this signaling pathway to drive tumor growth: Higher expres-
sion of LTBP4 in IDH1 wild-type primary GBM associated to poorer survival (Fig. 3.7B,
p-value=7×10-3), and silencing LTBP4 in two different cell lines decreases both prolifer-
ation and activity of TGF-β target genes. These results are consistent with recent animal
studies showing that TGF-β inhibitors reduce viability and invasion of gliomas(Fakhrai
et al. 1996) and advance the case for these molecules as potential anti-tumor therapeu-
tics. In conclusion, our study sketches the main routes of GBM evolution under therapy,
identifying a highly branched process with specific alterations and evolutionary patterns
associated to treated tumors.
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3.8 Methods
Patients and samples Recurrent GBM patients were collected from Besta Brain Tumor
Biobank (INCB, R001-R019), MD Anderson Cancer Center (MD Anderson, R020-R029),
The Cancer Genome Atlas (TCGA, R030-R042), University of California San Francisco
(UCSF, R043-R052), Kyoto University (KU, R053-R055), and Samsung Medical Center
(SMC, R056-R093, R094-R114). The specimens in cohort INCB originate from the Besta
Brain Tumor Biobank, which is partly funded by the Italian Minister of Health. All pa-
tients signed an informed consent for the use of their biological material for research
purposes. One case (R012) from this cohort had a history of lower grade glioma prior to
the first GBM. All patients were treated by standard Stupp treatment with surgery fol-
lowed by radiotherapy plus concomitant and adjuvant TMZ. Samples from cohort MD
Anderson were primary and recurrent paired tumor obtained from Henry Ford Hospi-
tal in accordance with institutional policies and all patients provided written consent,
with approval from the Institutional Review Board (IRB protocol #402). Three cases had
a history of lower grade astrocytoma prior to the first GBM (R022/R027/R029). All of
the recurrent GBMs had been treated with radiochemotherapy plus TMZ. Cohort TCGA
contains TCGA samples, following the publishing protocol of TCGA policies. All of the
recurrent GBMs had been treated with chemotherapy or radiation. Six patients were
not treated by TMZ (R031/R034-R038). Cohort MD Anderson and TCGA were initially
published by Kim et al. Cohort UCSF contains eight patients (R043-R050) collected from
the Neurosurgery Tissue Bank at the University of California San Francisco (UCSF), ap-
proved by the Committee on Human Research at UCSF. Two patients (R051-R052) from
this cohort were from University of Tokyo hospital and the study was approved by the
Ethics Committee of the University of Tokyo. Initial tumors of all patients in this cohort
were low-grade gliomas, and their recurrences were secondary GBM.This cohort was ini-
tially published by Johnson et al. Cohort KU makes use of data generated by Department
of Pathology and Tumor Biology, Kyoto University. Initial tumors of patients from KU
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were low-grade gliomas, and their recurrences were secondary GBM.Those patents were
initially published by Suzuki et al. Cohort SMC consists of GBM samples from Samsung
Medical Center (SMC), Korea, following the prior publication (Kim et al, Cancer Cell 2015,
R056-R093) and additional unpublished samples (R094-R114). All samples from SMC had
been collected with approval from the Institutional Review Board (IRB file #201004004
and #201310072). Initial tumors from R076-R078/R098/R105/R114 were secondary GBM,
with history of low-grade gliomas. Patient R103 had cervical cancer three years prior to
the first diagnosis of GBM. Detailed clinical information of all cohorts was provided in
Supplementary Table 10.
Sequencing andmappingGenomic DNA from initial tumor/recurrent tumor/matched
normal blood of patients R001-R016, and recurrent tumor of patients R017-R019 were ex-
tracted purified, quantitated, fragmented, quality controlled and used to create a library
of genomic DNA fragments. gDNA fragmentation was performed using the Covaris S220
AFA instrument to reproducibly generate fragments of a precise length, while quality con-
trol of both gDNA samples and library fragments (at a later time) was performed using
Agilent Bioanalyzer 2100 microfluidic device. Both untreated and treated tumor samples
of R009, R011, and R014, plus recurrent samples of patients R017-R019 were sequenced by
Agilent V3 50M kit, sequencing 90bp PE. Mapping files of untreated/normal samples of
patients R017-R019 were obtained from TCGA through CG-hub. All other DNA samples
from cohort INCB were sequenced by the protocol of Agilent SureSelect XT Human All
Exon v4 Kit, PE, 80M reads, 150X on target coverage. High-quality reads of those samples
were mapped by BWA to human genome assembly of hg19 with default parameters. All
mapped reads were thenmarked duplication by Picard to eliminate potential duplications.
Total RNA of samples in cohort INCB was collected to investigate the transcriptional pro-
filing by mRNASeq using Illumina technology. Upon quantification and quality controls,
mRNAs were reverse transcribed to cDNA and a library of fragments was synthesized
using Illumina TruSeq mRNA kits. Total RNA depleted of ribosomal RNA of patients
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R001-R005, R007-R008, R010 and R012 were sequenced by TrueSeq3 stranded prep (Illu-
mina). RNA samples of R006, R009, R017-R019 were sequenced in BGI. All reads were
mapped to human genome assembly of hg19 from UCSC genome browser, using a fast
splice junction mapper Tophat.
Mapping files of TCGA samples but R039 were downloaded through CG-hub from
TCGA. DNA mapping files of cohort UCSF, cohort MD Anderson, cohort KU, and R056-
R093 from cohort SMC were all downloaded from European Genome-phenome Archive.
Additional samples (R094-R114) from SMC followed the same sequencing protocols as the
previous samples in the prior publication (Kim et al, Cancer Cell 2015, R056-R093).
SAVI2 and driver gene selection To identify somatic mutations from whole-exome
sequencing data of triple samples (normal, initial tumor, and recurrent tumor) of GBM
patients, we applied variance-calling software SAVI2 (statistical algorithm for variant fre-
quency identification) based on the empirical Bayesian method. Specifically, we first gen-
erated the candidate variant list by successively eliminating positions without variant
reads, positions with low-depth, positions that were biased in one strand, and positions
containing only low-quality reads. Then the number of high quality reads of forward ref
alleles, reverse ref alleles, forward non-ref alleles, and reverse non-ref alleles were calcu-
lated in the remained candidate positions to build the prior and the posterior distribution
of the mutation allele fraction. Finally somatic mutations were determined based on the
posterior distribution of the difference of the mutation allele fraction between normal
and tumor samples. SAVI2 was able to assess mutations by simultaneously considering
multiple tumor samples, as well their corresponding RNA samples if available.
Common somatic mutations from Patients R078-R082 were unknown due to the lack
of normal DNA. The initial and recurrence exclusive mutations were calculated based on
the difference between initial and recurrent tumor DNA. Tumor DNA of Patient R083-
R093, R102, R111-R114 were not complete. The somatic mutations of these patients were
estimated based on RNA sequencing.
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The known driver list (Supplementary Table 2) used in this manuscript was generated
by combining GBM drivers from cancer gene census and our previous analysis of primary
GBM2.
The Analysis of Loss of heterozygosity (LOH) and Copy Number Change All com-
mon dbSNP variants of single samples were extracted to define Zygosity Score (ZS) as









where ZSti is zygosity score in tumor samples, and ZSNi is that of the normal samples.
If r<0.8 we thought the corresponding mutation is in a LOH region. Segmentation in
Supplementary Figure 3 was performed based on CBS algorithm.
The pipeline of EXCAVATOR was carried out to detect copy number alterations based
on whole-exome sequencing data. EXCAVATOR considers mean number of reads per
exon, and normalized the data by a three-step normalization procedure to eliminate the
bias introduced by GC content, the genomic mappability and the exon size. Segmentation
was then performed with a novel heterogeneous hidden Markov model algorithm, het-
erogeneous shifting level model (HSLM) algorithm, which considers the genomic distance
between consecutive exons. To confidently quantify variation arising in whole-exome se-
quencing (WES) data in each patient’s initial and recurrent sample compared to normal
data we calibrated WES CNV calls to SNP array data in available samples (Supplemen-
tary Figure 15). In addition toWESwe utilized segmentation data for TCGA samples from
Broad Firehose platform and when available SNP6 data pre-processed with AROMA and
normalized ArrayCGH obtained from Gene Expression Omnibus (GSE63035). To identify
statistical significant regions, GISTIC was applied in initial and recurrent tumors respec-
tively. GISTIC estimated the background rates for each amplification and deletion, and
then summarize the input samples to score the significance of copy number altered re-
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gions. To integrate mutation and copy number data, MutComFocal was separately per-
formed in initial and recurrent tumor. In the MutComFocal analysis, long proteins (with
more than 3500 amino acids), not expressed genes (mutations were not expressed in any
samples) and high-synonymous-rate genes (synonymous/non-synonymous>0.2) were not
considered.
Gene Fusion Detection and Structure Rearrangement of EGFR ChimeraScan was
used to generate the starting set of gene fusion candidates. To reduce the false positive rate
and nominate potential driving events, we applied the Pegasus annotation and prediction
pipeline. We reconstructed the entire fusion sequence on the basis of the breakpoint
coordinates and assigned a driver score to each candidate fusion via a machine learning
model trained largely on GBM data57. All candidates reported in Supplementary Table 8
were selected according to four criteria: 1. Pegasus score was >0.5; 2. Either more than
400 span reads or at least two split reads supported fusion; 3. The two fusion partner
was apart at least 50 kb. To check the rearrangement of EGFR, we applied prada-guess-if
from PRADA package. PRADA is a RNA sequencing analysis pipeline developed in MD
Anderson. Following the definition in Brennan et al. 2013, transcribed allelic fractions of
EGFRvIII were defined as the fraction of junction reads between exon1 and exon8.
Gene expression analysis and expression-based subtyping analysis of GBM sam-
ples Fragments Per Kilobase of exon model per Million mapped fragments (FPKMs) were
calculated by Cufflinks. To eliminate batch effect, we have normalized gene expression
by calculating Z-score in each batch. The gene expression was assessed by their corre-
sponding Z-scores. ssGSEA was applied to determine the subtype of GBM samples. For
each sample, Z-score was used to rank all genes to generate the rnk.file as the input of
GseaPreranked software. An enrichment score (ES) was generated for all four subtypes
initially defined in Verhaak et al. 2010. The subtype with the maximal ES was selected as
a representative subtype of each sample.
Moduli Space Analysis Clustering analysis of the patient data was performed as fol-
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lows. Each phylogenetic tree was represented as a point in the projective evolutionary
moduli space, which in this case is a triple (x1, x2, x3) such that x1 + x2 + x3 = 1, by
taking the raw mutation counts (z1, z2, z3) for the common, initial, and recurrent muta-
tions and normalizing, setting xi = zi/(z1 + z2 + z3). We discarded samples where any
of the mutation counts were missing, leaving 93 points (out of 114 patients). The metric
on the evolutionary moduli space was in this case simply the standard Euclidean metric.
Note that for purposes of constructing this space, the “branch lengths” of each patient’s
tree are simply mutation counts, in contrast to the evolutionary analysis described below,
which estimates branch lengths in years.
We then applied three clustering algorithms to this metric space: k-means clustering,
spectral clustering, and density-based spatial clustering (DBSCAN).We used the code pro-
vided as part of the scikit Python package. For k-means clustering and spectral clustering,
we set the number of clusters at three; DBSCAN determines the number of clusters from
the data, but we set the parameters to be ε=0.5 and minimum cluster size =5. For spec-
tral clustering, the affinity matrix was computed using the Gaussian kernel applied to the
Euclidean distance.
In order to ensure stability of the results, we performed cross-validation using Monte
Carlo simulations in which we sampled without replacement 95% of the data points and
performed clustering.
Tumor Purity Estimation and Cellular Fraction ABSOLUTE was used to infer tumor
purities and ploidy for each WES sample by integrating mutational allele frequencies and
copy number calls. PyClone was run for each sample using default parameters. Briefly,
we integrated both allele mutations, copy number calls and loh status for each sample as
input to obtain cellular frequencies. Cellular frequencies were then rescaled by median
adjustment and used as input for Tumor Evolutionary Directed Graph and Mathematical
modeling of tumor evolution.
Evolutionary Model We considered all 92 patients for whom mutations were se-
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quenced in both the initial and recurrent tumor samples. To exclude false positives, only
variants with an allele frequency of at least 5% were used. Variants occurring at a cellular
fraction of at least 95% were classified as clonal in a sample, and others were considered
subclonal. Check details of the model in Supplementary Note. In Supplementary Figure
16, we perform sensitivity analysis using alternate cutoffs for clonality. Related code is
provided in Supplementary Code.
TEDG reconstruction In order to reconstruct the order of events during tumor pro-
gression we followed the strategy inWang et al. 2014. We selected genes that were recur-
rently mutated and expressed in our samples. In hypermutated cases, we only considered
mutations of MSH6 and LTBP4. A mutation that was predicted to be clonal (cellular frac-
tion>0.8) in both initial tumor and recurrent tumor was defined as an early event, while a
mutation that was only present (variant allele fraction>5%) in one sample was defined as
a late event. To represent the order of clonal mutations, for each sample, directed edges
were added to connect early and late events. Then we combined all directed edges from
different patients to show a global landscape of GBM evolution. A copy number alteration
was defined as clonal if the absolute value of segmean was larger than one. A copy num-
ber alteration was defined as present at the threshold 0.5, and as absent at the threshold
0.1.
Hypermutation Score Hypermutation (HM) score was defined as:
HM = e(−(‖WMH−WM‖F )) − e(−(‖WMN−WM‖F ))
whereWM is the weight matrix of the DNA sequence logo of a given sample; WMH is the
weight matrix of all mutations in hypermutated samples; and WMN is the weight matrix
of mutations from all non-hypermutation samples.
Validation of mutations The genomic regions surrounding the predicted mutations
were amplified using AccuPrime Taq DNA Polymerase High Fidelity (Invitrogen, USA).
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Primers were summarized in Supplementary Table 11.
The PCR products were purified with ExoSAP-IT (Affymetrix, USA) and subjected
to Sanger Sequencing (Macrogen, USA). The amplicons containing the predicted genomic
mutationswere sequenced using BigDye Terminator Cycle Sequencing Kit v3.1 on theABI
Prism 3730xl DNA Analyzer (Applied Biosystems, USA). All Sanger validation figures are
in Supplementary Data 1. To assess the sensitivity of judging absence of a mutation in one
phase that is present in the other phase, we studied 15 variants in the panel that are absent
in one of the samples in WES, with median WES depth 117 [10-402]. Using CancerScan,
we found that no read reported the variant in the sample where it was deemed absent by
WES (Supplementary Table 12), median CancerScan depth 563 [217-1377].
Cell culture, lentivirus production and cell growth analysis U87 (ATCC HTB-14)
cell line was acquired through American Type Culture Collection. U251 (Sigma, cat-
alogue number 09063001) cell line was obtained through Sigma. Cell lines were cul-
tured in DMEM supplemented with 10% fetal bovine serum (FBS, Sigma). Cells were
routinely tested for mycoplasma contamination using Mycoplasma Plus PCR Primer Set
(Agilent, Santa Clara, CA) and were found to be negative. Lentivirus was generated by
co-transfection of the lentiviral vectors with pCMV-CMV-ors wpMD2.G plasmids into
HEK293T cells as previously described (Niola et al. JCI 2013; Carro et al. Nature 2010).
shRNA sequences for LTBP4 are in Supplementary Table 11. After infection cells were se-
lected with Puromycin (Sigma) at concentration of 2 mg/ml for 48 h. Cells were analysed
by western blot, qRT-PCR and growth assay 3 days later. Evaluation of cell growth was
performed using the MTT assay. Cells were plated at density of 2.5x103 cells/well into
96 well plates in 6 replicates and allowed to adhere for 24 h. Viability was assessed daily
by adding MTT ((3-[4,5-dimethylthiazol-2-yl]-2,5- diphenyltetrazolium, Sigma 5mg/ml in
PBS). Following 4h incubation period, medium was removed and formazan crystal were
solubilized with acidic isopropanol (0.1 N HCl in absolute isopropanol. The absorbance at
550 nm was measured with a plate reader.
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RT–PCR Total RNA was prepared with Trizol reagent (Invitrogen) and cDNA was
synthesized using SuperScript II Reverse Transcriptase (Invitrogen) as described (Carro
et al. Nature 2010; Zhao et al. Nature Cell Biol 2008). The quantitative RT–PCR was
performed with 7500 Real-Time PCR system, using SYBR Green PCR Master Mix from
Applied Biosystem. Primers used in qRT–PCR are summarized in Supplementary Figure
12.
Results are presented as the mean ± s.d. of three independent experiments each per-
formed in triplicate (n=9). Statistical significance was determined by using unequal vari-
ance t-test (two-tailed).
Western Blot Cells were lysed in RIPA buffer (50 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 1 mM EDTA, 1% NP40, 0.5% sodium dexoycholate, 0.1% sodium dodecyl sul-
phate, 1.5 mM Na3VO4, 50 mM sodium fluoride, 10 mM sodium pyrophosphate, 10 mM
-glycerolphosphate and EDTA-free protease inhibitor cocktail (Roche)). Lysates were
cleared by centrifugation at 15,000 r.p.m. for 15 min at 4 ℃. Protein samples were sep-
arated by SDS–PAGE and transferred to nitrocellulose membrane. Membranes were
blocked in TBS with 5% non-fat milk and 0.1% Tween20, and probed with primary an-
tibodies. Antibodies and working concentrations are: LTBP4 (1:200, sc-393666) obtained
from Santa-Cruz Biotechnology; P-SMAD7 (1:1000, #3101) and SMAD7 (1:1000, #5339)
obtained from Cell Signaling Technology; β-actin
Gene Fusion Validation For validation of fusion transcripts and RT-PCR assays were
performed. Total RNA was extracted from the tissues by AllPrep DNA/RNA Mini kit ac-
cording to the manufacturer’s instructions (Qiagen). The total RNA (0.5 μg) was reverse
transcribed to synthesize template cDNA by a random primer using the SuperScriptIII
First-Strand System(Life Technologies), and 20 μl synthesized cDNA was diluted 10 times
with DW. For RT-PCR, EzWay Taq PCR MasterMix (Komabiotech, KOREA) and 5 μl syn-
thesized cDNA as template were used. Thermal cycling was carried out under the follow-
ing conditions: 1 min at 95℃ followed by 30 cycles of 30 sec at 95℃, 30 sec at 55℃, 30 sec
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at 72℃.The primer pairs used in this experiment were designed to make the amplification
product including the breakpoints of the fusion genes. PCR products were analyzed by
agarose gel electrophoresis. The primers were summarized in Supplementary Table 11.
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Chapter 4
Spatiotemporal genomic architecture informs
precision oncology in glioblastoma
Nature Genetics, vol. 49, no. 4, p594-602, (2017)
4.1 Introduction
In glioblastoma (GBM)most clinical trials on targeted therapy have shown limited clinical
success([133]). Although recent genome-wide studies evaluating regional heterogeneity
([113],[134]) and longitudinal GBM pairs ([48], [110], [111], [62]) have suggested poten-
tial evolutionary models, there is little understanding which strategies can effectively
use genomic data to inform targeted therapies. To identify such strategies, we analyzed
somatic variants in 127 multi-region or longitudinal tumor specimens from 52 glioma
patients: 42 from Samsung Medical Center (SMC) Seoul, South Korea, and 10 from The
Cancer Genome Atlas (TCGA) GBM cohort [110], [111], [62] (Supplementary Table 1).
Additionally, we analyzed transcriptomes of 83 tumor specimens from 41 patients (bulk)
Material in this chapter is published wholly or in part in [132]: Jin-Ku Lee*, Jiguang Wang*, Jason K
Sa*, Erik Ladewig*, Hae-Ock Lee, In-Hee Lee, Hyun Ju Kang, Daniel S Rosenbloom, Pablo G Camara, Zhaoqi
Liu, Patrick van Nieuwenhuizen, Sang Won Jung, SeungWon Choi, Junhyung Kim, Andrew Chen, Kyu-Tae
Kim, Sang Shin, Yun Jee Seo, Jin-Mi Oh, Yong Jae Shin, Chul-Kee Park, Doo-Sik Kong, Ho Jun Seol, Andrew
Blumberg, Jung-Il Lee, Antonio Iavarone, Woong-Yang Park, Raul Rabadan and Do-Hyun Nam (2017).
*Equal author contributions.
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and 305 single cells from seven samples of three patients. Tumors were classified into
three distinct groups according to spatial and temporal tissue acquisition: from the same
location and time (locally adjacent), from different locations at the same time (multifo-
cal/multicentric, referred as multiple) ([135]), and from local and distant recurrences at
different times (longitudinal local or distant, respectively) (Fig. 4.1a).
4.2 GBM ITH cohort
We inferred clonal and subclonal alterations from cancer cell fractions in multiple sec-
tors (Methods, Supplementary Table 2). The average mutation rate was 2.2 mut/Mb for
non-hypermutated samples, consistent with previous studies [108], [38], [62]. IDH1 R132
mutations were clonal across all the regions in IDH mutant tumors ([108], [38], [62])
(6/6). PIK3CA mutations were always clonal and shared in all sectors (5/5), consistent
with our previous longitudinal analysis from tumor evolution directed graphs (TEDG)
that PIK3CA mutations are early events [62] (Fig.(4.1b), Supplementary Fig. 1a-b). Fur-
thermore, FGFR3-TACC3 fusions were highly expressed in all regions from two patients
([21]). These somatic variants that are shared in all tumor regions represent promising
therapeutic targets [136], [62], as they reflect truncal alterations suspected to be present
among all tumor cells. In contrast, PTEN alterations including copy number deletions
and mutations were shared in 10/20 (50%) and 5/7 (71.4%) tumor sectors, respectively.
Likewise, EGFR amplifications were observed as private events in 4/15 (26.7%) of EGFR-
amplified tumors, including two multiple cases (GBM5 and GBM9). Furthermore, EGFR
mutations were shared in 3/7 (42.9%) cases, including one harboring disjoint alterations
(GBM7-I1: L62R and R108K; GBM7-I2: A289V and C624S), suggesting that partial genetic
information of a single tumor biopsy can be inconclusive for assessing EGFR targeted





















































































































































































































































































































































































































































































































































































































Fig. 4.1: Mutational landscape of multi-region malignant glioma samples.
(a) A schematic representation of glioma genomic heterogeneity and differential drug re-
sponse analysis. Human glioma specimens were acquired based on their spatial order, or
longitudinal pairs and subjected for genomic analysis for identification of tumor-initiating
(truncal) events. (b) Somatic mutations including Single Nucleotide Variants (SNVs)
and small Insertions/Deletions, copy number alterations, and gene fusions of 83 glioma
multi-region or multisector-longitudinal specimens from 30 patients are demonstrated.
34 locally adjacent tumor fragments were from 14 patients, 13 multifocal/multicentric
(referred as multiple) tissues from 5 patients, and a longitudinal pair GBM14 with lep-
tomeningeal seeding were collected from Samsung Medical Center (SMC). We also cu-
rated 34 multisector-longitudinal tumor exomes and/or RNA sequencing from 10 patients
in TCGA cohort(Kim, Zheng et al. 2015). All somatic mutations called by SAVI with allele
frequency >5% were demonstrated. For each gene we calculated the copy number (CN)
based on Excavator. Clonal alterations were determined using ABSOLUTE with cancer
cell fraction >80%. (Methods).
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4.3 Quantifying ITH in GBM
To understand the association between spatiotemporal architecture and genetic relevance,
we calculated Nei’s genetic distance among multi-sector samples from the same patient
(Methods). Genetic diversity is greater in multiple tumors compared to locally-adjacent
tissues (q=4.7e-5, Fig. 4.2a), in distant compared to local recurrence (q=1.4e-5, Fig. 4.2a),
and in long-term recurrence compared to short-term recurrence (q=2.9e-3, Fig. 4.2a). A
multinomial logistic regression was applied to classify multi-sector sample pairs based on
genomic features (Supplementary Note). This analysis has highlighted that tumors from
distant regions or longer period separation compose a distinct evolutionary scenario in
GBM (Fig. 4.2b). In colorectal tumors, a Big Bang model ([67]) interprets that cells from
different biopsies of the same tumor share clonal and subclonal variants (Fig. 4.2c, left
panel). Consistent with this model, samples taken from locally adjacent tumors share a
large proportion of clonal and subclonal events (Supplementary a-b). In contrast, multiple
tumors contain fewer shared (higher private) clonalmutations compared to local (q=1.86e-
3, Supplementary Fig. 2a). We corroborated this finding by computing statistics on the
space of evolutionary trees (evolutionary moduli spaces, Supplementary Fig. 3, Methods).
Local tumors clustered near the tip of the space, indicating a higher shared mutation ratio
compared to multiple tumors (p=1.27e-2). These results indicate that in contrast to local
tumors, geographically separated multifocal tumors and/or long-term recurrent tumors
are seeded from distinct clones, a phenomenon we call the ‘Multiverse model’ (Fig. 4.2c,
right panel). Unlike the Big Bang model ([67]), in the Multiverse model, tumor samples
from different tumor masses share very few genomic alterations, indicating tumor clones
are geographically segregated at an early stage of evolution, and each clone acquires dis-
tinct “private” alterations, leading to the construction of multiple “universes”.
































































































Fig. 4.2: Comparison of genetic heterogeneity across glioma multisector / longitudinal
samples.
Patient samples were classified into five groups: Local, Multiple Lesion, S.T. (Short-Term)
Longitudinal Local, L.T. (Long-Term) Longitudinal Local and Longitudinal Distant for
comparative analyses. (a) Nei’s genetic distance of the indicated groups are shown. Q-
values were calculated by Wilcoxon Rank-Sum Test and corrected for false discovery rate
using Benjamini-Hochberg method. S.T. and L.T. Local indicates short-time (<18 months
surgical interval) and long-time recurrent tumors ( ≥18 months), respectively. (b) Illustra-
tion of leave-one-out results from multinomial logistic regression. Each point indicates
one pair of samples, and their coordinates are the probabilities to be local, multiple le-
sion/longitudinal distant, or longitudinal local. Long-Time recurrent samples were clas-
sified together with multiple lesion/longitudinal distant samples, indicating they might
follow the same evolutionary model. (c) Tumor evolution behind Big Bang and Multi-
verse models. The Big Bang model is indicated as a mixture of tumor cells that share
many clonal and subclonal alterations. The Multiverse model is indicated with a greater
proportion of private events at a clonal level. (d) Pie charts demonstrate the frequencies
of PIK3CA mutations in multifocal/multicentric (M-) GBMs (30%, 9/30) and solitary (S-)
GBMs (10%, 13/130). The p-value was calculated using Fisher’s exact test.
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GBM) or solitary (S-GBM) lesion in 160 treatment naïve patients from both SMC and
TCGA([135]) cohorts (Supplementary Fig. 4 and 5a, Supplementary Table 3, Methods).
Notably, non-synonymous mutations of PIK3CA were enriched in M-GBM (13/130 and
9/30 tumors in S- and M-GBMs respectively, p=7.905e-3, Fig. 4.2d). This conclusion re-
mains the same in IDH1wild type cohort (Supplementary Fig. 5b). PIK3CA inducesmulti-
potency of mammary tumors, suggesting its associative role in tumor multiplicity([137]).
Survival analysis indicates that both M-GBM and PIK3CA mutant patients have worse
prognosis (p-values: 0.0151 and 0.039, respectively, Supplementary Fig. 5c-d).
4.4 Single cell expression demonstrates ITH
To further characterize the heterogeneity of expression profiles, we curated single cell
RNA-Seq of seven different samples from three patients. Overall, expression-based cell
subtypes were not clearly determined by location or time (Fig. 4.3), consistent with a
previous report([40]). To make sure this observation is not due to the limitations of this
classification and to capture the transcriptional similarity among different cells, we used
topological data analysis (Methods), a recently developed technique to summarize and
reduce the dimensionality of large data sets while retaining local high dimensional struc-
ture([88], [89]).
GBM9 (Figs. 4.3a-d) consisted of samples from two primary tumors in the right and
left frontal lobes, and a recurrent tumor in the left frontal lobe that emerged after concur-
rent chemoradiotherapy (CCRT) and EGFR targeted treatment (Supplementary Note). We
found in bulk whole exome sequencing (WES) and confirmed using ultra-deep sequenc-
ing (Supplementary Table 4) and single-cell analysis that cells from the recurrent tumor
shared genomic and expression features with the left initial tumor cells (Supplementary
Figs. 6-8, Fig. 4.3b). Particularly, there are 61 somatic mutations shared between left and
recurrent, while only 42 between right and recurrent. Single-cell transcriptome analysis
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showed EGFR expression predominantly in the right tumor mass, but not in the left and
recurrent tumors (Fig. 4.3c). Interestingly, different single cells harbor different EGFR
alterations, implying they were late events during tumor evolution21. PIK3CA mutations
were detected from single cells in all three samples, consistent with the bulk WES that
PIK3CA mutations are founder events (Supplementary Figs. 1a and 6a). Our analysis also
revealed the presence of transcriptional heterogeneity within the individual samples. A
subset of left-initial tumor cells was characterized by upregulation of mitotic genes not
found in either right or recurrent sections (Fig. 4.3d).
Additionally, we profiled IDH1 mutant tumor cells distinguished by 5-Aminolevulinic
acid (5-ALA) uptake pattern (populations stained for tumor cellularity([138])) (GBM10,
Fig. 3e-f, Supplementary Figs. 6-7). Previous glioma studies suggested that low patho-
logic grade is associated with low uptake of 5-ALA([139], [138]); however, genomic de-
terminants for 5-ALA uptake remain elusive. Using single cell transcriptome analysis,
we found predominant enrichment of proneural cells on 5-ALA (-) sample, supporting
previous observations that GBM cells may be evolved from proneural precursors (p<0.01,
Fig. 3e,)([140]). We also found enrichment of several cell proliferation and migration
markers in the 5-ALA (+) section, including MET and CD44([141], [142], [143]). Notably,
5-ALA (-) tumors, which are conceived as less aggressive, are actually fully-fledged tu-
mors that harbor driver mutations and express tumor aggressive markers (Fig. 4.3e and
4.3f, Supplementary Fig. 6b, 7, 9a and 10). Finally, we studied main and margin samples
from GBM2—a locally adjacent hypermutated case, and found distinct subpopulations of
cells expressingmitotic cell markers andmigration-associated genes, including CD44 (Fig.



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 4.3: Single cell transcriptome from multi-region samples.
(a) Expression profile of individual tumor cells from three samples of GBM9 (left ini-
tial, right initial, and relapse), according to expression subtypes [38]. For each cell, the
subtype with the highest expression is marked with an asterisk. Several EGFR genomic
alterations can be identified in the single cell expression data (yellow), despite the abun-
dance of missing data (gray). (b) Topological representation of the expression data of
individual tumor cells from GBM9, labeled by sample of origin. Each node represents a
set of cells with similar transcriptional profile. A cell can appear in several nodes, and
two nodes are connected by an edge if they have at least one cell in common. Topologi-
cal representation of GBM9 labeled by expression of EGFR (c) and mitotic genes (d). (e)
Expression profile of individual tumor cells from GBM10 (two samples: 5-ALA (+) and
5-ALA (-)). The p-value between proneural and 5-ALA was obtained using Fisher’s exact
test. The p-value between mesenchymal and LTBP4 expression was calculated based on
Spearman’s correlation. ATRX fusion was validated by RT-PCR assays (Supplementary
Fig. 7b-c). Topological representation of expression data of individual tumor cells from
patients GBM10 (f) and GBM2 (g), labeled by the sample of origin. (h) Expression profile
of individual tumor cells from patient GBM2 according to the GBM expression subtypes.
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4.5 Drug Response from mutational analysis
To investigate the influence of genetic heterogeneity on drug response, we isolated 28
PDCs from 11 patients and screened 40 different cancer-related compounds (Supplemen-
tary Table 5)([144], [145]). We found that Nei’s genetic distance was associated with
drug response correlation (p=0.02; Fig. 4.4a). Consistently, both distant and longitu-
dinal samples showed significantly broader drug responses compared to local samples
(Fig. 4.4b). Importantly, we found that the PDCs from M-GBMs were more sensitive to
PI3K/AKT/mTOR (PAM) pathway inhibitors than those from solitary tumors (p=1.872e-6,
Fig. 4.4c and Supplementary Fig. 11). This indicates that PAM inhibitors could provide
clinical benefit for M-GBMs. In addition, we observed that PDCs from recurrent GBMs
were more resistant to EGFR inhibitors, compared to initial (p=2.9e-4, Supplementary
Figs. 12-13).
We hypothesized that clonal alterations found in all multi-sector samples (truncal al-
terations) represent better molecular targets. In agreement with this truncal target hy-
pothesis (Supplementary video), multisector PDCs were more sensitive to drugs that tar-
get shared alterations compared to private alterations (p=0.0381, Methods, Fig. 4.4d; Sup-
plementary Figs. 14-16). TheMultiversemodel implies that the extensive genetic diversity
of multiple tumors presents a special challenge. Accordingly, GBM9 showed a divergent
genetic profile and a highly heterogeneous drug response (Fig. 4.4e-f). PDCs from the
right-side tumor were highly sensitive to EGFR inhibitors but not to MEK inhibitors, and
vice-versa in the left side tumor. However, PAM pathway inhibitors were ubiquitously
effective, consistent with our hypothesis that targeting the PAM signaling pathway could
be a potent option to treat M-GBMs (Fig. 4.4c,f). Yet not all truncal alterations can serve
as drug targets. For example, “gatekeeper” genes, which are necessary for tumor initia-





















































































































































































Fig. 4.4: Chemical screening of multi-region patient-derived cells (PDCs).
(a) PDCs were treated with 40 chemical agents, targeting oncogenic signaling pathways
in diluted series from 20 μM to 4.88 nM. X-axis indicates Nei’s genetic distances between
fragments from the same patient, while y-axis indicates Spearman’s correlation coefficient
(SCC) of corresponding fragments based on drug sensitivities measured by Area Under
the Curve (AUC). (b) A violin plot for SCC of drug responses of the groups described
in Fig. 4a. (c) Mean values of AUCs for six PI3K/AKT/mTOR (PAM) inhibitors (BEZ235,
BKM120, BYL719, AZD5363, AZD2014 and Everolimus) of PDCs isolated fromM- (n=9) or
S-GBMs (n=22) were plotted. (d)The normalized Z-score in each PDC was plotted when
the corresponding tissues harbored associated genetic alterations, designated as “shared”
or “private”. The private group was determined when the drug response-associated ge-
netic alteration (i.e. EGFRmutations-EGFR inhibitors; PTENmutations-PI3K/AKT/mTOR
pathway inhibitors) was private, and vice versa for the shared group. (e) Preoperative
T1-weighted contrast-enhanced MR image and key genomic alterations found in the cor-
responding tumors and its derivative cells from a multicentric patient (GBM9). Right-side
‘R’ tumors encompassed the right frontal lobes and corpus callosum (CC). ‘L’ indicates
the left frontal tumor. Preoperative MRI showed a multifocal infiltrative lesion in both
the frontal lobe and CC. (f) Scatterplot of AUC for 40 cancer-targeting compounds on
GBM9 PDCs derived from the left and right side tumor. The R was obtained as Pear-
son’s correlation coefficient. All p-values in this figure were obtained using Wilcoxson
Rank-Sum test.
79
Vogelstein 1996). Although targeting subclonal mutations show limited effect, patients
might still benefit from the elimination of a subclone that has a bystander effect on sur-
rounding cells.
4.6 Conclusion
In conclusion, based on comprehensive bulk and single cell analyses, we have proposed
a Multiverse model to interpret the evolution of multiple GBMs. We showed M-GBMs
are more genetically diverse than locally adjacent tumors, and genetic similarity between
multi-region samples is associated with consistent drug response. Specifically, we found
an enrichment of PIK3CA mutations in M-GBMs and that PAM inhibitors are more effec-
tive in PDCs from this cohort. These findings support the truncal target hypothesis that
truncal mutations can inform more effective therapies.
Data Availability StatementThe European Genome-phenome Archive (EGA): Coor-
dinates have been deposited with accession code EGAS00001001880 (RNA-seq and WES
data).
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4.7 Methods
Glioma specimens and their derivative cells After receiving informed consents, glioma
specimens and clinical records were obtained from patients undergoing surgery at Sam-
sung Medical Center (SMC) or Seoul National University Hospital (SNUH) in accordance
with its Institutional Review Board (IRB file No. 2010-04-004). Surgical samples measur-
ing approximately 5 × 5 × 5 mm3 were snap-frozen using liquid nitrogen for genomic
analysis. We also curated whole exome and/or RNA sequencing of 33 multisector speci-
mens from 10 GBM patients in TCGA cohort(Kim, Zheng et al. 2015), and 22 previously
reported GBM longitudinal pairs([111], [62]). To investigate the genomic characteristics
of solitary and multifocal/multicentric GBMs, we curated 83 and 77 tumor exome se-
quencing data with matched normal DNA from SMC and TCGA(Kim, Zheng et al. 2015,
Liu, Liu et al. 2015), respectively. Portions of the surgical samples were enzymatically
dissociated into single cells, following the procedures reported previously with modifi-
cation of immune cell depletion(Lee, Kotliarova et al. 2006). Tumor cells were cultured
in neurobasal media with N2 and B27 supplements (0.5x each; Invitrogen) and human
recombinant basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF; 20
ng/ml each; R&D Systems). The patient-derived cells (PDCs) used here had shown no
obvious contamination of mycoplasma.
Radiological evaluation Both T1-weighted contrast-enhancement (T1CE) and fluid-
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attenuated inversion recovery (FLAIR)/T2 axial images of 160 treatment-naïve GBMs (83
and 77 tumors from SMC and TCGA cohort, respectively) were reviewed. MR images of
TCGA cohort have been obtained fromTheCancer ImagingArchive (TCIA)website([146],
[135], [147]). We excluded cases with any evidence of prior neurosurgical intervention ex-
cept biopsy, lack of treatment history, or loss of T1CE or FLAIR/T2 images. To distinguish
the multifocal/multicentric GBMs (M-GBM) from solitary ones (S-GBMs), we adapted an-
notations from the VASARI feature set for human glioma(Rios Velazquez, Meier et al.
2015). According to VASARI feature set, m-GBMs are defined as having at least one re-
gion of tumor, either enhancing or non-enhancing, which is not contiguous with the main
lesion and is outside of the region of signal abnormality (edema) surrounding the main
mass([148], [149], [135]). When FLAIR/T2 high signal intensity lesion resides outside of
the T1-weighted contrast-enhancement lesion, this lesion is considered as separate tumor
foci and counted as multifocal tumor in our study([150], [151]). In contrast, tumors which
present separate contrast-enhancement lesions within the FLAIR/T2 high-signal intensity
background are considered as solitary ones.
Whole-exome sequencing Agilent SureSelect kit was used for capturing the exonic
DNA fragments. Illumina HiSeq2000 was used for sequencing and generated 2 x 101 bp
paired-end reads.
Somatic mutation The sequenced reads in FASTQ files were aligned to the human
genome assembly (hg19) using Burrows-Wheeler Aligner version 0.6.2. The initial align-
ment BAM files were subjected to conventional preprocessing before mutation calling:
sorting, removing duplicated reads, locally realigning reads around potential small indels,
and recalibrating base quality scores using SAMtools, Picard version 1.73 and Genome
Analysis ToolKit (GATK) version 2.5.2. We used MuTect (version 1.1.4) and Somatic In-
delDetector (GATK version 2.2) to make high-confidence predictions on somatic muta-
tions from the neoplastic and non-neoplastic tissue pairs. Variant Effect Predictor (VEP)
version 73 was used to annotate the called somatic mutations. Additionally, we ran SAVI
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(Statistical Variant Identification) software to call somatic variants and indels for refining
the mutation calls from the above pipeline.
Copy number Excavator was used to generate estimated copy number alterations
in tumor specimens compared to its matching non-neoplastic part. For each gene we
calculated the copy number =2x+1), where x is the segmentation mean from Excavator
and defined as the log2 fold-change of tumor divided by normal. The gene was labeled as
“amplified” when the copy number was ≥ 3 and “deleted” when it was ≤ 1.
Cancer cell fractions and clonalityWe ran ABSOLUTE(Carter, Cibulskis et al. 2012)
using input of genomic variants and copy number data to infer sample purity and cancer
cell fractions (CCF) and removed those having <20% purity. We considered mutations as
clonal if indicated clonal in Absolute and with a cancer cell fraction of 80% or having CCF
of 100% and not marked as clonal or subclonal. The Absolute CCF estimates with regard
to hypermutated samples appeared disproportionately subclonal in sample GBM18 inital
and TCGA-14-1402 2nd recurrence and we reasoned the large mutational load may skew
estimates. In hyper mutated samples treatment-associated mutation coupled with defects
in mismatch repair are deemed largely responsible for a majority of observed mutations.
Therefore, mutations having cancer cell fractions greater than or equal to the maximum
mismatch repair CCF were marked clonal in these two samples.
If a mutation was found to be clonal in all sectors of a patient’s tumor, it was inferred
to be clonal throughout the entire tumor. We investigated the number of sequenced tumor
sectors or cores needed to obtain a reasonable false discovery rate (FDR) for this infer-
ence of clonality. We analyzed glioma patient LGG174 published recently by Suzuki et
al., where nine sectors from different locations of the same tumor mass were sequenced.
Based on Figure 7b from their paper([115]), 13 mutations have high cell fraction (>60%)
shared by all samples. To relate the number of sectors sequenced to the number of muta-
tions deemed to be clonal tumor-wide, we exhausted all possible sub-sampling strategies
(number of cores k = 1, 2, …, 9), and calculated the reported clonal mutations based on k
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cores. For example, if there are two cores (k=2), there are (9
2
)
= 36 potential sampling
strategies. We found that 22 out of 36 sampling strategies contained no false discoveries
in identifying clonal mutation. For each value of k, we calculated FDR (Supplementary
Fig. 17). Almost 90% of clonal mutations identified by two-core sequencing are true clonal
mutations, and over 95% identified by three-core sequencing are true clonal mutations.
Nei genetic distances Nei’s genetic distance is used in population genetics to assess
the similarity between populations, taking into account heterogeneitywithin populations.
Samples containing the same spatial or longitudinal category (Local, 5-ALA, Multiple Le-
sion, Longitudinal Local, Longitudinal Distant) were retained for statistical comparisons.
We calculated Nei distance of CCF for each patient’s sample as follows. Let X = all CCF
of sample 1 and Y = all CCF of sample 2:
D = − log
∑
(xiyi + (1− xi)(1− yi))√∑
(xi2 + (1− xi)2)
∑
(yi2 + (1− yi)2)
Themultiverse model of tumor evolutionWe found increased Nei’s genetic distance
in Multi-focal/multi-centric compared with locally-adjacent biopsies. In addition, private
clonal mutations appear frequently in multi-sectional and distant longitudinal samples,
but are infrequent in local samples (Supplementary Figure 2a). This spurred a hypothesis
that specific early event(s) can give rise to distinct mutational profiles in spatially sepa-
rated tumors (Fig. 4.2A). These differences in mutational load suggested distinct tumor
profiles may arise in separate ‘universes’ of clones rather than from one large growth
period followed by diversification.
For each somatic mutation we record the clonal status as determined by ABSOLUTE
and if the mutation is shared or private or if the clonal status changes between biop-
sies. Mutations are then classified into 5 patterns between every available pair of a pa-
tient’s samples. Themutational classes are labeled as the following: CC (clonal-clonal), CS
(clonal-subclonal), SS (subclonal-subclonal), CX (clonal-absent) or SX (subclonal-absent).
Order of the sample pair is not important: a mutation that is clonal in one sample and
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subclonal in the other is marked “CS,” regardless of sample identity.
These mutational classifications were used to predict whether the spatiotemporal con-
figuration of a sample pair fell into one of three groups: locally adjacent, local longitudi-
nal, or multi-sectional/distant-longitudinal. The fractions of mutations in a sample pair
that fit each of the five patterns were used as features in a multinomial-logistic regression.
Predictions were then made using leave-one-out cross validation.
Mutational pairs plotted on the simplex allowed us to visually separate multi-
sectional/distant-longitudinal, locally adjacent or local longitudinal sections in agreement
with most of our MRI classifications. The simplex axes represent the predicted probabili-
ties of outcomes for each observation. Curiously, the sample layout contained 3 longitu-
dinal local outliers closest to the multi-sectional point of the simplex. The time interval
between surgeries of the 3 pairs was 18 months or more. Moreover, their Nei distances
were significantly different from all other sections (p-value = 0.01652). We labeled all
samples exceeding surgical intervals of 18 months as long-term recurrence and colored
them in dark green. Analysis was performed in the [R] computing environment using the
multinom function from the nnet package (https://CRAN.R-project.org/package=nnet).
Isolation of single cells and RNA sequencingWe adopted the C1TM Single-Cell Auto
Prep System (Fluidigm) with the SMARTer kit (Clontech) to generate cDNAs from single
cells. 352R and L cells were captured as a single isolate in C1 chip (17-25 μm) determined
by microscopic examination as previous described. RNAs from pooled samples were also
processed using the SMARTer kit with 10ng of starting materials. Libraries were gener-
ated using Nextera XT DNA Sample Prep Kit (Illumina) and sequenced on the HiSeq 2500
using the 100bp paired-end mode of the TruSeq Rapid PE Cluster kit and TruSeq Rapid
SBS kit. Before mapping RNA sequencing reads to the reference, reads were filtered out at
Q33 by using Trimmomatic-0.30. TPM values were calculated from each single cell (as if
they are different samples) using RSEM (version 1.2.25)(Li and Dewey 2011) and expressed
as log2(1 + TPM).
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Gene fusion detection Chimerascan was applied to generate candidate list of gene
fusions(Iyer, Chinnaiyan et al. 2011). For bulk sequencing, only previously reported
in-frame, high expressing fusions, such as FGFR3-TACC3 [21], MGMT fusion [62],
EGFR-SEPT14(Frattini, Trifonov et al. 2013) and ATRX fusion were considered in this
manuscript. For single cell fusion analysis, if a fusion was highly expressed and indepen-
dently detected in multiple cells the fusion will be reported.
Expression based subtypes determination Gene expression was measured by RSEM
and then log2 transformed. To determine the expression-based subtype of GBM cells, we
first calculated z-scores for gene expression data across samples, and then applied ssGSEA
(version gsea2-2.2.1) on the normalized expression profile. For each cell, we ranked all
genes based on their expression values to create a .rnk file as the input of the software
GseaPreranked. An enrichment score was computed for all four subtypes initially defined
in Verhaak et al(Verhaak, Hoadley et al. 2010). The subtype with the maximal enrichment
score was used as the representative subtype for each cell.
Topological data analysis using Single cell transcriptomeWefiltered out normal cells
based on their expression profile. To that end, we considered expression signatures of nor-
mal oligodendrocytes, neurons, and astrocytes ([152]), microglia ([153]), endothelial cells
([154]), T-cells ([155]), and other immune cells ([156], [155]), and used a Gaussian mixture
model to classify individual cells according to their expression profile. 94/133, 82/85 and
90/137 cells, respectively for GBM9, GBM10, and GBM2, were classified as tumor cells. Af-
ter normalization of gene expression level by dividing total number of reads in each cell to
eliminate the potential bias caused by batch effect, we built topological representations of
these single cell data usingMapper algorithm ([88]), as implemented by Ayasdi Inc. Open-
source implementations of this algorithm are also available (http://danifold.net/mapper,
http://github.com/MLWave/kepler-mapper). We used the first two components of multi-
dimensional scaling (MDS) as auxiliary functions for the algorithm. The output of Mapper
is a low-dimensional network representations of the data, where nodes represent sets of
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cells with similar global transcriptional profiles (as measured by the correlation of the
expression levels of the 2,000 genes with highest variance across each patient). We iden-
tified individual genes that had an expression pattern localized in the network, and used
those to determine the sub-clonal structure of the samples at the level of expression.
PDC-based chemical screening and analysis PDCs grown in serum-free medium
were seeded in 384-well plates at a density of 500 cells per well in duplicate or tripli-
cate for each treatment. The drug panel consisted of 40 anticancer agents (Selleckchem)
targeting oncogenic signals. Two hours after the plating, PDCs were treated with drugs in
a fourfold and seven-point serial dilution series from 20  M to 4.88 nM using Janus Auto-
matedWorkstation (PerkinElmer, Waltham, MA, USA). After 6 days of incubation at 37oC
in a 5% CO2 humidified incubator, cell viability was analyzed using an adenosine triphos-
phate (ATP) monitoring system based on firefly luciferase (ATPLite™ 1step, PerkinElmer).
Viable cells were estimated using EnVision Multilabel Reader (PerkinElmer). Dimethyl
sulfoxide (DMSO) was also included as control in each plate. Controls were used for cal-
culation of relative cell viability for each plate and normalization per-plate basis. DRC
fitting was performed using GraphPad Prism 5 (GraphPad) and evaluated by measuring
Area Under the Curve (AUC) of dose response curve. After normalization, best-fit lines
were determined and the AUC value of each curve was calculated using GraphPad Prism,
ignoring regions defined by fewer than two peaks.
Cell viability was determined via calculating AUC values of dose–response curves
(DRCs) with exclusion of non-convergent fits(Huang and Pang 2012).
Moduli space analysis. To illustrate evolution histories of GBM patients, we applied
moduli space analysis(Ji and Yau 2011) in local and multiple group of patients. Multire-
gion pairs were compared to calculate number of shared and private mutations. In this
analysis, clonal mutations were separated based on their allele frequencies. Sector pairs
were put in left sphere based on the number of shared and private mutations with high al-
lele frequency mutations (>20%), while the same number of pairs were put in right sphere
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based on mutations with low allele frequency mutations (<20%). The same analysis was
then also performed based on inferred clonally.
Immunohistochemistry Tissue specimens were fixed by formalin and embedded in
paraffin. Paraffin-embedded sections were treated with 0.3% Hydorgen peroxide to block
endogenous peroxidase acitivty and antigens were retrieved by heating sections in 10
mM sodium citrate (pH 6.0) for 95 degree Celsius 30 min. Sections were incubated with
primary antibodies overnight at 4 degree Celsius, biotinylated secondary antibodies for 1
hr in RT and avidin-biotin complex for 1 hr in RT.
Western blot GBM PDCs were washed with cold PBS, harvested in lysis buffer (150
mM sodium chloride, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 50 mM Tris-
HCL and 2 mM EDTA), and a protease and phosphatase inhibitor cocktail added (Thermo
Scientific). Insoluble materials were removed by centrifugation at 12000 rpm for 15 min,
4℃. The proteins were separated by SDS-PAGE. Immunoblotting was performed using
antibodies against indicated proteins.
Limiting dilution assay GBM PDCs were dissociated into single-cell suspensions and
then plated into 96-well plates at 1–250 cells per well. Cells were incubated at 37℃ for
one to two weeks. At the time of quantification, each well was examined for formation
of neurosphere-like cell aggregates. Statistical significance was evaluated using Extreme
Limiting Dilution Analysis (ELDA; Walter+Eliza Hall Bioinformatics).
Gene fusion validation Validation of gene fusion transcripts were performed by re-
verse transcription polymerase chain reaction (RT-PCR) assays. Total RNA was extracted
from the tissues by AllPrep DNA/RNA Mini kit according to the manufacturer’s instruc-
tions (Qiagen). Total RNA (1 μg) was reverse transcribed to synthesize template cDNA by
a random primer using the SuperScriptIII First-Strand System(Life Technologies), and 20
μl of synthesized cDNAwas diluted 5 fold with DW. For RT-PCR, EzWay Taq PCRMaster-
Mix (Komabiotech, KOREA) and 5 μl of synthesized cDNA template was used. Thermal
cycling was carried out under the following conditions: 1 min at 95℃ followed by 30
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cycles of 30 sec at 95℃, 30 sec at 56℃, 30 sec at 72℃. The primer pairs used in this exper-
iment were designed to make the amplification product including the breakpoints of the
fusion genes. PCR products were analyzed by agarose gel electrophoresis. The primers





In the literature differing models of evolution describe a general progression of tumori-
genic clones. Clonal evolutionary models have proposed linear, branching, neutral, and
punctated evolution from intra-tumor mutational patterns observed in next generation
sequencing data [72, 86, 94, 157, 158]. In addition, the stem cell hypothesis proposes
a new hierarchical paradigm capable of long-term tumor maintenance and self-renewal
potential. While each model has theoretical merits branching evolution appears better
supported than others.
When considering patterns of ITH there is some confusion as to how one can sys-
tematically classify different patterns of evolution within the context of longitudinal and
multi-sectional sampling. Methods that dissect ITH and infer clonal relationships are ap-
propriate for this task but do not establish clear constraints to possible evolutions or a
general framework in which to work in.
Here is presented a general framework for evaluating pairs of sequenced tumor sam-
ples from longitudinal or multiple section biopsies within the context of evolutionary
models. The models of clonal evolution presented here are classifications that group to-
gether observed mutational patterns into one of six possible models of evolution. These
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mutational patterns are derived from somatic variant allele frequencies in each sample.
Sample pairs are then clustered and classified to obtain a simple score matrix. Each model
is depicted as a phylogenetic tree for visual and mathematical convenience. All models
conform to a set of assumptions that represent the most parsimonious explanation of the
observed data.
5.2 Models of Clonal Evolution
Here is defined a set of 6 models in which each model is depicted as a rooted mutational
phylogenetic tree Ti ∈ T (Fig. 5.1). Clonal evolution begins as a normal cell that acquires
mutations to eventually give rise to a clone with growth advantage. Such a clone will
evolve until either intrinsic or extrinsic forces prevent it, such as surgery and therapy
(see [2] and 1.2 for more details). In each model the root, a normal sample N represents
an ancestral line of germline DNA to the taxa.
A tree T represents acquired alteration(s) as branches. A branch that extends to the
leaves represents a process of clonal evolution in which mutations are acquired until each
of the respective tumors are observed. A split or clustering that occurs after the root
node represents a mutational event that created a new clone and distinguishes a different
genotype. The leaves, denoted as initial and recurrent represent the taxa. The x axis
represents a unitlessmeasurement of time fromwhich the normal (the source of the purple
branch) precedes both the initial and recurrent samples. Likewise the initial sample, (the
target of the blue edge) precedes a recurrent sample (represented as the target of the green
edge) in all models except 2B and 3B. A more formal definition of the tree topology can
be found in later within this chapter in section 5.6.
The 6 clonal models of evolution of 2 samples can be categorized into 3 classes: Type




The transition matrix pictured in the lower left corner of each model defines the possible
mutational prevalences, measured as the fraction of cells harboring a mutation and found
within the initial and recurrent biopsies. Each matrix is labeled on the x and y axis with
C,S,X for clonal, subclonal and absent, respectively to indicate the mutational clonality
in the initial and recurrent samples. The matrix layout permits only certain mutational
transitions to occur within each model. Each mutation is a unique identifier that is a con-
catenation of the genomic location and resulting amino acid change. Those mutational
identifiers in common to both initial and recurrent biopsies will be represented as (CC,
CS, SC, SS), where CC = clonal in both biopsies, CS = clonal in the initial and subclonal in
the recurrent, SC = subclonal in the initial and clonal in the recurrent and SS represents
subclonal in both. The representations are always read initial→ recurrent. Those muta-
tional identifiers absent in one sample will be labeled as (CX, XC, SX, XS). XX mutations
are not labeled as these would not be detected in either sample. The gray colored boxes
of the matrix are common transitions in all models, while the combination of yellow and
blue boxes are transitions to differentiate models. Additionally, the blue boxes indicate
subclonal → subclonal transitions only found in Type III models. An quick example, a
CS transition can only found in models 2B and 3B, as indicated by their transition matrix.
An initial clonal mutation that becomes a subclonal relapse mutation is not permitted in
any other models and therefore will not be found in other transition matrices. A formal

















































































Fig. 5.1: Six models of Clonal Evolution in Initial and Recurrence.
At the root of the tree is a normal ancestor, imagined as a normal cell (in purple). Muta-
tions accumulate in step-wise manner to produce an untreated/initial tumor sample (blue)
and/or a recurrent sample (green). The leaves of the initial and recurrent sample are indi-
cated with a triangle representing clonal diversity. The vertical dotted lines indicate time
of biopsy and hence removal of the sample from the tree. In the lower left corner of each
model is a transition matrix labeled C,S,X for clonal, subclonal and absent, respectively.
In every model are the same three compatible transitions: CC, SX, and XS. Model 1) A
monophyletic clade, Model 2A) Initial is senior, Model 2B) R is senior, Model 3A) Initial
is senior, Model 3B) R is senior, Model 3C) Initial is senior and the recurrent and initial
both have same MRCA.
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5.3 Methods
Genomic data from GBM patients were analyzed for somatic variant calling, copy num-
ber variation, purity and ploidy estimation using the methods described in chapter 3
and chapter 4. As described, mutational calls are made by comparison of a tumor to a
matched control. A unique biopsy label that includes the patient identifier and sampling,
e.g. patient1-initial and patient1-recurrent, or patient1-initial1 and patient1-initial2 using
multisector biopsies is given to the set of variants identified in each patient biopsy.
To assess clonality of mutations mutational alleles were clustered using the method
of SciClone. SciClone is a computational method for estimating the number and genetic
composition of subclones by analyzing somatic variant allele frequencies in diploid re-
gions without loss of heterozygosity from any two biopsies of the same patient. [15]. All
possible sample pairs were analyzed. Clonal clusters were determined by taking the max-
imum mean variant allele frequency per biopsy from among all clusters. It is possible,
for example, that a biopsy pair clusters clonal mutations of initial into a different cluster
than clonal mutations for recurrent. Clusters that were significantly different from the
clonal cluster were labeled appropriately subclonal or absent, otherwise they were labeled
clonal.
Each sample pair is organized into a transition matrix and the number of transitions
(e.g. clonal → clonal) are recorded as an element in the matrix. Incompatibilities are
assessed for each of the six models. The best fitting model is the one with the fewest
incompatibilities. If the sum of incompatible transitions in the transition matrix and the
best fitting model is greater than 0 it was noted in the output and manually reviewed.
Model ties are also possible if only a subset of transitions were detected by sequencing.
All models underwent manual review to resolve model incompatibilities and ties.
A visually depiction of the steps from sample to model selection is shown in (Fig. 5.2)
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➤ 96 cases with 
Initial/Relapse pairs 
with normal control 
(192 samples)➤ 52 cases with 
multisector biopsies 
(127 samples)
➤ Utilized in-house 
SAVI2 for variant 
analysis
➤ CNVs using multiple 
programs
➤ Purity, Ploidy, and 
LOH estimated from
SNVs and CNVs
➤Multiple methods to 
discern clonal 
compositions, results 
are based on SciClone
output.
➤ Clonal cluster is 
compared to all others 
to determine VAF calls 
as clonal, subclonal and 
absent.
Fig. 5.2: GBM model fitting
96 GBM whole exome cases from longitudinal study and 52 from multisectional study
(chapters 3, 4) were analyzed for somatic single nucleotide variants, including indels.
Copy number analysis was performed for all samples, purity and ploidy estimates as well
as loss of heterozygosity. Samples pairs were then input for clonal clustering using the
algorithm SciClone. Clusters were then compared for significant differences and labeled
as clonal, subclonal or absent
5.4 Results in NGS
All cases were manually inspected to verify a sensible best fit was chosen by our scoring
procedure with 0 incompatibilities. Clonal inference of hypermutated tumors yielded
unreliable results as all transitions appeared clonal→ clonal or absent→ subclonal and
were therefore removed from further model analysis.
Longitudinal GBM
Here 77 longitudinal GBM samples were analyzed for model fits in initial and recurrent
samplings. All 12 hypermutated cases were removed after manual review.
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Table 5.1: GBM Longitudinal Cohort Model Fits
Lesion¹ Model # Cases Lesion(%)²
Solitary 1 13 20
Solitary 2a 1 2
Solitary 2b 1 2
Solitary 3a 3 5
Solitary 3b 1 2
Solitary 3c 14 22
Solitary No Match³ 32 49
¹ Solitary cases N = 65
² There are 2 samples per case. This is the
percentage of cases with the indicated le-
sion and best fitting model.
³ Ambiguous or incompatible matches.
Summary Table 5.1 shows 49% of longitudinal pairs could not be confidently fit to a
model using strict criteria. Of these, 12 of 32 cases had incompatible transitions to a best
fit model, of the remaining 20, 12 were tied with one other model and 8 contained only
one cluster.
Model 3C accounted for 22% of solitary samples with a high degree of subclonal shar-
ing between samples.
Approximately 20% of cases fit to model 1. Of these, 5 contained ties (three in 2a and
two to 2b) and one contained an incompatibility and was manually adjusted.
Models 3A,3B, and 3C are similar and determining which model is the true one may
not always be possible in the case of a tie. In these cases 3C is chosen as it is the most
parsimonious of the three. Interestingly, both models 2B and 3B assume that the recurrent
tumor was the first genotype and that the initial tumor was descended from a recurrent
clone. Model 3B was never a best fit, meaning a clonal to subclonal transition did not
occur in the background of 3C. Although, model 2B was a best fit by case R062 having a
clonal→ subclonal cluster containing 4 missense and 1 synonymous variant, all variants
detected were in non-driver genes.
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Fit Details in Solitary GBM
The following cases were classified as Type I: R002, R005, R013, R016, R024, R026, R031,
R036, R048, R067, R098, R100, and R110 and are briefly reviewed here. Case R002 harbored
two mutated members of PI3K family PIK3CG, PIK3R1, and also an NF1 mutation in com-
mon to both initial and recurrence samples. The recurrent sample harbored a private
CDKN2A deletion and two shared CNV events in RB1 and PTEN.
Case 005 contained two frameshifting alterations in cluster 4 that would result in an
incompatible score. As such, cluster 4 was very near the clonal cluster and manually
promoted to Type I, the closest fit model. Both samples contained a missense variant
in gene PIK3CA and copy number alterations in EGFR, CDKN2A and PTEN. One EGFR
mutation was found exclusively in the initial sample.
Case R013 contained one shared missense PTEN variant and no detected driver CNV
events. Case R036, a primary GBM sample harbored IDH1(R132G), ATRX, and TP53 muta-
tions in initial and relapse samples. A shared deletion in CDKN2A and RB1, and amplifi-
cations of CDK4 and PDGFRA were private to the initial. R048 is a low grade glioma from
Johnson et al. [48] that was labeled Patient17 in their cohort. This case was noted in their
paper as having clonal TP53 and ATRX mutations not identified in the recurrent tumor,
but instead different mutations in these genes were acquired at relapse. This indicates a
parallel evolution. Case R100 contained PIK3R1 mutation in both samples and no obvious
copy number alterations in known GBM drivers. Case R110 appeared to harbor PIK3CA
clonal mutation in both samples, however sample purity of the diagnosis is low with a
maximum VAF of 28%.
Multisectional GBM




Only 6 out of 72 (8%) mutational pairs weremarked as having incompatible transitions. Of
these one was a comparison between initial2 and recur2 of a multicentric case GBM9 that
contained an incompatible cluster of 6 subclonal→ clonal mutations. The subclonal clus-
ter mean variant allele frequency differed from the clonal cluster by 5% (40.5/42.6). After
carefully reviewing the data a model 1 fit was chosen from among the most compatible
models.
Ambiguous fits to the 6 models accounted for 35% (25/72) of cases and of these model 3
constituted more than half (56%, 14/25). Solitary lesions fit to every model type, including
2 cases to type I. Overall, 59% of solitary samples having multiple biopsies could not be
confidently assigned a model using our strict criteria.
Eachmultiple lesion case GBM(5,6,8,9) had two initial biopsies best fit to a model 1 and
are reviewed here. Multifocal GBM5 harbored EGFR amplification and CDKN2A deletion
exclusively in the first initial sample. The second initial sample contained an exclusive
clonal TP53 mutation. No other GBM driver gene mutations were evident from the SNV
analysis in either sample, however 31 mutations were exclusively located in the initial
and another 25 only in the relapse.
There was no evidence for somatic point mutations within known cancer drivers in
GBM6 WES data, yet 4 distinct clusters corresponding to CC, XC, XS, CX were found to
have 5 or more supporting variants.
Fit Details in Multiple GBM
Below are the details of model fitting to the Intratumor heterogeneity cohort.
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Table 5.2: GBM IntraTumor Heterogeneity Cohort Model Fits
Lesion¹ Model # Cases Lesion (%)²
MultiLesion 1 4 100
Solitary 1 2 12
Solitary 2a 6 35
Solitary 2b 6 12
Solitary 3a 2 13
Solitary 3b 3 18
MultiLesion 3c 2 50
Solitary 3c 5 29
Solitary No Match³ 10 59
¹ Cases: Multilesion N = 4, Solitary N = 17
² There are multiple samples per case. This is
the percentage of cases with the indicated le-
sion and best fitting model.
³ Ambiguous or incompatible matches.
GBM8 contains two initial and one relapse sample. All samples contain the same
PIK3CA mutation. A model 1 fit describes initial1 and initial2 pairs. Also, initial1 and
recurrence1 fit a model 1. Interestingly, initial2 and recur1 are a type 3C model in which
all clonal and subclonal mutations are in common to both samples. This fit suggests an
MRCA of the recurrence was descendant of the initial2.
GBM9 consists of samples from two initial tumors in the right and left frontal lobes
and a recurrent tumor in the left frontal lobe that emerged after concurrent chemoradio-
therapy (CCRT) and EGFR-targeted treatment (Fig. 5.3). All samples harbored the same
PIK3CA mutation of phenylalanine to cysteine (F1016C) and a deletion of CDKN2A. An
EGFR amplification was only seen in the right side tumor. We confirmed our WES data
using deep sequencing that a putative clonal mutation of EGFR was only located in the
right side tumor (not found in 1639 deeply sequenced reads from the left tumor) and an
additional NF1 mutation found in the left initial and recurrent samples was undetected
in the right initial tumor (not found in 1070 deeply sequenced reads from the right). The
right initial (initial2) when compared to recurrence 1 fit a model 1, however when fit to
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recurrence 2 there appeared to be 6 shared subclonal mutations, that result in an incom-
patible model. Due to lower sequencing depth and the fewest number of incompatibilities
of all models we selected model 1 as the best fit.
The modeling revealed two solitary cases GBM4 and TCGA-06-0152 fit to model 1.
Both GBM4 initial tumors harbored a clonal mutation in the gene PIK3CA, and copy
number alterations that include EGFR amplification and CDKN2A deletion. In addition
an in-frame fusion of genes EGFR and SEPT14 was found in both initial RNA samples.
Interestingly, case TCGA-06-0152 composed of 4 samples, 2 in initial and 2 in relapse
contained 3 pairs that were most compatible with a Type I Model. Model 1 was fit to
initial 1 and initial 2, initial 1 to recurrence 1 and initial 1 to recurrence 2. Such fits could
indicate that the relapse samples were not derived from an ancestor generated by initial
1. Initial 2, however fit to recurrence 1 as model 2A and to recurrence 2 and model 3c.
An EGFR amplification was common to all 4 genomic samples Initial 1,2 and Recurrent
1,2. A CDK4 amplification was found in both initial samples but not detected in either re-
current samplings. However, a mutation of TP53 and deletion of CDKN2A found in both
recurrent samples was not detected in either initial sample. This may suggest clones con-
taining CDK4 amplification did not survive and that both TP53 mutation and CDKN2A
deletion were newly acquired mutations in recurrence. It is also plausible the CDK4 am-
plification exists in recurrence, or that TP53 or CDKN2A existed at initial, but we failed
to sample them in the sequencing. A third interpretation given by the data’s lack of sub-
clonal mutation and increased evidence for private clonal alterations suggests an EGFR
amplification gave rise to a most recent common ancestor that then diverged to form two
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Fig. 5.3: Model fit in multicentric GBM
Multicentric GBM9 model fits of all pairs. The left image in A,B,C,D contains a phyloge-
netic tree of the 4 samplings and magnetic resonance imaging of the tumor lesions within
the brain. A) Initial 1 and Initial 2 model 1 fit. The second panel of violin plots indicate the
4 clonal clusters inferred from 2 geographically separated locations (red,blue highlighted).
PIK3CA in the clonal groups, with EGFR in the initial2 clonal cluster and NF1 in the initial
1 clonal group. The scatter plot shows the variant allele frequencies per biopsy location.
The evolutionary model on the far right is a depiction of the inferred model with clonal
mutations in the branches. B) Recur 1 and Recur 2. C) Initial 1 and Recur 1 also Initial 1
and Recur 2. D) Initial 2 and Recur 1 also Initial 2 and Recur 2.
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Results
The majority of solitary cases were not adequately fit to one particular model (49% longi-
tudinal and 59% multisectional). Previous reports have shown that depth of sequencing
greatly influences the ability to perform clonality analysis and noted that at least 500x
coverage was needed before the majority of variants could be reliably assigned to the
correct subclone [15, 17]. Our longitudinal sample variants were sequenced to 155X (me-
dian=117x) and 162X (median=125x) depth in diagnosis and relapse, respectively. This is
roughly 32% of the recommended 500X depth to resolve subclones to cluster assignments.
In multisectional GBM 33% of the recommended depth of coverage was achieved in vari-
ants sequenced to amean depth of 167X (median=140X) averaged across 7 sections. Model
1 fits with the exception of one sample were not ambiguous as the exclusive combination
of CC, CX and XC were all estimated within the samples.
Discussion
Our previous longitudinal study in therapy treated Glioblastomas (GBM) has shown that
in a fraction of cases very few common mutations coincided with driver mutational loss
from the initial to the relapse sample (see chapter 3). This suggests that the evolution of
these tumors may not follow a common linear or branching model of evolution (Fig. 5.4).
Observations of intratumor heterogeneity in multiple-GBM samples found private
clonal alterations without common subclonal mutation between samples of the same pa-
tient. Significant differences in multiple-lesion sampling vs locally sampled tumors led
to a multiverse hypothesis to interpret the evolution of multiple GBMs (see chapter 4).
A multiverse hypothesis of multiple GBMs posits that, in contrast to locally adjacent tu-
mors, geographically separated multifocal tumors and/or long-term recurrent tumors are
seeded from distinct clones. Unlike most branching models that exhibit a high degree
of subclonal ITH, tumor biopsies derived from different tumor masses were geographi-





















Fig. 5.4: Branching model of evolution in GBM.
A branching model of evolution assumes multiple clones expand in parallel to produce
varying levels of intra-tumor heterogeneity (ITH). Clonal evolution of a normal cell pro-
gresses to produce subclones of differing genotypes. As the clones grow the tumor mass
expands to a detectable size where it is then nearly eliminated by surgery and therapy.
Clones that were not removed and resistant to therapy form the relapse mass, a related,
but selectively advantaged tumor to the one found at diagnosis.
alterations. TDA analysis provided our hypothesis with additional evidence as single cell
expression from multiple region biopsies clustered in geographically distinct patterns.
Based on the supposition that multiple-GBM tumors can be seeded by different clones
we refer to an alternative model of evolution as the migration model (Fig. 5.5).
The exact pathogenetic mechanisms of multiple gliomas are still unknown. Studies
have contributed to our existing knowledge regarding the genesis of these lesions. One
study suggested a two-step hypothesis of tumorigenesis may give rise tomultiple gliomas.
The first step can occur if the brain undergoes a transformation to make it susceptible
for malignant changes. In the second step, various kinds of excessive stimulation from






















Fig. 5.5: Migration model of evolution in GBM.
A Migration model of evolution depicts clonal growth from a normal cell to one that has
acquired a growth advantage. This clone separates into distinct clones that each acquire
private clonal alterations. Subsequent subclonal mutations remain private to each tumor
in the absence of parallel mutational events. One of these clones rapidly grows before
detection and elimination while another transforms into a therapy resistant tumor. One
can also imagine relabeling initial and relapse as 2 geographically distinct tumors.
giving rise to multiple gliomas [41].
A truncal mutation is one exhibited early in tumorigenesis or appears clonally in the
dominant clone during progression. Our data shows the same PIK3CA alteration exists
in all geographically separated samples and strongly indicates the existence of a most
recent common ancestor to all lesions originated in one location. Such a clone would
produce descendant(s) that migrated to different regions of the brain seeding separate
tumors. These results agree with our multiverse hypothesis introduced in chapter 4 that
these tumors were seeded by distinct clones.
A complimentary explanation to describe this phenomenon is the founder effect. Dur-
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ing the growth of the focus there may have been a clonal sweep in which one clone dom-
inated growth and effectively replaced all other clonal populations. The founder effect
occurs after loss of genetic variation in small populations to form a new population that
starts with a subset of the genetic variation present in the larger. Genetic drift could then
allow a subclonal mutation in the new smaller population to be overrepresented once it
has grown to normal size. Such an effect could explain the population dynamics that
underlie the multiverse hypothesis for multiple gliomas.
5.5 Simulations
It is common practice in computational sciences to check assumptions about a system by
simulating data from a definedmodel. Simulations can improve and test hypotheses about
real world systems including tumor cell populations to understand clonal growth and
timings. Detailed forward simulations were used to show the interplay between driver
and passenger mutations [159, 160]. Others have demonstrated the impact of deleterious
passengers on clonal growth [161, 162]. Simulations of cancer evolution in stem cells and
single cells have been implemented in Triple Negative Breast Cancer and Glioblastoma
[87, 163]. Simulations have become so common that a customizable, general simulator
with tunable parameters to modify parameters such as fitness effects, population size,
and numbers of drivers and passengers is available to researchers. [164].
A custom simulator was implemented based on a standard time continuous model to
simulate clonal growth, where cells can divide, die and mutate depending on the popu-
lation size and genotype [164]. The model of growth simulated makes two primary as-
sumptions: 1) that the probabilities that a cell either divides or dies are independent of all
other cells, and 2) that each cell division may result in a mutation, which produces a cell
of a different ‘type’, with different division and death rates which we call a clone. A clone






1. Number of cells to start
2. Mutation rates of driver/passenger
3. Number of drivers and passengers.
4. Fitness of driver/passenger
➤ Gillespie exact 
Algorithm
(Ground Truth)
➤ In-silico variants with 
gaussian noise added 
Fig. 5.6: Simulations pipeline
fitness effects, and birth/death rates. The basic flow of simulations to model selection is
found in Fig. 5.6.
Each simulation outputs a ”molecular sample” akin to a next generation sequencing
experiment that assays DNA from single cells. For computational convenience clones
instead of individual cells are tracked. The number of ”reference” and ”variant reads” are
provided as counts per site in each clone. This allows both driver and passenger mutations
to be exactly counted within every clone. The complete history of each clone is recorded
allowing hierarchical tree reconstruction of the tumor’s clonal population. Each division
or mitotic event will produce an exact replicate cell with the same genotype and increases
the number of that clone by one. Cells may undergo apoptosis which decreases by one
the number of cells for that clone. Finally, a cell may mutate to create either a driver or
passenger mutation. A mutation in a pre-existing clone gives rise to new clones. The
birth rate of new clones is determined at the time of its emergence as a function of its
genotype.
We assume that mutations follow an infinite sites model in which (1) the number of
sites to mutate is infinite, (2) each new mutation gives rise to a new allele never before
seen in the population, and (3) there is no recombination. Thus, any mutational event will
give rise to a new clone within the tumor population.
Mutations can occur either pre or post replication. Pre-replication mutation mim-
ics chromosomal segregation events in which both original cell and daughter cells are
mutated to a new genotype, creating a new clone of size 2. Post-replication mutation





























Fig. 5.7: Simulation and model fit
For each defined model roughly 12 simulations were run. The model simulated and the
the number of times it was simulated are represented on the x and y axes, respectively.
Colored bars indicate the best fit model for the run and labels above the bars are the
inferred model from the simulation pipeline show in, 5.6.
Simulation Results
Approximately 12 simulations per model were run using our stochastic approach. Since
many models share compatible transitions the simulator’s stochastic algorithm output
varying complexities of each model. Several runs resulted in ties between the differing
models. Yet, there were no incompatibilities or false assignments of simulations (Fig. 5.7).
Manual inspection of each simulation shows that tiedmodels were in fact compatible with
both called. In Fig. 5.7 each model is represented on the x axis and the number of times
simulated on the y-axis. The label for the inferred model is above each bar.
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Fig. 5.8: Model Simulations
Models 1,2A,2B,3A,3B,and 3C are depicted as trees. For each model there are 3 graphics.
Left: Simulated clones form a tree-like structure. Right top: The variant allele frequencies
generated from the simulation. Bottom right: Thecompatibilitymatrix for the simulation.
108
Simulator
Traditional approaches to modeling biochemical kinetics over a period of time have re-
lied on continuous deterministic mathematical models. Such models do not incorporate
unpredictability, but rather describe smooth continuous changes of the model’s elements
using mathematical rules. A more recent stochastic approach regards the time evolution
of molecular elements similarly to a random-walk process that is governed by a single
differential difference equation called the ”master equation” [165]. Unfortunately, the
chemical master equation is often mathematically intractable. Fortunately, there exists a
Monte Carlo procedure called a ”stochastic simulation algorithm” or more commonly the
Gillespie Algorithm, proposed by Daniel T. Gillespie that can numerically simulate the
time evolution of a given chemical system [166].
Clonal dynamics
Clonal dynamics are influenced through parameters that define fitness and rates for
drivers and passengers. We used parameters for birth and death according to the lit-
erature [162]. Driver fitness was assumed to be significant (driver.fitness = 0.1, drivers
increase the growth rate by approximately 10%). The growth rate assumed by passen-
ger mutations were a slight disadvantage to the growth of the clone (passenger,fitness =
0.001). The target size for driver mutations (the number of locations that represent driver
alleles) td = 710 (700 + 10). This was based on previous estimates of mutational hotspots
in oncogenes in which 70 genes X 10 activating mutations per gene were modeled pre-
viously [159]. Tumor suppressors have a much larger target size, however mutational
effects should remain mostly silent until a loss of heterozygosity event. In nuanced cases,
such as haploinsufficiency we estimate a target of 10 genes. The target size for passenger
mutations is estimated at 10,000,000, tp = 107.
The mutation rate µ = 10−8 is an approximate of the number of cells that have ac-
quired a mutator phenotype and based on previous simulations [159].
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We clearly define the following parameters: td = 700, tp = 107, µ =
10−8, driver.rate = td ∗ µ, passenger.rate = tp ∗ µ, driver.fitness = 0.01,
passenger.fitness = 0.001
Simulations may vary the implementation of birth and death rates so that one or both
are variable. Here the decision was made to vary the birth rate while the death rate
remains constant at 1. The birth rate of a particular clone is based on the number and
fitness of drivers and passengers and is defined in the following equation:
birth.rate = (1+driver.fitness)number.drivers ∗ (1+ passenger.fitness)number.passengers
(5.1)
Algorithm
AGillespieDirect Method implementation was used to simulate clonal population growth.
See Pseudocode for the direct method 1. The simulator is written primarily in C++ and
utilizes the RCPP framework to interface with the R computing environment.
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Algorithm 1 Simulate clone birth and death process
Require:
1: Input:
maxtime, maxsize, driver.rate, passenger.rate, driver.fitness,
passenger.fitness
2: Output:




4: while T < maxtime and N > 0 and N < maxsize do
5: tr ← CalculateTotalRate(C) ▷ Calculate total rate




8: if rand.uniform() < b then ▷ Is birth: Duplicate, Driver, or Passenger?
9: N ← N + 1 ▷ Increase population
10: t← GetBirthType(driver.rate, passenger.rate)
11: if t = ”driver” then
12: C∗ ← Append(AddDriver(C)) ▷ Add new clone with driver
13: else if t = ”passenger” then
14: C∗ ← Append(AddPassenger(C)) ▷ Add new clone with passenger
15: else
16: AddCloneCount(C ,1) ▷ Increase clone count by 1
17: C∗ ← Update(C)
18: end if
19: else
20: N ← N − 1 ▷ Decrease population
21: end if
22: τ ∼ exp(totalrate) ▷ How long event took





Here we provide a mathematical proof that supports such an alternative model. First, we
will define several objects including the basic construction of the tree.
Definition 5.6.1. A directed graph G = (V, E) consists of a finite set of nodes V and a finite
set of edges E, where each edge e ∈ E is of the form (v, w), with v, w ∈ V
Here we say that e = (v, w) is directed from v to w, where v is the source and w the
target of e. e is an out-edge of v and an in-edge of w. The indegree of a node u is the
number of in-edges of u and the outdegree of u is the number of out-edges of u.
Definition 5.6.2. A tree is a connected graph with no (undirected) cycles.
Edges are also denoted as branches. An external node is also denoted as a leaf.
Definition 5.6.3. A rooted tree T denoted as T = (V, E, ρ), distinguishes one node ρ as
the root.
Definition 5.6.4. Given a set of taxa X , a rooted phylogenetic tree consists of a rooted
tree T = (V, E, ρ) and a taxon labeling λ: X → V that assigns exactly one taxon to every
leaf and none to any internal node.
Note, there is an abuse of notation to refer to T as a phylogenetic tree and also a
graph-theoretical tree on which it is based.
The degree of a leaf is the sum of its indegree and outdegree. In this section a rooted
tree was chosen, as placement of the root generally connotes direction of time 5.9.
Next we will define our data set. Ψinitial is a list of N unique mutations found at
time 1, which we call initial and labeled with a unique identifier that is the amino-acid


































(a) Taxa (b) Tree (c) Phylogenetic Tree (d) Rooted Phylogenetic Tree
Fig. 5.9: Taxa, Tree, Phylogenetic Tree, Rooted Phylogenetic Tree
(a) a set of taxa X , (b) Tree, (c) Phylogenetic Tree T on X , (d) a rooted phylogenetic tree
on mammals, position of root determined by the outgroup chicken. Figure adapted from
”..”
unique mutations found at time 2, called recurrent and labeled by amino-acid change per
genome position. In addition, for each unique identifier there is a record of the mutation’s
cellular-frequency at that time.
Definition 5.6.5. Let Ψ be the set containing the union of all mutation identifiers found
in initial and recurrent samples, s.t. Ψ = Ψinitial ∪ Ψrecurrent.
Definition 5.6.6. Given a set of mutations Ψ, a rooted mutational phylogenetic tree con-
sists of a rooted phylogenetic tree T = (V, E, ρ, λ) and an assignment V → {0, 1}ψ which,
for each v ∈ V indicates the mutation state (0 or 1) at where 0 = not mutated and 1 =
mutated.
Our models use an infinite sites model that makes the following assumptions:
1. The number of sites to mutate is infinite.
2. Each new mutation gives rise to a new allele never before seen in the population.
3. There is no recombination.
Here we define a few methods for convenience
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Definition 5.6.7. Themost recent common ancestor denoted as MRCA of any set of indi-
viduals is the most recent taxon from which all taxa in the group are directly descended.
MRCA(T n): takes in a set of nodes and outputs the MRCA.
Definition 5.6.8. A clade (from Ancient Greek: klados, ”branch”), also known as mono-
phyletic group, is a group of organisms that consists of a most recent common ancestor
and all its lineal descendants, and represents a single ”branch” on the ”tree of life”
Definition 5.6.9. A cluster is any subset of the taxa X , excluding both the empty set ∅
and the full set X
Definition 5.6.10. mut is denoted by the function that takes in a node n in a rooted mu-
tational phylogenetic tree and outputs a set of mutations.
Definition 5.6.11. mutNodes: takes in a tree T and a mutation x and outputs the set of
nodes in T that contain mutation x. mutNodes(T , x) = {T ∈ T s.t. x ∈ mut(T)} Let T x be
the set of nodes that contain mutation x, s.t. Im = mutNodes(I , m). Let T ¬x be the set of
nodes that do not contain mutation x, s.t. I¬x = T \ T x
As previously mentioned for each mutation inΨwe also record the cellular frequency
at each timepoint as the percentage of tumor cells it is found to be in. A strict definition
refers to mutations with cellular frequency = 1 (100%) as clonal (C). Mutations not found
at a particular time point are absent (X), and all other existing mutations are referred to
as subclonal (S). These designations correspond to the rows and columns of our matrix
M. Time 1 and time 2 designate all rows and all columns of M and are labeled Initial
and Recurrent, respectively. Each mutation within the set Ψ is classified as either clonal,
subclonal, or absent.
Let I be the set of all nodes with label I andR be the set of all nodes with label R.
Next we state the lemmas.
Lemma 5.6.1. C→ X ‖ X→ C is incompatible with S→ S.
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Proof. A clonal mutation x induces a clustering of the tree T so that there are two clades
labeled I and R. Let I be the set of all nodes with label I andR be the set of all nodes with
label R. Since x is clonal in nodes labeled I and also absent in nodes labeled R I = Ix and
Rx = ∅
An S → S mutation means there exists a mutation m defined as an edge or branch e
that induces a cluster separating the nodes labeled I into two populations. Let Im be the
set of nodes that contain mutation m, Im = mutNodes(I , m) and I¬x = I \ Ix. Likewise,
we have a cluster C’ separating the nodes labeled R into two subpopulations: Rm and
R¬m.
Let δ be the target node of edge e. Since δ is the target of e, it must contain mutation
m and must also be an ancestor of Im andRm.
By infinite sites assumption nomutation can occurmore than once. Thismeans δmust
be a descendant of MRCA(I), and we know the MRCA(I) contains mutation x. Therefore
δ must contain mutation x. However, we know that nodes labeled R are not mutated for
x. Since δ is an ancestor ofRm it cannot contain mutation x. This is a contradiction.
By symmetry we make the same argument that X → C is incompatible with S → S
by simply swapping the labels I and R.
Lemma 5.6.2. S→ C is incompatible with C→ S.
Proof. An S→Cmutation can be represented as Si → Cr in which there exists a mutation
x defined as an edge or branch e that induces a cluster separating the nodes with label I
into two subpopulations. As before let Ix be the set of nodes in I that contain mutation
x, Ix = mutNodes(I , x) and I¬x = I \ Ix.
Let α be the target node of edge e. Since, α is the target of e it must contain mutation
x and also be an ancestor of Ix.
Since x is a clonal mutation inR, x ∈MRCA(R). α is the target of x so α must be an
ancestor of MRCA(R). It follows that α is an ancestor to both Ix, andR.
115
A C → S mutation means there exists a mutation y defined as an edge or branch e’
that induces a cluster separating the tree T so that there are two clades those with nodes
mutated for y and those with nodes not mutated for y. Let I be the set of all nodes with
label I and R be the set of all nodes with label R. Since y is clonal in nodes labeled I
nodes(I) = mutNodes(I ,x) and since y is subclonal in nodes labeled R Let Ry be the set
of nodes that contain the mutation y,Ry = mutNodes(R, y). andR¬y be the set of nodes
that does not contain the mutation y.
Let β be the target node of edge e’. Since, β is the target of e’ it must contain mutation
y and be an ancestor ofRy. Additionally, β must be a descendant of MRCA(R)
α is an ancestor toR and β is ancestor toRy but notR¬y, so αmust be an ancestor to
β. However, β is an ancestor to I and α is an ancestor to Ix and not I¬x, thus β must be
an ancestor to α! α cannot be both an ancestor to β and a descendant of β unless α = β
which is a contradiction to the subclonality!
Lemma 5.6.3. C→ X is incompatible with S→ C.
Proof. A clonal mutation x induces a clustering of the tree T so that there are two clades
labeled I and R. Since x is clonal in nodes labeled I and also absent in nodes labeled R
nodes(I) = mutNodes(I ,x) and mutNodes(R,x) = ∅
An S→ C mutation can be represented as Si → Cr in which there exists a mutation
m defined as an edge or branch e that induces a cluster separating the nodes with label
I into two subpopulations. Let Im be the set of nodes in I that contain mutation m and
I¬m = I \ Im.
Let α be the target node of edge e. Since, α is the target of e it must contain mutation
m and also be an ancestor of Im, but not an ancestor to I¬m. Sincem is a clonal mutation
inR, m ∈MRCA(R). α must also be an ancestor ofR. It follows that α is an ancestor to
both Im, andR.
By infinite sites assumption no mutation can occur more than once and this means
α must be a descendant of MRCA(I) and we know the MRCA(I) contains mutation x.
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Therefore α must contain mutation x. However, we know that nodes labeled R are not
mutated for x, but α is an ancestor ofR. This is a contradiction.
Lemma 5.6.4. X→ C is incompatible with C→ S.
Proof. Proof is symmetric to proof of lemma 5.6.3
A proposition can be stated here as follows:
Proposition 5.6.5. The six labeled trees represent the only possible maximally parsimo-
nious evolutionary models summarizing a two-sample data-set consisting of a list of mu-




In this thesis we have reviewed some of the theory and examples from cancer literature
surrounding evolutionary heterogeneity in cancers. Correct identification of mutational
events from next generation sequencing data is foremost to identifying intra-tumor
heterogeneity. Evidence of patterns in driver and passenger mutations have given way
to classifying tumors, identifying mutational signatures, and defined different possible
models of evolution. The foundational model of cancer evolution, the clonal evolutionary
model was proposed by Nowell in 1976 and continues as the most widely accepted model
of tumor growth. Alternative models of growth have shown promise and may continue
to provide evidence with newer technologies in sequencing such as single cell.
A detailed study in clonal evolution of Glioblastoma under treatment identified
important biomarkers in glioma, obtained a potential order to their appearance and
hypothesized that the clone at the initial presentation is not necessarily a descendant to
a clone at relapse. The appearance of relapse specific alterations indicate that many of
the drivers of glioma are already present in the tumor clone and that therapy may play
a leading role in later alterations. Mutational abundance was able to identify a group of
hypermutated patients that contain therapy driven signatures of mutation that appear
to be the adaptation of the cancer to treatment. Expression profiles from longitudinal
studies do not appear to be stable markers of glioma subtypes.
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A second study identified multiple GBMs as more heterogeneous than solitary tumors
using a metric of intratumor heterogeneity. The appearance of great numbers of private
clonal mutation coupled with few to no subclonal mutations between tumor sections led
to a multiverse hypothesis in multiple gliomas. Single cell expression data supported our
observations of heterogeneity in multiple GBMs. Topological data analysis demonstrated
clustering of expression profiles strongly associated to physical location of biopsies.
From patient derived cell lines subjected to treatment we observed genetic distance was
associated with to correlation of treatment outcome. Truncal mutations did respond
better to matched targeted therapy than subclonal alterations. Indicating mutations
found in all tumor clones could represent a potent cancer weakness.
In our final study we proposed the migration model of growth in which tumors, par-
ticular those in multiple GBMs are seeded by separate clones from a common progenitor
early in progression. This phenomenon was observed entirely in our multiple GBM co-
hort and in a few solitary cases. Our 6 models of evolution describe the phenomenon
of multiverse and provide a more general structure for evaluating paired genomic sam-
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Abstract
Dissecting the pathogenesis of classical Hodgkin lymphoma (cHL), a common cancer in
young adults, remains challenging due to the rarity of tumor cells in involved tissues (usu-
ally <5Here, we analyzed the coding genome of cHL bymicrodissecting tumor and normal
cells from 34 patient biopsies, for a total of 50,000 singly isolated lymphoma cells. We
uncovered recurrently mutated genes, namely STAT6 (32% of cases), GNA13 (24%), XPO1
(18%) and ITPKB (16%), and document the functional role of mutant STAT6 in sustaining
tumor cell viability. Mutations of STAT6 genetically and functionally cooperated with dis-
ruption of SOCS1, a JAK-STAT pathway inhibitor, to promote cHL growth. Overall, 87of
cases showed dysregulation of the JAK-STAT pathway by genetic alterations in multiple
genes (also including STAT3, STAT5B, JAK1, JAK2, PTPN1), attesting to the pivotal role
of this pathway in cHL pathogenesis, and highlighting its potential as new therapeutic
target in this disease.
Introduction
Classical Hodgkin lymphoma (cHL), a common cancer in young adults, can be cured by
chemotherapy and/or radiotherapy in the majority of cases [167]. However, about 20%
of patients are refractory to, or relapse early after treatment, with consequent subop-
timal outcome, thus representing an unmet medical need. Furthermore, the burden of
Material in this chapter is published wholly or in part by Enrico Tiacci*, Erik Ladewig*, Gianluca
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late-onset therapy-induced toxicities (e.g, lung and heart dysfunction; secondary cancers;
infertility) is of increasing concern in all cHL patients receiving chemo-radiotherapy at a
young age1. A deep understanding of cHL biology is therefore highly desirable. However,
the pathogenesis of cHL in general, and its underlying genetic lesions in particular, have
proven difficult to elucidate because of the rarity of Hodgkin and Reed-Sternberg (HRS)
tumor cells in the involved lymph nodes. HRS cells usually account for <5% of the total
cellularity, and are embedded in an immune suppressive inflammatory background that
is thought to be recruited by the HRS cells themselves for fostering their growth and for
evading the host anti-tumor response2,3. Progress in understanding the biology of cHL
has therefore required the laborious purification of HRS cells from tissues (by microdis-
section or FACS sorting), which led to clarifying the genetic origin of HRS cells from
normal germinal center B cells despite the dramatic loss of the typical B-cell phenotype
[168, 169]. Various genetic lesions have then been found to be recurrent in fractions of
cHL cases, which result in constitutive activation of the anti-apoptotic and pro- inflam-
matory NF-κB and JAK-STAT signaling pathways (e.g, TNFAIP3 and SOCS1 disruption,
respectively) as well as in immune evasion (e.g., PDL1/PDL2 copy number gain; B2M
and CIITA disruption) [168, 169]. However, a comprehensive characterization of cHL by
whole-exome sequencing, beyond that of a few cell lines [170, 171] and primary cases6,
is currently lacking. Here, we fill this gap and unravel identify several genes that are
mutated at notable frequencies and may represent new therapeutic targets in this disease.
Materials and Methods
Laser microdissection and whole-exome sequencing (WES)
Full details are provided in the Supplemental data, including a novel bioinformatics
pipeline for calling somatic mutations and the methodological approaches (targeted se-
quencing and digital PCR) used to validate it.
Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) for JAK2, TNFAIP3 and B2M was performed
according to standard protocols described in the Supplemental data.
Functional experiments in cHL cell lines
L1236, HDLM2, L540 and L428 cells were subjected to lentiviral transduction of anti-
STAT6 short-hairpin RNAs (shRNA) or the SOCS1 coding sequence, followed by mon-
itoring of cell death, as described in the Supplemental data. These data are shown in the
main text as raw percentages of viable cells (and in supplementary figures as percentage
of viable cells relative to the corresponding infected negative control set at 100%) because
cHL cell lines are notoriously difficult to infect and their viability often decreases after
infection, which may potentially influence the sensitivity of each cell line to different
treatments.
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The same four cHL cell lines as well as two additional ones, i.e. SUPHD1 and UHO1,
were also treated with the JAK2 inhibitor fedratinib and/or the XPO1 inhibitor selinexor,
and then monitored for apoptosis and/or viability as detailed in the Supplemental data.
The experiments with fedratinib, which were aimed at confirming pharmacologically
the apoptosis induction observed upon genetic silencing of the JAK-STAT pathway with
STAT6 sh-RNAs, were performed with fedratinib concentrations in the low micromolar
range (1.5 μM and 3μM) based on the drug concentration (1.5 μM) previously established
to cause 50% of maximal growth inhibition (IC50) in the STAT6 wildtype cHL cell line
L428 [172]. The experiments with selinexor aimed at providing an initial assessment of
the potential dependency of HRS cells on XPO1, andwere performed at the dose of 100 nM
based on the median IC50 value of 123 nM that was previously established in 23 hema-
tological and solid tumor cell lines (including the B-cell lymphoma line Ramos, where
selinexor IC50 was also 123 nM) [173].
Western blotting was performed to verify STAT6 downregulation and exogenous
SOCS1 expression following lentiviral transduction, as well as to analyze the phospho-
rylation status of STAT transcription factors basally and after JAK2 inhibition, using the
procedures and reagents described in the Supplemental data. All experiments were inde-
pendently performed at least twice, giving reproducible results.
Results
The cHL coding genome
In order to define the genetic basis of cHL, we laser-microdissected HRS cells [174]
(n=1200- 1800 per case), along with a similar number of adjacent non-neoplastic cells,
from hematoxylin/eosin-stained frozen lymph node sections of 34 cHL patients (Table S1;
Fig. S1). DNA from each tumor and matched normal sample was subjected in duplicate
to whole-genome amplification (WGA) and independent whole-exome sequencing (WES)
of the duplicates in order to control the bias introduced by the WGA reaction, by means
of a novel bioinformatics pipeline ad hoc designed (see Supplemental data). Unamplified
germline DNA from peripheral blood cells was also included as control in 26/34 patients.
The median coverage depth in WGA-tumor, WGA-normal and unamplified normal
samples was 99, 114 and 142, respectively (Table S2; Fig. S2). We identified a median of
47 non-silent somatic mutations per tumor that were present at ≥20% variant allele fre-
quency (VAF), hence, presumably in the major tumor clone (median: 43 single-nucleotide
variants and 3 short indels per tumor (Fig. S3; Table S3). Deeper sequencing analysis of
WGA-DNA for 150 candidate tumor- specific changes, identified across 26 samples previ-
ously subjected toWES, confirmed the presence of 139 mutations (93%), including 130/139
(93%) single-nucleotide variants and 9/11 (82%) short indels, validating the high specificity
of the approach (Table S4). Importantly, allele frequency estimates of somatic mutations
in the deep targeted sequencing experiment were highly similar to those obtained in the
WES experiment (correlation=0.88, p-value <2.2e-16, Fig. S4). Somatic mutations of se-
lected genes were also validated by Sanger sequencing on tumor versus normal WGA-
DNA (Table S5), and somatic variants of the most recurrently targeted gene (STAT6) were
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also confirmed by digital PCR to be present in unamplified DNA from whole-tissue sec-
tions at frequencies (Table S6) consistent with the low percentage of HRS cells typically
present in lymph node biopsies.
In addition to previously known targets of genetic lesions in cHL (B2M; TP53; SOCS1,
JAK2 and PTPN1; and the NF-κB pathway inhibitors TNFAIP3 and NFKBIE) [168, 169,
175], this analysis revealed several recurrently mutated genes that had not been previ-
ously implicated in the genetics of cHL or had not been functionally assessed, the most
common of which were STAT6 (32% of cases), GNA13 (24%), XPO1 (18%) and ITPKB (16%)
(Fig. 1 and Table S3).
Pervasive mutational targeting of JAK-STAT pathway genes in cHL
The most prominent genetic hallmark of cHL was represented by mutations in the
JAK/STAT signalling pathway (Fig. S5), with STAT6 and SOCS1 being the two most com-
monly affected targets (32% and 59% of cases, respectively). Missense mutations (n=18) of
the STAT6 DNA binding domain were found in 11/34 (32%) cases (Figs. 1 and 2), including
a highly recurrent hotspot at the N417 residue (9/18 mutations) and two additional ones
at D419 and N421 within the same binding loop region (3/18 mutations each). These
variants largely overlap with those reported in primary mediastinal B-cell lymphoma
(PMBCL), relapsed-refractory germinal center B (GCB)- type DLBCL, and follicular lym-
phoma, where their role as gain-of-function or loss-of-function events with respect to
STAT6 transcriptional activity is controversial [176–179]. Mutations were heterozygous
in all cases, except one (no. 8) showing an 83% VAF, possibly indicating loss of the wild-
type allele or, as already shown to occur in cHL, amplification of the mutant allele [177,
180]. In 6 cases, the same allele was targeted by multiple mutations affecting up to 3
distinct codons (Figs. 2A and S6).
Because gains/amplifications of JAK2 and mutations of the JAK-STAT pathway in-
hibitor SOCS1 are frequent in cHL [168, 181–183], we examined the distribution of these
lesions relative to STAT6 mutations across the 34 cases. JAK2 copy number increase, de-
tected in 11/33 evaluable cases, was not preferentially associated with STAT6-mutations
(4/10 STAT6 mutated cases, 40%; versus 7/23 wild-type cases, 29%; p-value: 0.7, Fisher’s
exact test). Conversely, SOCS1 mutations, composed predominantly of frame-shifting
and non-sense events, were significantly enriched in STAT6- mutated cases (n=9/10, ver-
sus 7/17 STAT6-unmutated lymphomas; p=0.018) (Fig. 1). This preferential association
was significant even when considering only SOCS1 disruptive variants (n=8/10 versus
6/17; p=0.046) and suggests a genetic interaction between STAT6 mutations and SOCS1-
inactivating events in cHL.
Besides STAT6 and SOCS1 mutations, multiple genetic lesions predicted to activate
transducers of JAK-STAT signaling (JAK1, JAK2, STAT3, STAT5B) or to inactivate its in-
hibitor PTPN1 were found in 8 additional STAT6 wild-type cases lacking (or not evaluable
for) SOCS1 (Fig. 1, Tables S3 and S5). Thus, 87% (26/30) of the evaluable cHL cases carried
genetic lesions in members of the JAK/STAT cascade (Fig. 1). Together, these findings
point to a key pathogenetic role for this signaling pathway in cHL through pervasive
genetic targeting of JAK-STAT members (Fig. S5).
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Genetic and functional cooperation between STATs mutation and
inactivation of the JAK-STAT inhibitor SOCS1
STATs transcription factors become activated upon phosphorylation by JAK tyrosine ki-
nases that transduce cytokine receptor signals, leading to STATs dimerization and translo-
cation to the nucleus19 (Fig. S5). In cHL, phosphoSTAT6 expression by primary HRS cells
is observed in the vast majority of cases ( 80%)20-22, suggesting constitutive activation of
this transcription factor downstream of JAK signaling. To assess the relevance of STAT6
and SOCS1 mutations in the growth and survival of the cHL clone, we independently
tested the consequences of STAT6 silencing or SOCS1 reconstitution on cell viability, us-
ing 3 phosphoSTAT6+ cHL cell lines harbouring STAT6 and SOCS1 alleles in different
configurations, i.e. L428 and HDLM2 (both carrying inactivating SOCS1 mutations and
wild-type STAT6), and L1236 (carrying an inactivating SOCS1 mutation, and expressing
an amplified N417Y-STAT6 mutant allele but not wild-type STAT6 [177]), whereas the
L540 cHL cell line, which lacks mutations in both genes and shows no STAT6 phospho-
rylation, was used as control [170–172, 177, 184, 185].
ShRNA-induced knock-down of total (and phospho) STAT6 with either of two inde-
pendent shRNAs consistently caused marked apoptosis in the STAT6 mutated L1236 cells,
while it had no or a less pronounced effect in the 3 STAT6wild-type cell lines, independent
of whether they showed STAT6 phosphorylation (Fig. 3; Fig. S7). Thus, STAT6 mutations
may contribute to sustaining the growth of cHL cells through a mechanism that is distinct
from (and beyond that) of STAT6 phosphorylation.
We then transduced wild-type SOCS1 alleles in the same four cell lines. As ex-
pected, exogenous SOCS1 expression significantly suppressed STAT6 phosphorylation
in the three pSTAT6+ cells (Fig. 4, top). However, this was accompanied by significant
apoptosis only in the two cell lines harboring concurrent mutations of SOCS1 and STAT
family members, i.e. L1236 and HDLM2 (Fig. 4, bottom), the latter carrying an acti-
vating heterozygous D661Y hot-spot mutation of the STAT3 SH2 domain (COSMICv76
database; [171]). The D661Y mutation is recurrent in T/NK-cell neoplasms and was pre-
viously shown to be associated both with STAT3 constitutive phosphorylation and with
increased transcriptional activity [186]. Indeed, western blot analysis confirmed basal
STAT3 phosphorylation in this cell line, which was abrogated upon enforced expression
of exogenous SOCS1 (Fig. S8).
Consistent with these findings, treatment with the JAK2 selective inhibitor fedratinib
was toxic to L1236 and HDLM2, but not to L428, despite efficient dephosphorylation of
STAT6 and STAT3 (Figure 5).
Collectively, these data suggest a cooperative activity between mutations of STAT
family members and genetic inactivation of SOCS1 in sustaining cHL growth. In sup-
port of this model, 2/8 cHL tumors with SOCS1 disruptive mutations and wild-type
STAT6 alleles carried activating mutations in other STAT family members, including a
T628S substitution in the SH2 domain of STAT5B (also described in T-cell prolympho-
cytic leukemia)[187] and a D661Y substitution of STAT3 (Fig. 1 and Table S3).
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Recurrent GNA13 mutations in cHL
A second finding of this study is the identification target of recurrent mutations in cHL
was GNA13, encoding for the Gα13 subunit of heterotrimeric G-proteins (n= 8/34 cases,
24%) (Figs. 1 and 6A; Table S5). By transmitting signals from the G-protein coupled recep-
tors S1PR2 and P2RY8 that result in inhibition of AKT phosphorylation, Gα13 ensures the
proper confinement of proliferating GCB cells within secondary lymphoid follicles, and
at the same time constrains their expansion by facilitating apoptosis in this potentially
dangerous niche [188–190].
GNA13 variants in cHL were mostly heterozygous and included non-sense, frame-
shifting and missense mutations. This pattern overlaps with that observed in Burkitt
lymphoma and diffuse large B-cell lymphoma (DLBCL) of the GCB-type, and is com-
patible with loss of Gα13 signalling activity [189–195]. Mutations of GNA13 in cHL were
strongly associated with STAT6 mutations, being detected in 7/11 STAT6-mutated sam-
ples (64%) as compared to 1/25 (4%) STAT6-unmutated patients (p-value 0.0003, Fisher’s
exact test) (Fig. 1).
Frequent inactivating mutations of ITPKB in cHL
Four of 25 (16%) evaluable case harbored heterozygous somatic mutations in ITPKB (Fig.
6B). ITPKB encodes for a kinase converting the second messenger inositol trisphosphate
(IP3) to IP4, a soluble antagonist of the AKT-activating PI3K-product IP3 [196]. All 4
ITPKB-mutated lymphomas showed disruptive frame-shifting variants predicted to gen-
erate truncated proteins lacking the kinase domain and, therefore, to boost PI3K-AKT
signalling, a characteristic and growth-promoting feature of HRS cells that is amenable
to pharmacologic inhibition [197, 198]. Additionally, one of these 4 cases harbored 3 mis-
sense mutations in the gene exon 2, the significance of which remains to be established.
Recurrent hot-spot mutations of XPO1 correlating with cHL cell
vulnerability to the clinical XPO1 inhibitor selinexor
Heterozygous missense mutations of XPO1 at the hot-spot residue E571 were found in
6/34 patients (18%) (Figs 1 and 7A); this amino acid is known to contact a prototypic nu-
clear export signal (NES) [199, 200] and is also recurrently targeted by somatic mutations
in PMBCL and, at a lower frequency, in CLL [179, 201]. E571-XPO1 mutations have been
also detected in whole biopsies of cHL cases, although formal proof of their actual pres-
ence in HRS cells was missing. XPO1 (alias CRM1) shuttles outside the nucleus over 200
cargo proteins harbouring a NES, including known tumor suppressors involved in cHL
lymphomagenesis and functioning in the nucleus (e.g., TP53 and NFKBIA) [168, 199, 202–
205]. XPO1 is overexpressed in various cancers and inhibition of its activity appears more
toxic to tumor cells than normal cells [204–206]. We thus tested the antitumor effect of
selinexor, a clinical compound that inhibits XPO1 function by covalently binding to the
C528 residue in its NES-binding groove [207], in 6 cHL cell lines with wild type or mu-
tated XPO1 alleles. Interestingly, selinexor reduced growth and caused apoptosis in two
cHL cell lines carrying the E571Kmutation (SUPHD1 and UHO1), but not in four cell lines
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that lacked this mutation (L428, L540, HDLM2) or had a low mutant allele burden (L1236)
(Fig. 7B; Fig. S9).
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Fig. 1: Recurrently mutated genes in the tumor cells of cHL
(Top) Total number of nonsilent somatic mutations present in each of the 34 cHL cases,
identified by their identification number and annotated based on histological subtype (ld,
lymphocyte depletion; lr, lymphocyte-rich; mc, mixed cellularity; nc, not classifiable; ns,
nodular sclerosis). EBV infection status, presence/absence of JAK2 copy number gains,
and the status of 3 JAK-STAT pathway genes (PTPN1, STAT3, and STAT5B) that were
found mutated in ,3 cases are provided for individual cases (columns) in the heat map be-
low, along with the mutation pattern of genes found mutated in ≥ 3 cases (rows). Color
codes at the bottom denote the type of mutation. The bar plots on the right give the per-
centage and absolute number of cases showing the feature displayed in the corresponding
row across all samples.
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Other recurrently mutated genes
Genes encoding inhibitors of the NF-κB pathway (in particular NFKBIE, NFKBIA and TN-
FAIP3) are known to be recurrently targeted by inactivating mutations and/or deletions
in cHL [180, 184, 208–212]. Accordingly, disruptive somatic mutations of the NF-κB path-
way inhibitor NFKBIE (encoding for IκBɛ) were identified in 5/34 (15%) cases (Figs. S10,
Tables S3 and S5). While we observed monoallelic deletions of TNFAIP3 in 12/33 (36%)
cases by FISH, no mutations were detected in this gene by WES, and targeted deeper se-
quencing (performed on 28/34 cases) only identified a non-sense mutation in one case
(Table S5). The low frequency of TNFAIP3 mutations in our series does not seem to be
explained by insufficient coverage depth, as the mean percentage of TNFAIP3 coding nu-
cleotides with ≥20X coverage in the targeted deep-sequencing data of the tumor samples
was 87% (interquartile range, IQR: 83-94%). The NFKBIA gene, encoding another NF-κB
pathway inhibitor (i.e., IκBα) less frequently mutated (17% of cHL cases [210, 213–215]),
was also not affected in our series both upon WES and upon targeted deeper sequencing
(average percentage of coding nucleotides with ≥20X coverage in tumor samples: 76%,
IQR-63-95%). Overall, genetic lesions in negative regulators of the NF-κB pathway oc-
curred in 44% of cHL cases (15/34) confirming their important role in the pathogenesis of
this disease.
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Figure 2. STAT6mutations in cHL. (A) Secondary structure of the STAT6 protein, with the mutations found in cHL cases (green circles) clustering in the DNA binding domain.
The latter is enlarged below to depict individual STAT6 alleles from 6 patients each carrying multiple monoallelic STAT6 mutations. (B) Sanger-sequencing validation in
1 representative case confirms the presence of a heterozygous STAT6mutation (D419G) in both tumor WGA-DNA duplicates, but not in matched normal WGA-DNA. (C) Digital
polymerase chain reaction analysis allows the backtracking of a somatic N417Y mutation in the unamplified tumor DNA of case 14 extracted from whole-tissue sections of a
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Fig. 2: AT6 muta i ns in cHL.
(A) Secondary structure of the STAT6 protein, with the mutations found in cHL cases
(green circles) clustering in the DNA binding domain. The latter is enlarged below to de-
pict individual STAT6 alleles from 6 patients each carrying multiple monoallelic STAT6
mutations. (B) Sanger-sequencing validation in 1 representative case confirms the pres-
ence of a heterozygous STAT6 mutation (D419G) in both tumor WGA-DNA duplicates,
but not in matched normal WGA-DNA. (C) Digital polymerase chain reaction analysis
allows the backtracking of a somatic N417Y mutation in the unamplified tumor DNA of
case 14 extracted from whole-tissue sections of a lymph node biopsy (left), but not in the
DNA of a peripheral blood sample analyzed as a negative control (right); the same muta-
tion had been originally identified by WES in the WGA-DNA of microdissected tumor vs
normal cells. The low variant allele frequency (0.9%) reflects the known paucity of cHL
tumor cells in the involved tissues (see supplemental Table 6 for the full results of digital
polymerase chain reaction validation).
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In agreement with a previous study [184], somatic mutations of B2M, encoding a pro-
tein indispensable for MHC-class I expression on the cell surface, were observed in 9/34
(26%) cases, including 7 with disruptive variants (non-sense, frame-shifting, splice site or
start-codon loss) and 2 with missense variants (Fig. 1, Tables S3 and S5). Monoallelic
deletion of B2M were observed in 2/29 evaluable cases, one of which (no. 2) also carried
a splice site mutation of the other allele. Furthermore, one additional case (no. 29) had a
heterozygous splice site inactivation of NLRC5 (Table S3), which encodes for the master
MHC class I transactivator CITA and has been shown to be a target of immune evasion
in solid cancers [216]. In cHL, another genetic mechanism of immune escape is repre-
sented by relative copy number gain or amplification of 9p24 [217], which we observed
by FISH in 11/33 (33%) evaluable cases (Fig. 1). The gained/amplified region includes, be-
sides JAK2, the PDL1 and PDL2 genes encoding for surface ligands that inhibit activation
of T cells expressing the PD1 receptor. Overall, genetic lesions fostering immune eva-
sion 10 (mutations/deletions of B2M or NLRC5; copy number gain/amplification of 9p24)
were observed in 53% (18/34) of cases (Fig. 1 and Table S3), confirming their important
contribution to cHL lymphomagenesis.
Notably, somatic mutations of the chromatin-modifying genes KMT2D (alias MLL2),
CREBBP, EP300 and EZH2, which are frequent in diffuse large and follicular B-cell lym-
phoma [193, 218, 219], were only occasionally observed in cHL (Table S3), and included a
heterozygous hotspot mutation R1446H affecting the CREBBP acetyl-transferase domain
in one case (no. 37).
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suggesting constitutive activation of this transcription factor down-
stream of JAK signaling. To assess the relevance of STAT6 and
SOCS1 mutations in the growth and survival of the cHL clone, we
independently tested the consequences of STAT6 silencing or
SOCS1 reconstitution on cell viability, using 3 phosphoSTAT61 cHL
cell lines harboring STAT6 and SOCS1 alleles in different configu-
rations (ie, L428 and HDLM2, both carrying inactivating SOCS1
mutations and wild-type STAT6, and L1236, carrying an inactivating
SOCS1 mutation and expressing an amplified N417Y-STAT6
mutant allele but not wild-type STAT612), whereas the L540
cHL cell line, which lacks mutations in both genes and shows no
STAT6 phosphorylation, was used as control.4-7,12,20
ShRNA-induced knockdown of total (and phospho) STAT6 with
either of 2 independent shRNAs consistently caused marked
apoptosis in the STAT6-mutated L1236 cells, whereas it had no
or a less pronounced effect in the 3 STAT6 wild-type cell lines,
independent of whether they showed STAT6 phosphorylation
(Figure 3; supplemental Figure 7). Thus, STAT6 mutations may
contribute to sustaining the growth of cHL cells through a
mechanism that is distinct from (and beyond that) of STAT6
phosphorylation.
We then transduced wild-type SOCS1 alleles in the same 4 cell
lines. As expected, exogenous SOCS1 expression significantly
suppressed STAT6 phosphorylation in the 3 pSTAT61 cells
(Figure 4, top). However, this was accompanied by significant
apoptosis only in the 2 cell lines harboring concurrent mutations
of SOCS1 and STAT family members; that is, L1236 and HDLM2
(Figure 4, bottom), with the latter carrying an activating het-
erozygous D661Y hot-spot mutation of the STAT3 SH2 domain
(COSMICv76 database; Hudnall et al5). The D661Y mutation is
recurrent in T/NK-cell neoplasms and was previously shown to
be associated with both STAT3 constitutive phosphorylation and
increased transcriptional activity.23 Indeed, western blot analysis
confirmed basal STAT3 phosphorylation in this cell line, which
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Figure 3. Downregulation of STAT6 triggers apoptosis of STAT6-mutated cHL tumor cells. (Top) ShRNA-mediated downregulation of total and phophoSTAT6 by western
blotting in 4 cHL cell lines (1 representative experiment per cell line is shown, of 2-4 independently performed, that gave reproducible results); b-tubulin is used as a loading
control, and the normalized levels of total and phosphoSTAT6, quantified by densitometry, are shown below the respective blots (solid lines denote distinct gels that were
loaded with the same protein lysates and blotted separately). (Bottom) Raw percentage of live cells (AnnexinV-negative by flow cytometry) over time, after transduction of STAT6
shRNA-1 and control shRNA (day 0 5 96 hours after transduction and 48 hours after puromycin selection). Error bars (standard error of the mean) refer to at least 2 or
3 independent experiments per cell line per time point. P values refer to unpaired, 2-tailed t test. Supplemental Figure 14 shows the same data after normalizing the percentage
of live cells in the shRNA-1 sample to the corresponding nontargeting shRNA control sample (set at 100%).
Figure 2 (continued) lymph node biopsy (left), but not in the DNA of a peripheral blood sample analyzed as a negative control (right); the same mutation had been originally
identified byWES in theWGA-DNA of microdissected tumor vs normal cells. The low variant allele frequency (0.9%) reflects the known paucity of cHL tumor cells in the involved
tissues (see supplemental Table 6 for the full results of digital polymerase chain reaction validation).
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Fig. 3: Down egul tion of STAT6 triggers apoptosis of STAT6-mutated cHL umor cells.
(Top) ShRNA-mediated downregul tion of total and phophoSTAT6 by wes ern blotting in
4 cHL cell lines (1 representative experiment per cell line is shown, of 2-4 independently
performed, that gave reproducible results); b-tubulin is used as a loading control, and
the normalized levels of total and ph sphoSTAT6, q antified by densitometry, are shown
below the respective blots (solid lines denote distinct gels that were loaded with the same
protein lysates and blotted separately). (Bottom) Raw percentage of live cells (AnnexinV-
negative by flow cytometry) over time, after transduction of STAT6 shRNA-1 and control
shRNA (day 0 5 96 hours after transduction and 48 hours after puromycin selection). Error
bar (standard error of the mea ) refer to at least 2 or 3 indep ndent experi e ts per cell
line per time point. P values refer to unpaired, 2-tailed t test. Supplemental Figure 14
shows the same data after normalizing the percentage of live cells in the shRNA-1 sample
to the corresponding nontargeting shRNA control sample (set at 100%).
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Consistent with these findings, treatment with the JAK2 selective
inhibitor fedratinib was toxic to L1236 and HDLM2, but not to
L428, despite efficient dephosphorylation of STAT6 and STAT3
(Figure 5).
Collectively, these data suggest a cooperative activity between
mutations of STAT family members and genetic inactivation of
SOCS1 in sustaining cHL growth. In support of thismodel, 2/8 cHL
tumors with SOCS1 disruptive mutations and wild-type STAT6
alleles carried activatingmutations in other STAT familymembers,
including a T628S substitution in the SH2 domain of STAT5B
(also described in T-cell prolymphocytic leukemia)24 and a D661Y
substitution of STAT3 (Figure 1; supplemental Tables 3 and 5).
Recurrent GNA13 mutations in cHL
A second target of recurrent mutations in cHL was GNA13,
encoding for the Ga13 subunit of heterotrimeric G-proteins
(n5 8/34 cases [24%]; Figures 1 and 6A; supplemental Table 5).
By transmitting signals from the G-protein-coupled receptors
S1PR2 and P2RY8 that result in inhibition of AKT phosphoryla-
tion, Ga13 ensures the proper confinement of proliferating
germinal center B cells within secondary lymphoid follicles and
at the same time constrains their expansion by facilitating ap-
optosis in this potentially dangerous niche.25-27
GNA13 variants in cHL were mostly heterozygous and included
non-sense, frame-shifting, and missense mutations. This pattern
overlaps with that observed in Burkitt lymphoma and diffuse
large B-cell lymphoma of the germinal center B-cell type, and is
compatible with loss of Ga13 signaling activity.25,27-32 Mutations
ofGNA13 in cHL were strongly associated with STAT6mutations,
being detected in 7/11 STAT6-mutated samples (64%) com-
pared with 1/25 STAT6-unmutated patients (4%; P value5 .0003,
Fisher’s exact test; Figure 1).
Frequent inactivating mutations of ITPKB in cHL
Four (16%) of 25 evaluable case harbored heterozygous somatic
mutations in ITPKB (Figure 6B; supplemental Table 5). ITPKB
encodes for a kinase converting the second messenger inositol
trisphosphate (IP3) to IP4, a soluble antagonist of the AKT-
activating PI3K-product IP3.33 All 4 ITPKB-mutated lymphomas
showed disruptive frame-shifting variants predicted to generate
truncated proteins lacking the kinase domain and, therefore, to
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Figure 4. Reconstitution of wild-type SOCS1 causes cell death in cHL lines carrying concurrent mutations of SOCS1 and STAT genes. (Top) Western blot analysis of
phosphoSTAT6 after lentiviral transduction of myc-tagged SOCS1 in 4 cHL cell lines (1 representative experiment per cell line is shown, of 2-4 independently performed, that
gave reproducible results); b-tubulin is used as loading control, and the normalized levels of total and phosphoSTAT6, quantified by densitometry, are shown below the
respective blots. (Bottom) Raw percentage of live cells (based on forward/side scatter parameters by flow cytometry) over time (day 05 48 hours after SOCS1 transduction). Error
bars (standard error of the mean) refer to at least 3 independent experiments per cell line per time point (except HDLM2/d 1, n5 2 replicates). The induction of cell death on
SOCS1 transduction in HDLM2 and L1236 is statistically significant (P values, .05 for each cell line based on 2-way ANOVA). Supplemental Figure 14 shows the same data after
normalizing the percentage of live cells in the SOCS1-vector sample to the corresponding empty-vector control sample (set at 100%).
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Fig. 4: Reconstitut n of wild-type SOCS1 caus s c ll dea h in cHL li es carryi g c n-
current mutations of SOCS1 and STAT genes.
(Top) Western blot analysis of phosphoSTAT6 after lentiviral transduction of myc-tagged
SOCS1 in 4 cHL cell lines (1 representative experiment per cell line is shown, of 2-4 inde-
pendently performed, that gave reproducible results); b-tubulin is used as loading control,
and the ormalized levels of total and phosphoSTAT6, qua tified by de sitometry, are
shown below the respective blots. (Bottom) Raw percentage of live cells (based on for-
ward/side scatter parameters by flow cytometry) over tim (day 0 5 48 hours after SOCS1
transduction). Error bars (standard error of the mean) refer to at least 3 independent ex-
periments per cell line per time point (except HDLM2/d 1, n 5 2 replicates). The induction
f cell death on SOCS1 trans uction in HDLM2 and L1236 is statistically significant (P
values , .05 for each cell line based on 2-way ANOVA). Supplemental Figure 14 shows the
same data after normalizing the percentage of live cells in the SOCS1-vector sample to
the corresponding empty-vector control sample (set at 100%).
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Finally, the tumor suppressor TP53 harbored somatic missense mutations of its DNA
binding domain in 3/34 (9%) cases (Fig. 1 and Table 3) [220].
EBV-associated variation in somatic mutation burden
Despite representing a very small subset in our panel, the 4 cHL cases with latent Epstein-
Barr virus (EBV) infection of the tumor cells [169] showed a strikingly lower number of
somatic mutations (non-silent: 0 to 33; silent/non-coding: 0 to 31) compared to the 30
EBV- cases (median: 50 and 60, respectively; p-value <0.01 in both cases (Fig. S11A). In
particular, three EBV+ cases, all of the mixed cellularity histological subtype (MC) (Fig. 1)
had no (pts. 32, 33) or only 3 somaticmutations in total (non-silent and silent/non-coding).
This finding was not due to technical differences in the exome sequencing coverage be-
tween the 30 EBV+ cases and the 4 EBV- cases, as coverage metrics for these two groups
were comparable (Table S2). We confirmed the association between low somatic mutation
burden and EBV infection of the tumor cells when we restricted the analysis to the MC
histological subtype, as the 6 EBV- MC cases harbored 48 - 144 SNVs (median 111) while
the 3 EBV+MC cases showed 0-3 mutations (p-value 0.024; Fig. S11B). Conversely, no sig-
nificant difference was observed when comparing the 6 EBV- MC cases with the 20 EBV-
cases of the most frequent histologic subtype (nodular sclerosis; median of total somatic
mutations: 107) (Fig. S11B), suggesting that histology is unlikely to be correlated with
mutation burden in cHL. Similarly, the 4 EBV- cases previously exposed to chemother-
apy had a comparable number of total somatic mutation (79 to 215) as the 26 EBV- cases
studied before chemotherapy (median 10 142) (Fig. S11C).
Although the number of EBV+ cases we studied is small (n=4) and more cases should
be analyzed to confirm these findings, these data may suggest a link between latent EBV
infection and low somaticmutation burden inHRS cells. Because EBV is known to provide
critical signals that promote early cHL lymphomagenesis by rescuing pre-apoptotic GC B
cells [169], it is conceivable that its expression may relieve the pressure toward selection
for exome-wide mutagenic mechanisms.
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feature ofHRS cells that is amenable topharmacologic inhibition.34,35
In addition, 1 of these 4 cases harbored 3 missense mutations in the
gene exon 2, the significance of which remains to be established.
Recurrent hot spot mutations of XPO1 correlating
with cHL cell vulnerability to the clinical XPO1
inhibitor selinexor
Heterozygous missense mutations of XPO1 at the hot-spot
residue E571 were found in 6/34 patients (18%; Figures 1 and
7A; supplemental Table 5); this amino acid is known to contact
a prototypic nuclear export signal (NES)36,37 and is also recurrently
targeted by somatic mutations in primary mediastinal B-cell
lymphoma and, at a lower frequency, in chronic lymphocytic
leukemia.14,38 E571-XPO1 mutations have been also detected in
whole biopsies of cHL cases, although formal proof of their
actual presence in HRS cells was missing.39 XPO1 (alias CRM1)
shuttles outside the nucleus over 200 cargo proteins harboring
a NES, including known tumor suppressors involved in cHL lym-
phomagenesis and functioning in the nucleus (eg, TP53 and
NFKBIA).2,36,40-43 XPO1 is overexpressed in various cancers, and
inhibition of its activity appears more toxic to tumor cells than
normal cells.42-44 We thus tested the antitumor effect of selinexor, a
clinical compound that inhibits XPO1 function by covalently binding
to the C528 residue in its NES-binding groove,45 in 6 cHL cell lines
with wild-type or mutated XPO1 alleles. Interestingly, selinexor
reduced growth and caused apoptosis in 2 cHL cell lines carrying
the E571K mutation (SUPHD1 and UHO1), but not in 4 cell lines
that lacked this mutation (L428, L540, HDLM2) or had a lowmutant
allele burden (L1236) (Figure 7B; supplemental Figure 9).
Other recurrently mutated genes
Genes encoding inhibitors of the NF-kB pathway (in particular
NFKBIE, NFKBIA, and TNFAIP3) are known to be recurrently tar-
geted by inactivating mutations and/or deletions in cHL.6,15,46-50
Accordingly, disruptive somatic mutations of the NF-kB pathway
inhibitor NFKBIE (encoding for IkBe) were identified in 5/34 (15%)
cases (supplemental Figure 10; supplemental Tables 3 and 5).
Although we observed monoallelic deletions of TNFAIP3 in 12/33
(36%) evaluable cases by FISH, no mutations were detected in
this gene by WES, and targeted deeper sequencing (performed
on 28/34 cases) only identified a non-sense mutation in 1 case
(validated by Sanger sequencing; supplemental Table 5). The low
frequency of TNFAIP3mutations in our series does not seem to be
explained by insufficient coverage depth, as themean percentage
of TNFAIP3 coding nucleotides with$203 coverage in the targeted
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Figure 5. JAK2 inhibition leads to STATs dephosphorylation and apoptosis in cHL tumor cells carrying STAT6 or STAT3mutations. (A) Western blot analysis of STAT6,
STAT3, and STAT5 phosphorylation in L1236, L428, and HDLM2 cells analyzed 24 hours after treatment with the JAK2 inhibitor fedratinib (at the indicated concentrations) or with
vehicle (dimethyl sulfoxide) as control (1 representative experiment per cell line is shown, of 3 independently performed, that gave reproducible results). Normalized levels of
total STATs relative to b-tubulin, and of phospho-STATs relative to the corresponding total STATs, were quantified by densitometry and are shown below the respective blots.
(B) Percentage of live cells (AnnexinV-negative by flow cytometry) in the same cell lines, measured 48 hours after treatment with fedratinib, relative to the vehicle set at 100%. Error
bars (standard error of the mean) refer to 4 independent experiments, each done in duplicate; P values were computed by 2-way ANOVA.
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Fig. 5: J K2 inhibition le s to STATs dephosphorylation and apoptosis in HL tumor
ce ls carrying STAT6 r S AT3 mutatio s.
(A) Western blot analysis of STAT6, STAT3, and STAT5 phosphorylation in L1236, L428,
and HDLM2 cells analyzed 24 hours after treatment with the JAK2 inhibitor fedratinib (at
the indicated concentrations) or with vehicle (dimethyl sulfoxide) as control (1 represen-
tative experiment per cell line is shown, of 3 independently performed, that gave repro-
du ible results). Normalized levels of total STATs relative to b-tubulin, and f ph spho-
STATs relative to the corresponding total STATs, were quantified by densitometry and
are shown below the respective blots. (B) Percentage of live cells (AnnexinV-negative
by flow cytometry) in the same cell lines, measured 48 hours after treatment ith fedra-
tinib, relative to the vehicle set at 100%. Error bars (standard error of the mean) refer to




Here we provide a comprehensive analysis of the cHL coding genome based on a rela-
tively large number of primary cases (n=34), uncovering frequent mutations in several
previously 20 unappreciated genes that are likely to have relevant pathogenetic functions
and could be amenable to targeted therapeutic strategies. Key in our effort was the suc-
cessful overcoming of two technical challenges, i.e. the purification of the rare HRS cell
from tissue samples through microdissection; and an efficient bioinformatics control of
the bias introduced by the whole-genome amplification (WGA) reaction when applied to
a few cells, through independent sequencing of duplicate WGA reactions. While this bias
was successfully overcome with regard to the correct calling of point mutations and short
indels, it did complicate a reliable exome-wide calling of somatic copy number alterations
(see also Supplementary Materials and Methods), which represents a limitation of our
work.
A main finding of our study is the almost ubiquitous ( 90% of cases) genetic target-
ing of a variety of JAK-STAT pathway members, which goes beyond previous estimates
based on the presence of copy number gains of JAK2 and the mutational disruption of
the SOCS1 and PTPN1 inhibitors [168, 169, 175], and includes activating mutations of
JAK1 and of multiple STAT transcription factors (STAT3; STAT5B) together with highly
recurrent mutations of STAT6 (32% of cases). Although necessarily limited to cell lines,
the observation that genetic and pharmacologic inhibition of STAT6 elicited significant
apoptosis in STAT6-mutated but not in STAT6 wild-type HRS cells 10 even if express-
ing phosphorylated (i.e., activated) STAT6, suggest that STAT6 variants may promote the
growth of the cHL clone in a manner distinct from STAT6 phosphorylation. Since mu-
tations clustered in the DNA binding domain, one possible mechanism by which STAT6
mutants could confer survival advantage to HRS cells might imply an aberrant target
gene recognition and transactivation following the phosphorylation-dependent nuclear
translocation of mutant STAT6, a hypothesis that will need to be tested in future research.
Although the biochemical consequences of STAT6 mutations towards DNA binding and
target gene transcription are controversial [177, 178], the fact that both pharmacological
blockade of phosphorylation and genetic silencing of STAT6 induced marked apopto-
sis of L1236 cHL cells, which only express the mutant N417Y allele, is consistent with a
gain-of-function of this mutant towards tumor clone growth 20 downstream of JAK-STAT
pathway activation.
Interestingly, STAT6 mutations and activating mutations of STAT3 and STAT5B were
enriched in cHL cases harboring disruptive mutations of the SOCS1 inhibitor. The obser-
vation that exogenous SOCS1 restoration, as well as selective JAK2 inhibition downstream
of SOCS1, proved selectively toxic to SOCS1-disrupted HRS cells that concomitantly car-
ried a mutant STAT family member suggests functional dependence between the activity
of these mutant alleles in sustaining tumor growth.
The pervasive targeting of JAK-STAT signaling genes in cHLmakes clinically available
JAK or STAT inhibitors [221, 222] an attractive therapeutic approach in this disease in the
context of a comprehensive targeted genotyping of patients.
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range, 83%-94%). The NFKBIA gene, encoding another NF-kB
pathway inhibitor (ie, IkBa) less frequently mutated (17% of cHL
cases48,51-53), was also not affected in our series, both on WES and
on targeted deeper sequencing (average percentage of coding
nucleotides with $203 coverage in tumor samples, 76%; inter-
quartile range, 63%-95%). Overall, genetic lesions in negative reg-
ulators of the NF-kB pathway occurred in 53% of cHL cases (18/34),
confirming their important role in the pathogenesis of this disease.
In agreement with a previous study,6 somatic mutations of B2M,
encoding a protein indispensable for major histocompatibility
complex class I expression on the cell surface, were observed in
9/34 (26%) cases, including 7 with disruptive variants (non-sense,
frame-shifting, splice site or start-codon loss) and 2 with missense
variants (Figure 1; supplemental Tables 3 and 5). Monoallelic
deletion of B2M was observed in 2/29 evaluable cases, 1 of which
(no. 2) also carried a splice site mutation of the other allele. One
additional case (no. 29) had a heterozygous splice site inactivation
of NLRC5 (supplemental Table 3), which encodes for the master
major histocompatibility complex class I transactivator CITA and
has been shown tobe a target of immuneevasion in solid cancers.54
In cHL, another geneticmechanismof immuneescape is represented
by relative copy number gain or amplification of 9p24,55 which we
observed by FISH in 11/33 (33%) evaluable cases (Figure 1). The
gained/amplified region includes, in addition to JAK2, the PDL1
and PDL2genes encoding for surface ligands that inhibit activation
of T cells expressing the PD1 receptor. Overall, genetic lesions
fostering immune evasion (mutations/deletions of B2M orNLRC5;
copy number gain/amplification of 9p24) were observed in 53%
(18/34) of cases (Figure 1; supplemental Table 3), confirming their
important contribution to cHL lymphomagenesis.
Notably, somatic mutations of the chromatin-modifying genes
KMT2D (aliasMLL2),CREBBP, EP300, and EZH2, which are frequent
in diffuse large and follicular B-cell lymphoma,30,56,57 were only
occasionally observed in cHL (supplemental Table 3) and included
a heterozygous hotspot mutation R1446H affecting the CREBBP
acetyl-transferase domain in 1 case (no. 37).
Finally, the tumor suppressor TP53 harbored somatic missense
mutations of its DNAbinding domain in 3/34 (9%) cases (Figure 1
and supplemental Table 3).58
EBV-associated variation in somatic
mutation burden
Despite representing a very small subset in our panel, the 4 cHL
cases with latent Epstein-Barr virus (EBV) infection of the tumor
cells3 showed a strikingly lower number of somatic mutations
(nonsilent, 0-33; silent/noncoding, 0-31) compared with the
30 EBV2 cases (median, 50 and 60, respectively; P value , .01)
(supplemental Figure 11A). In particular, 3 EBV1 cases, all of the
mixed cellularity histological subtype (MC; Figure 1), had no
(patients 32 and 33) or only 3 (patient 35) somaticmutations in total
(nonsilent and silent/noncoding). This finding was not a result of
technical differences in the exome sequencing coverage between
the 30 EBV1 cases and the 4 EBV2 cases, as coverage metrics for
these 2 groups were comparable (supplemental Table 2). We
confirmed the association between low somatic mutation burden
and EBV infection of the tumor cells when we restricted the
analysis to the MC histological subtype, as the 6 EBV2 MC cases
harbored 48 to 144 mutations (median, 111) whereas the 3
EBV1 MC cases showed 0 to 3 mutations (P value 5 .024;
supplemental Figure 11B). Conversely, no significant differ-
ence was observed when comparing the 6 EBV2MC cases with
the 20 EBV2 cases of the most frequent histologic subtype
(nodular sclerosis; median of total somatic mutations, 107) (sup-




























































































Figure 6. GNA13 and ITPKB mutations in cHL. (A) Schematic representation of the GNA13 protein and its functional domains, with the 11 mutations found in 8 cHL cases
depicted above. (B) Schematic representation of the ITPKB protein and its functional domains, with the 7 mutations found in 4 cHL cases depicted above.
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Fig. 6: GNA13 and ITPKB mutations in cHL.
(A) Schematic representation of the G A13 protein and its fun tional do ains, with the
11 mutations found in 8 cHL cases depicted above. (B) Schematic representation of the
ITPKB protein a d its functional d mai s, with the 7 mutations found in 4 cHL cases
depicted above.
The second most commonly mutated gene was GNA13 (24% of cases). The G-protein
subunit encoded by GNA13 transduces critical signals that constrain GC B cells within
secondary lymph id follicles, but also favors their apoptosis as a balance to the risk of
genomic instability posed by the high rate of cell proliferation and DNA damage physi-
ologically occurring during the germinal center reaction to ensure proper affinity matu-
ration and class switch r combination of immu oglobulin ge es [188–190, 223]. B cause
the GNA13 mutation pattern resembles that observed in other 10 GC B-cell derived lym-
phomas and is consistent with loss of function25,27,29-32, GNA13 is likely to play a tu-
mor suppressor function in cHL. GNA13 is also recurrently mutated in PMBCL14, which
shares several clinico-pathological, molecular and gen tic fea ures with cHL [174, 224].
Conversely, GNA13 mutations are rare in the ABC-type of DLBCL [188, 190, 191, 193–
195], suggesting a specific pathogenetic role in GC B-cell derived aggressive lymphomas.
In the context of cHL, inactivating GNA13 mutations may facilitate lymphomagenesis by
rescuing crippled GC B cells (the proposed HRS cell precursors2) from apoptosis and by
romoting their dissemination utside the lymphoid follicles, here HRS cells are indeed
observed upon analysis of lymph nodes with early, partial involvement by cHL63.
We also identified missense mutations of the XPO1 nucleo-cytoplasmic shuttling pro-
tein 20 recurring in 18% of cases at the hotspot residue E571. Intriguingly, exposure of
cHL cell lines to a low dose of the specific, clinically available XPO1 inhibitor selinexor
reduced growth and caused apoptosis in a manner correlated with the XPO1mutant allele
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burden. This finding points to XPO1- E571 mutations as potential gain-of-function events
on which HRS cells may depend for survival. Although the functional consequences of
E571 mutations in cHL needs to be mechanistically worked out, our data suggest a vul-
nerability that could be exploited therapeutically, considering the clinical feasibility of
XPO1 inhibition [225] and the likely larger therapeutic window afforded in cHL by the
greater sensitivity to selinexor shown by XPO1-mutated HRS cells.
Finally, ITPKB was disrupted in 16% of cHL cases by truncating mutations that elimi-
nate the kinase domain of ITPKB and, consequently, are predicted to blunt its antagonistic
activity towards the AKT kinase [196]. Although the function of ITPKB and the pathways
that may be modulated by its activity have not been studied in normal GC B cells, ITPKB
inactivation may provide a genetic basis to the aberrant PI3K-AKT signalling activity that
is known to support HRS cells viability and that is, again, potentially susceptible of phar-
macologic inhibition [197, 198].
We did not observe any grossly evident enrichment of specific mutated genes in sam-
ples 10 analyzed at relapse versus initial diagnosis, with the limitation of the small number
of relapsed cases analyzed (n=6). Similarly, although certain genes (e.g., B2M, GNA13,
STAT6, SOCS1) appear more frequently mutated in nodular sclerosis than mixed cellu-
larity cHL tumors, this was robust comparison, and larger studies focused on relapsed
and MC cases will need to be performed to reliably determine whether specific genes are
preferentially mutated/unmutated in these groups.
In summary, our analysis of the cHL coding genome uncovered recurrent mutations
in several previously unappreciated genes, most notably GNA13, XPO1, ITPKB, STAT6
and multiple other members of the JAK-STAT signalling pathway, pointing to a critical
role for these genes in the pathogenesis of cHL. The high frequency of mutations in JAK-
STAT pathway genes provides a 20 genetic explanation for the constitutive activation of
this cascade in almost 90% of cases. While additional studies will be needed to mecha-
nistically document the dependency of the mutated cHL cell lines on the affected genes,
the observed association between the presence of specific gene mutations and the suscep-
tibility to targeted pathway inhibition suggests new therapeutic targets in this common
lymphoma. Finally, the landscape of recurrently mutated genes that we have defined in
cHL can be harnessed to develop liquid biopsy strategies for non-invasive monitoring of
the response to therapy. This could improve the imperfect prognostic accuracy of PET
imaging in not statistically significant. However, the small number of MC cases in our
series (n=9) prevents a guiding treatment escalation or deescalation, and thereby reduce
the overall toxicity burden associated to chemo-radiotherapy.
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correlated with mutation burden in cHL. Similarly, the 4 EBV2
cases previously exposed to chemotherapy had a comparable
number of total somatic mutations (79-215) as the 26 EBV2
cases studied before chemotherapy (median, 142; supple-
mental Figure 11C).
Although the number of EBV1 cases we studied is small (n 5 4)
and more cases should be analyzed to confirm these findings,
these data may suggest a link between latent EBV infection and
low somatic mutation burden in HRS cells. Because EBV is known
to provide critical signals that promote early cHL lymphoma-
genesis by rescuing pre-apoptotic GC B cells,3 it is conceivable
that its expression may relieve the pressure toward selection for
exome-wide mutagenic mechanisms.
Discussion
Here we provide a comprehensive analysis of the cHL coding
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Figure 7. XPO1 mutations in cHL. (A) Schematic representation of the XPO1 protein and its functional domains, with the mutations found in cHL cases shown above. (B)
Percentage of nonapoptotic cells (AnnexinV-negative by flow cytometry) assessed in 6 cHL cell lines at the indicated times after exposure to a low dose (100 nM) of the XPO1
inhibitor selinexor, or drug vehicle (dimethyl sulfoxide) as negative control (set at 100%). Day 0 corresponds to 48 hours of culture with selinexor or vehicle. Error bars refer to 3
independent experiments, each performed in triplicate; P values were calculated by 2-way ANOVA.
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Fig. 7: XPO1 mutatio s in cHL.
(A) Schematic representation of the XPO1 protein and its functional domains, with
the mutations found in cHL cases shown above. (B) Percentage of nonapoptotic cells
(AnnexinV-negative by flow cytometry) assessed in 6 cHL cell lines at the indicated times
after exposure to a low dose (100 nM) of the XPO1 inhibitor selin xor, or drug vehicl
(dimethyl sulfoxide) as negative control (set at 100%). Day 0 corresponds to 48 hours of
culture with selinexor or vehicle. Error bars refer to 3 independent experiments, each
perfor ed in triplicate; P values were calculated by 2-way ANOVA.
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